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Stroke is one of the major causes of death and disability worldwide. Ischaemic stroke 
constitutes 80% of stroke incidents. Reperfusion injury following ischaemic stroke has been 
shown to contribute to major neurological damages. Current conventional treatments for 
ischaemic stroke, whether surgical or pharmaceutical, focus on restoring cerebral blood flow 
and preventing expansion of ischaemic damage, but have limited impact on neuron damage 
or restoring damaged neurological functionalities. 
NXQ, a standardised, patented herbal extract derived from Diospyros kaki L., offers 
potential therapeutic for apoplexy syndrome, including ischaemic stroke. However, NXQ’s 
effects on ischaemic stroke are unclear. In particular, the mechanisms underlying NXQ’s 
effects and the key active components responsible for these effects, are not fully understood.  
Aims 
This study aims to determine the effects of NXQ and its role in the treatment of ischaemic 
stroke. The study comprised of two parts. 
First part to determine the effects of NXQ for ischaemic stroke by evaluating its vascular 
protective effects and angiogenic effects. This study further identifies the chemical profiles of 
the NXQ extract and determines which compound/s are responsible for the therapeutic 
functions for ischaemic stroke. The second part of the study aimed to evaluate the clinical 
effects of NXQ on ischaemic stroke patients. A study protocol for a randomised, double-blind, 
placebo-controlled trial was developed to facilitate future studies on the clinical efficacy and 
safety profile of NXQ for ischaemic stroke patients. 
Methods 
vi 
A chemical profile was conducted to identify the key active components of the raw extract of 
NXQ provided by Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co. These 
compounds are quantified, and the ratio of the key flavonoids quercetin and kaempferol were 
determined using HPLC-PDA. The vascular protective effects of NXQ and its key active 
components are evaluated in H2O2-induced reactive oxygen species (ROS) generation and 
lactate dehydrogenase leakage (LDH) leakage models in EA.hy926 cells. To evaluate the 
angiogenic effects of NXQ, cell proliferation and cell migration assays are conducted using 
EA.hy926 cells.  
The results of NXQ was compared with quercetin, kaempferol, and quercetin and kaempferol 
combination to see which of the compounds are responsible for its vascular protective actions 
and whether there is a potential synergism within the kaempferol and quercetin combination 
at a fixed ratio identified in NXQ extract.  
The angiogenic effects of NXQ were further evaluated using VRI-inhibited zebrafish 
Tg(fli1:EGFP) embryos and the growth of SIV vessels promoted by NXQ. A hypoxia model in 
zebrafish was developed to evaluate the protective effects of NXQ in vivo. Due to the time 
limitation, and technical challenges, only the results of this model development were included 
in this thesis. In addition, a randomised, double-blinded controlled trial  protocol was 
developed and included in this thesis for the future study on evaluation of the clinical efficacy 
and safety of NXQ in ischaemic stroke.  
Results 
NXQ significantly attenuated H2O2-induced ROS generation, LDH leakage and restored cell 
viability. This effect was superior to that of kaempferol and quercetin alone, suggesting 
potential synergistic reaction between the two compounds. Additionally, NXQ significantly 
induced angiogenesis in VRI-inhibited Tg(fli1:EFGP) zebrafish embryos; however, NXQ did not 
vii 
promote cell proliferation or migration in EA.hy926 cells. This potential re-vasculaturisation 
property of NXQ may be beneficial in ischaemic stroke recovery.  
Conclusion 
NXQ possesses vascular protective effects against H2O2-induced damage that may protect 
endothelial cells from reperfusion-induced damage. Additionally, NXQ possesses potential 
angiogenesis and revascularisation properties, which may contribute to its therapeutic action 
during ischaemic stroke recovery.   
viii 
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Chapter 1. Introduction 
  
2 
1.1 Background to research 
Ischaemic occurs when the an artery  to the brain is blocked leading to rapid development of 
clinical signs indicating focal or global disturbance in cerebral functionality, with symptoms 
lasting for 24 hours or longer, potentially resulting in death (WHO, 1988).  
Ischaemic stroke is one of the leading causes of death in Australia, and more than 65% of 
stroke survivors are left with permanent disabilities severe enough to affect their 
employability (Coffey C. Edward, 2000; NSF, 2013). It is estimated that treatment of stroke 
costs A$5 billion each year in Australia (Cadilhac, Carter, Thrift, & Dewey, 2009; NSF, 2013). 
In 2017, more than 56,000 new and recurrent stroke incidences were reported in Australia. 
Until 2017, more than 475,000 people living with the effects of stroke and this number is 
expected to increase to one million by 2050. The cost is expected to increase from 1.6 – to 
4.6 folds by 2051 compared with 2011 (NFS, 2017) 
Conventional treatments for ischaemic stroke, both surgical and pharmaceutical, aim to 
restore cerebral blood flow to avoid tissue damage. Some of these agents, including anti-
platelet, anti-coagulant and thrombolytic agents, act on the thrombosis or embolism by 
thinning the blood but usually have a limited impact on neuroprotection against reperfusion 
injury. It has been reported that 70% of neuron damage results from reperfusion injury rather 
than the ischaemic event itself (Hausenloy & Yellon, 2013). Therefore, a novel agent that can 
act against reperfusion-induced neuron damage is required.  
Chinese herbal medicine has been used as a therapeutic agent against ischaemic stroke-
related conditions for thousands of years. Its novel therapeutic principles may provide viable 
options for the treatment of ischaemic stroke, especially in the area of rehabilitation and 
prevention of future attacks.  
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NXQ, manufactured by Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co. 
Ltd. (HGB), is a single herbal extract of Diospyros kaki leaves, also known as leaf of persimmon. 
NXQ has been used in China as a therapeutic agent for apoplexy syndromes and ischaemic 
conditions such as angina, coronary artery diseases and cerebral ischaemia. Several clinical 
trials have conducted in China to evaluate its potential effects (which may include lowering 
lipids, scavenging radicals and improving blood flow improvements) on apoplexy syndromes; 
however, the methodology of these trials appears to be lacking in rigour and precision. To 
date, there has been no clinical trial evaluating the neuroprotective effects of NXQ using 
adapted standardised outcome measures. In addition, there is lack of preclinical data to 
support evaluation of NXQ’s effects and the mechanisms underlying its potential 
cerebrovascular and neuroprotective benefits. 
1.2 Aims and hypotheses 
This research aims to evaluate the effects and associated risks of NXQ, a standardised, 
patented herbal extract, on ischaemic stroke. The research comprises four studies designed 
to evaluate the mechanisms underlying NXQ’s effects on ischaemic stroke (including the 
vascular protective and angiogenic effects of NXQ) and to design a randomised clinical trial to 
evaluate the effectiveness and safety of NXQ in patients with ischaemic stroke.  
The initial focus of this research was on undertaking a pilot randomised clinical trial of NXQ 
in patients with subacute ischaemic stroke supplemented by in vivo studies using zebrafish 
models to evaluate the potential neuroprotective effects of NXQ. A protocol for the clinical 
trial was completed, ethics approval obtained, case-report forms prepared and recruitment 
centres established. However, the trial sponsor eventually failed to secure Good 
Manufacturing Practice accreditation from the Australian Therapeutic Goods Administration 
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(TGA) to manufacture the trial medications needed. This led to major changes to the research 
plan. In this thesis, the clinical trial protocol and key supplementary documents are included 
(Chapter 7) as they represent a substantial amount of the work completed for this doctoral 
thesis.   
The aims of and hypotheses for each of the sub-studies are outlined below.  
Study 1. Chemical analysis of NXQ 
The aim of this study is to determine the ratio of two key bioactive constituents of NXQ, 
kaempferol and quercetin, in the finished NXQ tablets. We hypothesised that kaempferol and 
quercetin can be identified and quantified.  
Study 2. Vascular protective effects of NXQ 
The aim of this study is to evaluate the effects of NXQ on oxidative stress-induced endothelial 
cellular damages. We hypothesised that the two key bioactive constituents, kaempferol and 
quercetin, are responsible at least in part for NXQ’s therapeutic actions and that NXQ’s effects 
were superior to those of kaempferol or quercetin alone, indicating the presence of a 
potential additive or synergistic effect in NXQ.  
Study 3. Angiogenesis effects of NXQ 
The aim of this study is to evaluate the angiogenic effects of NXQ using endothelial cells and 
transgenic zebrafish Tg(fli1:EGFP) embryos. We hypothesised that NXQ possesses angiogenic 
effects and that the two key bioactive constituents, kaempferol and quercetin, exert additive 
or synergistic effects at the ratio presented in NXQ tablets. 
Study 4. Effectiveness and safety of NXQ for ischaemic stroke – a pilot, multicentred, 
randomised control trial protocol 
5 
The aim of this study is to design a randomised, double-blind, placebo-controlled trial to 
evaluate the effectiveness and safety of NXQ in patients with ischaemic stroke. We 
hypothesised that 12 weeks treatment of NXQ could improve neurological, motor and 
cognitive functional outcomes of ischaemic stroke patients during rehabilitation phase. 
1.3 Structure of the thesis 
This thesis comprises eight chapters. 
Chapter One provides a brief introduction to this research, including the background to 
the thesis, research aims and hypothesis, and thesis structure. 
Chapter Two provides a comprehensive review of the literature relevant to the thesis topic, 
including findings on the prevalence, aetiology, risks and pathophysiology of ischaemic stroke 
and current medical interventions for the management of the disease. 
In Chapter Three, relevant background information, current scientific evidence and 
knowledge gaps associated with the use of Chinese herbal medicine for ischaemic stroke 
(focusing on NXQ) are summarised.  
Chapter Four contains a chemical analysis of NXQ, details of the research methodology for 
the chemical evaluation, method validations and a presentation and discussion of results. 
Chapter Five discusses the vascular protective effects of NXQ. This chapter contains 
background, experimental methodology, results and discussions of an in vitro study using 
EA.hy926 cells to evaluate vascular protective effects induced by H2O2 damage. In addition, 
the research protocol, model development methodology, troubleshooting, results and 
presentation of a hypoxia model in zebrafish are included and the results discussed. 
Chapter Six discusses the angiogenic effects of NXQ. This chapter contains background, 
experimental methodology, results and discussion of an in vitro study of the angiogenic 
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effects of NXQ on EA.hy926 cells. In addition, the development of an angiogenesis model in 
transgenic zebrafish Tg(fli1:EGFP) embryos, issues and some preliminary results are 
presented.  
Chapter Seven explores the effects of a standardised, patent herbal extract (NXQ) for 
ischaemic stroke through a pilot randomised controlled trial. This chapter contains a clinical 
trial protocol in which the background, clinical trial design, inclusion and exclusion criteria, 
primary and second outcome measures and assessment schedules are presented and 
discussed.  
Chapter Eight provides a summary of the background of this research and the results of 











Chapter 2. Atherosclerosis, Cerebral Ischaemia and Ischaemic Stroke 
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2.1 Introduction to ischaemic stroke 
Stroke, also known as cerebrovascular accident, is the brain equivalent of a heart attack. It is 
a disease with multiple overlapping risk factors, primarily of vascular origin and typically 
complicated by ageing and lifestyle factors such as dietary habits and smoking. Stroke is 
defined as the rapid development of clinical signs indicating focal or global disturbance in 
cerebral functionality, with symptoms lasting for 24 hours or longer and potentially resulting 
in death with no apparent cause other than it being of a vascular origin (WHO, 1988). Stroke 
can be categorised into ischaemic and haemorrhagic subtypes. Ischaemic stroke (IS) is 
typically associated with disturbance in blood supply and generally incurs smaller lesions, 
while haemorrhagic stroke (HS) refers to the rupturing of blood vessels, resulting in larger 
lesions. IS is the more common type, accounting for approximately 80% of all cases. However, 
the mortality rate is generally lower in comparison to HS (Andersen, Olsen, Dehlendorff, & 
Kammersgaard, 2009b). 
Stroke is one of the leading causes of death in Australia (after coronary heart disease) and 
most survivors are left with permanent disabilities. In 2017, over 475,000 Australians were 
living with the effects of stroke (Tursunov & Akbarkhodjaeva, 2017). According to the National 
Stroke Foundation (NSF), this number is expected to rise to one million by the year 2050 due 
to the complexity of risk factors and the increase in the aged population of Australia. Sixty-
five per cent of stroke survivors suffer from a disability severe enough to decrease their 
employability (Coffey C. Edward, 2000; NFS, 2017; NSF, 2013), and two-thirds of these cases 
require assistance in daily living activities and long-term care (NSF, 2013). 
The treatment of stroke in Australia costs an estimated A$5 billion dollars each year 
(Cadilhac et al., 2009; NSF, 2013); in 2012 alone, A$49.3 billion was spent on stroke 
prevention, treatment, rehabilitation and disability care (NSF, 2013). Given that the number 
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of disabled survivors is increasing, the total cost of stroke treatment is expected to increase 
proportionally (Broderick, 2004; NFS, 2017; NSF, 2013). Conventional treatments for stroke 
focus predominantly on IS due to its higher incidence; HS therapies are limited due to the 
rapid and extensive physiological damage, truncated therapeutic window and poor overall 
prognosis associated with HS.  
The goal of acute stroke treatment in general is to increase the survival rate and reduce 
the dependency level of the patient (Dirnagl, Iadecola, & Moskowitz, 1999). Currently, 
approved treatments (both surgical and pharmaceutical) for acute ischaemic stroke aim to 
restore cerebral blood flow to prevent rapid tissue damage resulting from disturbed blood 
supply to the local tissue. Some of the pharmacological agents promoting blood flow, such as 
anti-platelet, anti-coagulant and thrombolytic drugs, act on thrombosis or embolisms by 
thinning the blood, but their value is usually time-limited and plays a minimal role in 
neuroprotection (Gubitz, Sandercock, & Counsell, 2008; Sandercock, Counsell, Gubitz, & 
Tseng, 2008; Wardlaw, Murray, Berge, & Del Zoppo, 2009). While local ischaemia does 
damage the affected brain tissues, it is alarming that reperfusion injury – a series of 
pathophysiological events after regaining blood flow – is a greater risk for damage to cerebral 
tissues. A significant 70% of neuro-damage is caused by reperfusion injury and only 17% is of 
ischaemic origin (Simon, Haj-Yehia, & Levi-Schaffer, 2000). Therefore, neuroprotection is 
considered an important therapeutic strategy in reducing neuron damage and dependency 
levels; in IS, this strategy has focused on expanding the treatment window and reducing 
reperfusion injury (Cheng, Al-Khoury, & Zivin, 2004; Ginsberg, 2008). However, the research 
on neuroprotective agents, such as glycine antagonists and calcium channel blockers, reveals 
discrepancies in the therapeutic benefits in animal studies and clinical trials (Cheng et al., 
2004). Some researchers suggest this could be due to species-dependent differences and that 
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animals such as rodents may be more amenable to neuroprotection than evolutionarily 
higher mammals, such as humans (Dirnagl et al., 1999). 
Rehabilitation is a combination of therapeutic modalities, including physiotherapy, 
occupational therapy, and speech and language therapy, designed to assist stroke survivors 
to restore functionality lost due to neurological damage (Feigenson, 1979). It is typically a 
long-term and continuous process and, depending on the severity of disability, the majority 
of survivors do not regain full functionality. In addition to rehabilitation therapies, long-term 
pharmaceuticals are typically prescribed for the management of vascular and thrombotic risk 
factors to prevent recurrence of stroke (Ringleb et al., 2007). Despite the preventative 
medications, there are no currently known pharmaceuticals shown to improve cognitive and 
functional outcomes. There is, therefore, an urgent need for alternative therapeutic options 
to mitigate the impact of ischaemic stroke, both by reducing the damage to the brain and 
improving functional outcomes. 
2.2 Prevalence, aetiology and risk factors 
2.2.1 Prevalence 
Stroke is one of the most significant cardiovascular diseases (CVDs) leading to death, after 
cardiac arrest. In 2015, 442.7 million cases of CVD, accounting for 17.7 million deaths, were 
identified globally. Nearly half of these deaths were caused by stroke (Roth et al., 2017). 
Ischaemic stroke outranked haemorrhagic and other strokes, with the greatest number of 
cases in high-income nations such as North America. However, the highest prevalence of 
stroke is in the countries and islands of Oceania due to the increased metabolic and 
cardiovascular risks associated with the regional lifestyle (Roth et al., 2017). Such figures 
reflect the major risk factors associated with cardiovascular and cardiometabolic disease, 
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such as hyperlipidaemia, hypertension and hyperglycaemia. Managing these risk factors is 
regarded an important focus for preventing IS incidents.  
2.2.2 Aetiology 
Ischaemic stroke is caused by deprivation of oxygen and energy supply to the brain cell. It can 
be categorised into thrombotic and embolic ischaemic stroke (Lees, Bath, & Naylor, 2000). 
Thrombotic stroke (TS) is the most common type and occurs when a blood clot adhering to 
the vessel wall (mural occlusive thrombus) reaches a sufficient size to completely block 
cerebral artery blood flow. The development of an occlusive thrombus due to atherosclerosis 
is a major risk factor for stroke (Allen & Bayraktutan, 2008).  
Atherosclerosis is a condition in which plaque builds up within an artery, causing a 
narrowing of the blood vessel. The formation of this plaque has shown to be associated with 
fatty materials such as low-density lipids (LDL) and triglycerides. However other factors such 
as hypertension, diabetes, smoking and ageing have also been shown to contribute to 
atherosclerosis (H. Adams et al., 1993; Allen & Bayraktutan, 2008). Atherosclerosis is 
associated with the development of athoromas during plaque formation in cerebral arteries. 
The first concern regarding the formation of atheromas is the narrowing of the relatively small 
arteries in the brain, resulting in increased blood pressure and reduced blood flow. 
Furthermore, should the fibrous cap of an atheroma ulcerate, the subsequent thrombogenic 
material released may induce thrombus formation overlying the atheroma. This can result in 
rapid occlusion of the artery and, hence, ischaemic stroke. In addition to ischaemic stroke, 
atheromas produce enzymes that enlarge the arteries over time, and this excessive widening 
may lead to the creation of an aneurysm, with subsequent rupture resulting in a 
haemorrhagic stroke (Dzau, 1994; Kher & Marsh, 2004). 
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In contrast, embolic strokes occur when an embolus (e.g. a blood clot, atherosclerotic 
plaque, fat globule or gas bubble) is carried by the bloodstream to the brain, where the larger 
arteries branch off into smaller vessels. The embolus reaches a point at which it can travel no 
further, thereby plugging a smaller cerebral artery and cutting off the blood supply to that 
area of the brain. Most blood clot emboli are caused by non-vascular factors such as atrial 
fibrillation (AF), where the two small upper chambers of the heart quiver, causing the blood 
to pool and form clots (H. Adams et al., 1993; Lees et al., 2000). 
2.2.3 Risk factors 
A number of risk factors have shown to be associated with an increased risk of ischaemic 
stroke. They can be stratified into modifiable and non-modifiable risk factors. Modifiable risk 
factors include those resulting from the environment and lifestyle choices, such as a high-fat 
and high- glucose diet, lack of exercise and smoking. These risks correspond to 
cardiometabolic risks and are typically manageable with the help of healthcare professionals, 
pharmaceutical treatment and continuing education. Non-modifiable risk factors encompass 
hereditary or natural aspects, such as ethnicity and ageing (Allen & Bayraktutan, 2008). 
Among these risks, complications and conditions attributable to CVD are considered as having 
the greatest impact for IS. For instance, cardiometabolic risk is regarded one of the most 
significant risks for CVD and has shown to be a potential threat to vascular health, with 
increased or unsustainable blood lipids and blood glucose levels. The resulting impaired 
metabolic function, including increased viscosity of the blood and narrowing of the arteries, 
stresses the vascular system and has been shown to increases the risk of developing 
atherosclerosis. This has been supported by studies suggesting that patients with Type 2 
diabetes (T2D) are at a greater mortality risks from CVD than individual without T2D. 
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Furthermore, patients with impaired metabolic functions or dyslipidaemia are more 
susceptible to inflammation of the blood vessels and, therefore, at increased risk of both 
thrombosis and embolism (Barrett-Connor & Khaw, 1988; Idris, Thomson, & Sharma, 2006).  
2.3 Pathophysiology 
IS is typically the result of a transient or permanent reduction in cerebral blood flow to a major 
arterial branch within the brain caused by the occlusion of arterial blood flow either by an 
embolus or through local thrombosis. Brain injury following transient or permanent focal 
cerebral ischaemia develops from a complex series of pathophysiological events that evolve 
in time and space (Collins, Dobkin, & Choi, 1989; Dirnagl et al., 1999). 
The brain is the centre of the nervous system and exerts critical centralised control over 
most of the physiological and cognitive functions of the body. As a result, brain tissue has a 
relatively high consumption of oxygen and glucose and depends almost exclusively on 
oxidative phosphorylation for energy production (Collins et al., 1989; Dirnagl et al., 1999). 
2.3.1 The ischaemic core and the penumbra 
During an ischaemic attack, focal impairment of cerebral blood flow restricts the delivery of 
oxygen and glucose, leading to severe focal hypoperfusion, and the cerebral injury continues 
over hours and days following the incidence. The degree and duration of the ischaemia 
determines the size and severity of the cerebral injuries. The region of the brain with severe 
hypoperfusion are referred to as the ‘ischaemic core’ and experience rapid and irreversible 
injury (Astrup, 1981; Marc Fisher & Garcia, 1996; Furlan, Marchal, Derlon, Baron, & Viader, 
1996; Hossmann, 1994; Obrenovitch, 1995). The cells in the core are rapidly killed by lipolysis, 
proteolysis, disaggregation of the microtubules, total bioenergy failure and disruption of ion 
homeostasis (the functional failure of the cellular membrane of ion channels, such as 
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potassium (K+), sodium (Na+) and chloride (Cl-) pumps, which causes the plasma membrane 
of neurons to depolarise). The resultant cascade of pathophysiological processes – 
excitotoxicity, peri-infarct depolarisation, inflammation and apoptosis – directly and/or 
indirectly lead to the death of neurons (Dirnagl et al., 1999; Kehrer & Smith, 1994).  
A region of functionally impaired but structurally intact tissue lying between the lethally 
damaged core and the normal brain is referred as the ischaemic penumbra. This partially 
functional area has constrained blood flow but the cellular metabolism is reserved; hence, it 
has been associated with the neurological recovery (Baron, 1999; Markus et al., 2004; Nagesh 
et al., 1998; Read et al., 1999). It is also an area where ischaemic cascade triggers several 
deleterious mechanisms, resulting in ongoing cellular injury and infarct processes which 
expand the damaged core. Within hours of ischaemic onset, the penumbra may be consumed 
by progressive insults leading to apoptosis and necrosis. However, the penumbra can be 
rescued by improving the blood flow and/or interfering with the ischaemic cascade in a timely 
manner – usually up to 48 hours of the initial ischaemic attack (Katsura, Kristián, & Siesjö, 
1994; R. Martin, Lloyd, & Cowan, 1994). 
2.3.2 Cellular bioenergetic failure 
Brain tissues are highly sensitive to oxidative phosphorylation for energy production. Focal 
hypoperfusion restrains the delivery of essential substrates such as oxygen and glucose, 
leading to the failure production of adenosine triphosphate (ATP) within the normal brain cell 
process. This leads to dysfunction of energy-dependent ion transport pumps and 
depolarisation of neurons and glia (Aliev, Obrenovich, Smith, & Perry, 2003).  
As a consequence of the membrane depolarisation, the substantial influx of calcium (Ca2+) 
allows for excitatory amino acids such as glutamate to be released into the extracellular space 
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(Dirnagl et al., 1999). At the same time, energy-dependent processes such as presynaptic re-
uptake of excitatory amino acids are impeded, further increasing the accumulation of excitatory 
amino acids in the extracellular space. The presence of these excitatory amino acids results in 
the activation of N-methyl-D-aspartate (NMDA) receptors, a specific glutamate receptor 
subtype known as metabotropic receptors. The combined over-activation of these receptors 
from accumulated extracellular excitatory amino acids contributes to the cellular Ca2+ overload 
in the neural cell (Dirnagl et al., 1999; Kehrer & Smith, 1994; Nicholls & Attwell, 1990).  
Additionally, reduced oxygen availability results in anaerobic glycolysis and accumulation of 
lactate (Brouns et al., 2008; Nicoli et al., 2003; Schneweis et al., 2001), which has been identified 
as a marker of anaerobic metabolism in stroke. The anaerobic metabolism is also a possible 
cause of secondary damage leading to infarct expansion and poor clinical outcome, particularly 
in cortical infarctions (Brouns et al., 2008; Dohmen et al., 2007; Uyttenboogaart et al., 2007). 
2.3.3 Excitotoxicity 
Excitotoxicity refers to the secondary damage caused by the pathological activation and Ca2+ 
uptake by neurons due to abnormal release of excitatory neurotransmitters from dying cells 
(Choi, 1988; Meldrum, Evans, Griffiths, & Simon, 1985; Rothman & Olney, 1986). As described 
above, excitatory neurotransmitters, especially glutamate, accumulate in the extracellular 
space, resulting in overstimulation of a-amino-3-hydroxy-5-methul-4-isoxazole propionic acid 
(AMPA), kinate and NMDA receptors on neurons. The ensuing efflux of K+ and influx of Na+ 
and Cl- across the cell membrane following deploarisation causes increased water permeation 
into the neural cells via osmosis. The oedema can negatively affect the perfusion of blood to 
the regions surrounding the infarct epicentre and can also have remote effects due to 
increased intracranial pressure, vascular compression and herniation (Marinis et al., 2010). 
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This increase in Ca2+ is thought to initiate a series of cytoplasmatic and nuclear events that 
result in cellular destruction and activate inflammatory responses, thereby generating free 
radical species that overwhelm endogenous scavenging mechanisms (Dirnagl et al., 1999; 
Ginsberg, 2008) and activation of Ca2+-dependent enzymes. These enzymes include 
proteolytic enzymes that degrade cytoskeletal proteins (Z.-L. Chen & Strickland, 1997) and 
extracellular matrix proteins (Choi, 1988, 1995), as well as phospholipase A2, calpain, 
endonucleases, adenosine triphosphatase, cyclooxygenase and NO synthase type I, resulting 
in extensive cellular damage and generating further free radical species. These free radical 
species and degradative enzymes damage the cellular membrane, allowing further 
permeability of Ca2+ ions leading to acute cell death through necrosis. However, the 
excitotoxic mechanisms can also initiate molecular events that leads to apoptosis. In addition, 
the intracellular signalling pathways activated during excitotoxicity trigger the expression of 
the genes that initiate post-ischaemic inflammation that further contributes to the ischaemic 
injury (J. T. Coyle & Puttfarcken, 1993). 
2.3.4 Oxidative stress 
Oxidative stress occurs when the production of free radicals overpowers the endogenous 
scavenging capacity of the cellular anti-oxidant defences. There is considerable evidence that 
reactive oxygen and nitrogen molecules are important mediators of tissue injury in an acute 
ischaemic stroke (P. H. Chan, 2001; Cui, Holmes, Greene, & Liu, 2000; El Kossi & Zakhary, 2000; 
Epe, Ballmaier, Roussyn, Briviba, & Sies, 1996; Fridovich, 1978; P. J. Kelly et al., 2008; Kontos, 
1985, 2001; Love, 1999; Nelson, Wei, Povlishock, Kontos, & Moskowitz, 1992; Siesjö, Agardh, 
& Bengtsson, 1989; Waring, 2002). Brain ischaemia generates superoxide (O2-), through 
xanthine oxidase and leakage from the mitochondrial electron transport chain. Superoxide is 
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the primary radical from which hydrogen peroxide (H2O2) is formed. Hydrogen peroxide, in 
turn, is the source of hydroxyl radical (OH) (Beckman & Koppenol, 1996). Nitric oxide (NO), a 
water- and lipid-soluble free radical produced from L-arginine by three types of NO synthases 
(NOS). NOS types I and III are Ca2+-dependent and constitutively expressed, primarily in nerve 
tissues and endothelial cells respectively. Upregulation of NOS type II, a form of inducible 
enzyme, is mediated transcriptionally by a variety of cytokines (Masters, 1994). Ischaemia 
causes a surge in NOS I and III activity in neurons and vascular endothelium respectively. At a 
later stage, the elevated NOS type II activity occurs in a range of cells, including glia and 
infiltrating neutrophils (F. Zhang, Xu, & Iadecola, 1995). In the context of brain ischaemia, NOS 
type I and II are deleterious. However, the production of NO in blood vessels by NOS type III 
improves blood flow to ischaemic penumbra through several mechanisms. For instance, NOS 
type III can induce vessel dilation and inhibition of platelet adhesion. It also scavenges oxygen 
radicals and has an anti-inflammatory effect through inhibition of leukocyte adhesion to the 
endothelial cell. Inhibition of NOS by asymmetrical dimethylarginine may result in decreased 
NO bioavailability (MacAllister, Whitley, & Vallance, 1994) which is associated with 
vasoconstriction (Calver, Collier, & Vallance, 1993; Kielstein et al., 2006), and increasing 
generation of free radicals (Calver et al., 1993), platelet aggregation and leukocyte adhesion 
on the endothelial surfaces, a process that may in turn aggravate cerebral ischaemia.  
The formation from superoxide and NO decomposes spontaneously to produce the 
hydroxyl radicals such as of H2O2 and O2- (Beckman, 1996; Beckman & Koppenol, 1996; 
Beckman, Ye, Chen, & Conger, 1996; L. L. Dugan & Choi, 1994; Fridovich, 1978; Iadecola, 1997; 
E. Wei & Kontos, 1990; E. P. Wei, Kontos, & Beckman, 1996). Remote effects of these hydroxyl 
radicals are possible, as H2O2 is lipid-soluble and readily crosses cell membranes while O2- 
traverses the cell membrane via the anion channel (Kontos, 2001). Hydroxyl radical is 
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regarded as very short lived but the most reactive oxygen radical, causes the most tissue 
injury (Evans & Cooke, 2004; Lennon, Martin, & Cotter, 1991; P. K. Liu et al., 1996).  
The free radicals exhibit a spectrum of harmful cellular effects, including inactivation of 
enzymes, release of calcium ions from intracellular stores, protein denaturation, lipid 
peroxidation, damage to the cytoskeleton and DNA and chemotaxis (Evans & Cooke, 2004; 
Lennon et al., 1991; P. K. Liu et al., 1996). While mitochondrial function is impaired by free 
radical-mediated disruption of the inner mitochondrial membrane, oxidation of proteins that 
mediate electron transport, H+ extrusion and ATP production, cytochrome C is released from 
mitochondria promotes a trigger for apoptosis. Given that severe oxidative stress causes cell 
death through necrosis, moderate oxidation can also progressively trigger tissue apoptosis, 
responsible for the ischaemic tissue (Marinis et al., 2010). 
Besides cerebral cellular damage, oxidative stress also increases blood–brain barrier (BBB) 
permeability through (a) activation of matrix metalloproteinases (MMP), in particular MMP-
9, a class of enzyme involved in extracellular matrix degradation (Montaner et al., 2003; G. 
Rosenberg, Estrada, & Dencoff, 1998), and (b) through endothelial cell damage (P. H. Chan, 
2001; Kontos, 1985; Siesjö et al., 1989). Moreover, free radicals influence cerebral blood flow, 
as they are strong cerebral vasodilators (E. P. Wei, Kontos, Christman, DeWitt, & Povlishock, 
1985) and, due to interaction between NO and superoxide, alter vascular reactivity to CO2, 
thereby inducing vasoconstriction instead of vasodilation (Kontos, 2001). Additionally, oxygen 
radicals increase platelet aggregability (Love, 1999). 
3.3.5 Blood–brain barrier (BBB) dysfunction  
The BBB is a network of semipermeable membranes ensuring the protection of neuronal 
microenvironments. The BBB separating the blood from the cerebral spinal fluids constitutes 
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a barrier to the passage of cells, particles and large molecules. The BBB is formed by the brain 
endothelial cells and allows the passage of water, some gases and lipid-soluble molecules by 
passive diffusion, as well as selective transport of molecules – such as glucose and amino acids 
– that are crucial to neural function. The disruption of the BBB during an acute ischaemic 
stroke may vary from 15% to 66% depending on the severity of the stroke and the timing and 
methodology of therapeutic treatments (Bang et al., 2007; Hjort et al., 2008; Hornig et al., 
1985; Hornig, Busse, Dorndorf, & Kaps, 1983; Kidwell et al., 2008; Latour, Kang, Ezzeddine, 
Chalela, & Warach, 2004; Lorberboym, Lampl, & Sadeh, 2003; Niebroj-Dobosz, Mariam, 
Lukasiuk, & Rafałowska, 1992; Suzuki, Kelley, Reyes-Iglesias, Alfonso, & Dietrich, 1995). The 
damage to the BBB has a biphasic mechanism and the damage is particularly significant after 
reperfusion (Belayev, Busto, Zhao, & Ginsberg, 1996; Huang, Xue, Karbalai, Buchan, & Preston, 
1999; Kuroiwa, Ting, Martinez, & Klatzo, 1985). The endothelial basal lamina – a thin planar 
assembly of extracellular matrix protein that supports all epithelial, muscle and nerve cells 
outside the central nervous system, which act as semipermeable filters for macromolecules 
– starts to dissipate approximately two hours after the onset of ischaemia (Hamann, Okada, 
Fitridge, & Del Zoppo, 1995) followed by rapid increase in BBB permeability (Belayev et al., 
1996). Early reperfusion may temporarily alleviate BBB alternation; however, the use of 
thrombolytic therapy and delayed reperfusion have been shown to be conversely exacerbate 
the endothelial injury (Bang et al., 2007; Hjort et al., 2008; Kastrup, Engelhorn, Beaulieu, de 
Crespigny, & Moseley, 1999; Kidwell et al., 2008). Loss of BBB function may lead to 
accumulation of bradykinin, an inflammatory mediator that causes vasodilation and drop of 
blood pressure (Aschner, Lum, Fletcher, & Malik, 1997; Kamiya, Katayama, Kashiwagi, & 
Terashi, 1993). This also affects vascular endothelial growth factor, a signalling protein that 
stimulates angiogenesis and triggers formation of new blood vessels (Abumiya et al., 1999). 
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In addition, loss of BBB functions also causes thrombin – a serine protease participant in a 
clotting process – to activate and initiate coagulating reactions (Okada, Copeland, Fitridge, 
Koziol, & Del Zoppo, 1994). Lastly, BBB activates the matrix metalloproteinases (MMPs) – a 
group of enzymes capable of degrading all kinds of extracellular matrix proteins – and other 
protease activities (A. W. Clark, Krekoski, Bou, Chapman, & Edwards, 1997; Gasche, Copin, 
Sugawara, Fujimura, & Chan, 2001; Gasche et al., 1999; Gidday et al., 2005; Heo, Han, & Lee, 
2005; Heo et al., 1999; Hosomi et al., 2001; P. J. Kelly et al., 2008; Montaner et al., 2001; 
Opdenakker et al., 2001; Rosell et al., 2008; Serena et al., 2005; S. Wagner et al., 2003). As 
described previously in Section 3.3.4, oxidative stress initiates early injury to the BBB and may 
trigger the release of MMP-9 by neurons, glia and endothelial cells that damage the BBB 
through digestion of the endothelial basal lamina (Gasche et al., 2001; Gidday et al., 2005; 
Heo et al., 1999; S. Wagner et al., 2003). After the early damage to the BBB, a second phase 
of severe BBB injury typically occurs within 24–72 hours of infarction (Kastrup et al., 1999; 
Lorberboym et al., 2003). The second phase is more complicated and results in greater tissue 
damage through leukocyte infiltration and marked MMP-9 release from neutrophils 
transmigrating to the ischaemic brain (Gidday et al., 2005; Rosell et al., 2008).  
Furthermore, the disruption of BBB allows leakage of blood components into the brain 
parenchyma, a functional tissue distinguished from connective tissue and supporting tissue. 
Extravasation of high molecular weight molecules, followed by water from osmosis, leads to 
vasogenic oedema, which contributes to secondary damage through increased intracranial 
tension. The extravasation of red blood cells may lead to haemorrhagic transformation of the 
infarct area that may turn into haemorrhagic stroke (G. J. Del Zoppo & Hallenbeck, 2000). The 
leaking BBB facilitates the transmigration of inflammatory cells, which has been shown to 
promote the post-ischaemic inflammatory response (G. J. Del Zoppo & Hallenbeck, 2000). 
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2.3.6 Ischaemic-induced vascular damage 
A series of ischaemic events targets the microvasculature, resulting not only in cerebral tissue 
damage through increased endothelial cell permeability and matrix degradation, but also in 
loss of autoregulation, the intrinsic ability of the brain to maintain a constant blood flow 
despite changes in perfusion pressure. In addition to the disrupted autoregulation, vascular 
damage can also trigger a range of aggregating factors, forming a ‘no-reflow’ phenomenon 
that contributes further to the damage from the ischaemia. 
Cerebral autoregulation is the intrinsic ability of the cerebrovascular bed to maintain a 
constant perfusion in spite of change in blood pressure (O. Paulson, Strandgaard, & Edvinsson, 
1990; Rapela & Green, 1964). When the cerebral blood pressure falls, a series of metabolic 
factors (such as hypoxia), myogenic processes (such as smooth muscle relaxation) and 
endothelial mechanisms (such as releasing of NO), all contribute to arteriolar vasodilation to 
reduce the vascular resistance in attempt to maintain the blood flow (O. B. Paulson, Olesen, 
& Christensen, 1972; Yanagisawa et al., 1988). 
The pathophysiology of impaired cerebrovascular autoregulation in acute ischaemic stroke 
is still controversial. However, the damage of focal and even global impairments has been 
demonstrated via the reperfused ischaemic brain, and ischaemia-induced endothelial 
damage may play a key role here. Endothelial injury reduces the release of NO (an 
endothelial-derived relaxing factor acting on smooth muscle for vasodilation) and 
prostacyclin (an effective vasodilator that inhibits platelets aggregation), and induces 
endothelin-1 production, which is a potent vasoconstrictor. These processes lead to increased 
vascular tone, which may further impair the blood flow in the ischaemic core and penumbra, 
negatively affecting the necessary blood flow in the ischaemic area. Endothelin-1 – which has 
been shown to be marked sensitive in the cerebral microvessels and is associated with 
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cerebral oedema – is elevated during ischaemic stroke. In addition to vasoconstriction, 
impaired autoregulation potentially leaves the vulnerable ischaemic penumbra unprotected 
against harmful blood pressure changes. Hypotension during acute ischaemic stroke is known 
to be detrimental to tissue, and hypertension may improve outcome after stroke in some 
patients but be harmful in others (Ahmed, Näsman, & Wahlgren, 2000; Cole, Drummond, 
Osborne, & Matsumura, 1990; Leonardi-Bee, Bath, Phillips, & Sandercock, 2002; Oliveira-
Filho et al., 2003; Shin et al., 2008; Zazulia, Videen, & Powers, 2007). 
The ‘no-reflow’ phenomenon and post-ischaemic inflammation are additional 
consequences of cerebral microvasculatory injury. The obstruction of the downstream 
microvascular bed after reperfusion of the occluded supply arteries is due to the presentation 
of leukocyte adhesion receptors on endothelial cells. This phenomenon is attributed to 
extrinsic compression from oedema, endothelial swelling and intravascular obstruction due 
to local activation of leukocytes, platelets and coagulations (G. Del Zoppo, 1994; G. J. Del 
Zoppo & Mabuchi, 2003; G. J. Del Zoppo, Schmid-Schönbein, Mori, Copeland, & Chang, 1991; 
Mori, Del Zoppo, Chambers, Copeland, & Arfors, 1992; Okada, Copeland, Fitridge, et al., 1994). 
2.3.7 Homeostatic activation 
Endothelial cell injury results in exposure of tissue factors to the blood that triggered the 
coagulation cascade. Subsequently, tissue factors act to convert with factor VIIa and 
phospholipid to convert factor IX to IXa. The main role of factor VII is to initiate the process 
of coagulation, in conjunction with tissue factor. Tissue factor is found on the outside of blood 
vessels and is only exposed during a vessel injury. Factor VIIa is a result of bonding between 
tissue factor and factor VII, which catalyses the conversion of factor IX to IXa, a component 
responsible for the ‘prothrombinase’ complex that converts prothrombin to thrombin 
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(Borensztajn, Peppelenbosch, & Spek, 2008). Thrombin cross-links the fibrin clots via 
cleaveation of fibrinopeptides. The fibrin molecules can aggregate, trapping platelets, clotting 
factors and erythrocytes to form blood clots (Green, 1998, 2006). In addition, 
procarboxypeptidase U, an unstable carboxypeptidase U, is formed through thrombin during 
the clotting process, which attenuates the fibrolysis (Bajzar, Morser, & Nesheim, 1996; 
Björkman, Abrahamsson, Nerme, & Mattsson, 2005; Bouma & Meijers, 2003; Hendriks, 
Scharpe, Sande, & Lommaert, 1989; Klement, Liao, & Bajzar, 1999; Knecht et al., 2006; Judith 
Leurs & Hendriks, 2005; J Leurs, Nerme, Sim, & Hendriks, 2004; Marx, Dawson, Bouma, & 
Meijers, 2002; Mattsson et al., 2002; Minnema et al., 1998; Nagashima et al., 2000; Schneider, 
Brufatto, Neill, & Nesheim, 2004; Walker & Bajzar, 2004; J. L. Willemse & Hendriks, 2007). A 
marked decrease in procarboxyoeotudase U activity occurs in the first 72 hours after 
ischaemic stroke (Heylen, Brouns, Willemse, De Deyn, & Hendriks, 2009) and in patients with 
poor response to thrombolytic therapy, probably reflecting the stronger activation of the 
procarboxypeptidase U/carboxypeptidase U pathway and thrombus propagation (Brouns et 
al., 2009; J. Willemse, Brouns, Heylen, De Deyn, & Hendriks, 2008). 
Platelets are typically activated under conditions of ischaemia and high shear stress 
(Gawaz, 2004; J. A. Zeller, Tschoepe, & Kessler, 1999). The accumulation of platelets in 
microvessels is seen within two hours of vascular occlusion (Mark Fisher & Francis, 1990; Lip 
et al., 2002), releasing a variety of biochemical mediators and catalysing interactions between 
coagulation factors that contribute to the ‘no-reflow’ phenomenon, by adhering to both 
leukocytes and microvascular endothelial cells (J. R. Chan et al., 2000; Htun et al., 2006; J. 
Zeller, Lenz, Eschenfelder, Zunker, & Deuschl, 2005; Zhaozhong, Qiuping, & Jianning, 2001). 
Platelets also can cause temporary vasospasm via release thromboxane A2 and free radicals, 
which exacerbate the inflammatory cascade by releasing chemotactic mediators for 
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leukocyte migration (Okada, Copeland, Mori, et al., 1994; J. Zeller et al., 2005). However, 
whether these mechanisms are important in ischaemic stroke remains to be elucidated. The 
endogenous fibrinolysis in ischaemic stroke is usually outweighed by ongoing activation of 
coagulation cascade and platelet activation (Barber, Langhorne, Rumley, Lowe, & Stott, 2004, 
2006; Fassbender et al., 1999; Feinberg, Erickson, Bruck, & Kittelson, 1996; Haapaniemi, 
Soinne, Syrjälä, Kaste, & Tatlisumak, 2004; J. Kelly et al., 2003; Tanne, Macko, Lin, Tilley, & 
Levine, 2006; Zhaozhong et al., 2001), which may affect overall homeostasis and indirectly 
affect the ischaemic cascade. 
2.3.8 Post-ischaemic inflammation 
Multiple cells are involved in post-ischaemic inflammation. First, microglia and astrocytes are 
activated by elevation of ROS. Astrocytes are can secrete cytokines, chemokines and the 
inflammatory factors and induce NO synthase (X. Che, Ye, Panga, Wu, & Yang, 2001; Y. Dong 
& Benveniste, 2001; Hewett et al., 1996; Yamagami et al., 1999). Microglia are the resident 
macrophages of the brain and play a critical role as resident immunocompetent and 
phagocytic cells in the central nervous system (Morioka, Kalehua, & Streit, 1993). During the 
ischaemia, microglia can transform into phagocytes and release a variety of cytotoxic or 
cytoprotective substances. Within 4–6 hours of ischaemic onset, circulating leukocytes 
adhere to the vessel walls and migrate into the brain, releasing more pro-inflammatory 
mediators leading to secondary injury of potentially salvageable tissues in the penumbra 
(Barone & Feuerstein, 1999; Becker, 1998; Chamorro & Hallenbeck, 2006; Danton & Dietrich, 
2003; Emsley & Tyrrell, 2002; Hallenbeck, 1996; Q. Wang, Tang, & Yenari, 2007). Adhesion 
molecules play a pivotal role in the infiltration of leukocytes into the brain parenchyma 
(DeGraba, 1998). The interaction between leukocyte and vascular endothelium is mediated 
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by adhesion molecules such as selectins, Vascular Adhesion Molecule-1 and Intercellular 
Adhesion Molecule-1. Neutrophils are the first leukocyte subtype; they are significantly 
upregulated in gene expression and infiltrate the area of ischaemic brain tissues (Buck et al., 
2008; Y. Tang et al., 2006), with infiltration of monocytes observed after several days of 
ischaemic onset (Buck et al., 2008; X. Che et al., 2001; Grau et al., 2001; Morioka et al., 1993; 
Stoll, Jander, & Schroeter, 1998; Y. Tang et al., 2006). 
Cytokines are important inflammatory mediators that are produced by immune cells and 
resident brain cells after ischaemia (Allan & Rothwell, 2001; Feuerstein, Liu, & Barone, 1994; 
Rothwell & Hopkins, 1995). The most studied cytokines related to inflammation in stroke are 
interleukin-1, tumour necrosis factor-alpha (TNF-a), interleukin-6 and interleukin-10 
(Fassbender et al., 1994; Tarkowski et al., 1995; Vila, Castillo, Dávalos, & Chamorro, 2000; Vila 
et al., 2003). Interleukin-1 is the main pro-inflammatory cytokine; TNF-a has pleiotropic 
function and may influence apoptosis or survival through different pathways (Hallenbeck, 
2002). Interleukin-6, on the other hand, is thought to be a largely pro-inflammatory cytokine, 
but its role in ischaemic stroke is more obscure (Tarkowski et al., 1995). Increased production 
of pro-inflammatory protein-1a and chemokines such as fractalkine following focal ischaemia 
is thought to have a deleterious effect by increasing leukocyte infiltration (Stamatovic, Keep, 
Kunkel, & Andjelkovic, 2003). In addition to the chemotactic properties, signalling for 
microglia to find debris cells, chemokines are found to directly affect blood–brain barrier 
permeability (Dimitrijevic, Stamatovic, Keep, & Andjelkovic, 2006). 
Other inflammatory cascades include upregulation of several enzymes, such as 
phospholipase A2, which enhances intracellular calcium levels leading to excitotoxicity 
reactions (as described in Section 3.3.3) and enhances the arachnoid acid cascade. The 
hydrolysis of these enzymes leads to release of arachidonic acid, which is metabolised to 
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prostaglandins or leukotrienes by cyclooxygenase and lipoxygenase respectively. Of the two 
forms of cyclooxygenase, type 1 is constitutively expressed in microglia and leukocytes 
(Schwab & Schluesener, 2003) whereas cyclooxygenase type 2 is upregulated after ischaemia 
and exerts toxic effects (Kawano et al., 2006; Nogawa, Zhang, Ross, & Iadecola, 1997) mainly 
through prostaglandins rather than ROS, although it can generate both (Manabe et al., 2004; 
Nogawa et al., 1997). The understanding of lipoxygenase pathways in brain ischaemia remains 
limited; however, leukorines known to be potent chemoattractants are believed to be 
implicated in BBB dysfunction, oedema and neuronal death (Rao, Hatcher, Kindy, & Dempsey, 
1999; Tomimoto et al., 2002). It is worth mentioning that inflammatory cells also generate 
ROS and produce MMPs, inducing more damage to the ischaemic brain (Gidday et al., 2005). 
2.3.9 Ischaemia-induced cell death 
Ischaemic injury produces necrosis, a fulminant form of cell death associated with failure of 
the plasma membrane and cytotoxic oedema of both the cell and internal organelles (Johnson 
Jr & Deckwerth, 1993; L. J. Martin et al., 1998). When the cell dies through necrosis, more 
glutamate and toxins are released into the nearby environment, affecting the surrounding 
neurons. Meanwhile, abundant brain cells undergo apoptosis during ischaemia as 
consequence of a genetically regulated program that allows cells to die with minimal 
inflammation or release of genetic materials (Choi, 1996; Hara, Niwa, Yoshimi, & Mori, 1997; 
J.-M. Lee, Zipfel, & Choi, 1999; Namura et al., 1998). Several factors determine which process 
predominates, including the local degree of ischaemia, cell maturity, the concentration of 
intracellular Ca2+ and the cellular microenvironment (Choi, 1995; J.-M. Lee et al., 1999; Leist 
& Nicotera, 1998b). Activation of glutamate receptors may promote apoptosis non-
specifically by inducing sufficient cellular injury to activate cellular sensors linked to the 
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apoptosis cascade (Choi, 1995, 1996; Leist & Nicotera, 1998a; Leist et al., 1997; Namura et al., 
1998; Thornberry & Lazebnik, 1998). In addition or alternatively, early mitochondrial 
production of ROS (L. Dugan et al., 1995) reduction of intracellular K+ (S. P. Yu et al., 1997) 
and enhancement of toxic Zn2+ influx (S.-J. Lee & Koh, 2010) may all trigger apoptosis. In 
addition, caspase-mediated apoptosis is also initiated by the release of cytochrome C, a large 
transmembrane protein from mitochondria during the apoptosis complex, which in turn 
activates caspase 3 (Green, 1998), protein-cleaving enzymes that are particularly important 
in modifying homeostasis and repairing proteins in a ischaemia-induced apoptosis. Necrosis 
is the predominant mechanism that follows acute permanent vascular occlusion in the core, 
whereas milder injury, particularly within the ischaemic penumbra, often results in apoptosis. 
2.3.10 Cerebral reperfusion injury 
The prompt restoration of the blood supply has been a priority in an attempt to reduce infarct 
size through salvation of the penumbra and to improve clinical outcomes in patients with 
ischaemic stroke (Schaller & Graf, 2004). However, reperfusion may exacerbate so-called 
cerebral reperfusion injury through multifactorial aetiology (G. J. Del Zoppo, VON KUMMER, 
& Hamann, 1998; Kidwell et al., 2001; Kuroda & Siesjö, 1997). Early recanalisation in patients 
with severe ischaemia also carries an increased risk of reperfusion related brain haemorrhage, 
which may be due to microvascular injury (Albers et al., 2006). Leukocytes appear to be 
responsible for reperfusion injury as they damage the endothelium (obstructing 
microcirculation), disrupt BBB and infiltrate the brain tissue and release cytokines, which 
propagate inflammation (Pan, Konstas, Bateman, Ortolano, & Pile-Spellman, 2007). It has 
been reported that there may be a surge in the generation of ROS during cerebral ischaemia, 
particularly at the onset of reperfusion. ROS – including superoxide, hydrogen peroxide and 
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hydroxyl radicals – are highly reactive and can break down cell membranes, damage DNA and 
create oxidation of proteins, amino acids and inactive specific anti-oxidant enzymes. Neurons 
contain abundant polyunsaturated fatty acids and produce low amounts of anti-oxidant 
enzymes, and are therefore are highly susceptible to ROS (Kehrer & Smith, 1994). 
Here, platelets play a more potent synergistic role, enhancing leukocytes in the reperfusion 
injury via the ‘no-reflow’ phenomenon discussed in Section 3.3.7 and releasing a variety of 
biochemical mediators that may lead to vasospasm and exacerbation of oxidative stress as 
well as inflammatory cascade (Crack & Wong, 2008; J. Zeller et al., 2005; Zhaozhong et al., 
2001). Additionally, breakdown of BBB and post-ischaemic hyper-perfusion may exacerbate 
vasogenic brain oedema and haemorrhage (G. A. Rosenberg et al., 2001), which further 
contribute to the neural damage. 
In summary, ischaemic injury leads to a sequence of interlinked cellular injuries through 
multiple factors with an emphasis on vascular vulnerabilities. A therapeutic target for 
ischaemic stroke leads to a complex assessment of the vascular vulnerability as well as the 
severity of ischaemia. Due to the complex cell degradation cascade during the ischaemic 
attack, neuroprotection is also becoming an important critical strategy that is as yet relatively 
underdeveloped for minimising neuron damage. Although recent research focuses on the 
survival of neurons via neuroprotection and anti-thrombotic therapies, little attention has 
been directed to investigating the role of angiogenesis (Krupinski, Kaluza, Kumar, Kumar, & 
Wang, 1994).  
While necrosis at the core of ischaemic infarct is irreversible, studies suggest that the 
penumbra may remain viable for several hours after an ischaemic event due to alternative 
blood supply from collateral arteries (Dirnagl et al., 1999). A study by Krupinski et al. (1994) 
investigating angiogenesis and ischaemic stroke suggests that adequate perfusion through 
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the penumbra can initiate angiogenesis. Evidence suggests that high blood vessel density is 
correlated with improved patient survival, independency and clinical outcome after stroke 
(Choo, 1993). There is also a strong correlation between the extent of spontaneous 
neurological recovery and the volume of penumbra that escapes infarction (Cheng et al., 2004; 
Dirnagl et al., 1999). Therefore, enhancing the angiogenic effect is another key aspect of 
improving clinical outcomes in stroke recovery. 
 2.4 Conventional management for ischaemic stroke 
Conventional management for ischaemic stroke can be summarised into three main 
therapeutic strategies, prevention, general treatment and rehabilitation (Ringleb et al., 2007). 
Each of these therapeutic domains is broad and complicated due to the nature of stroke and 
vulnerabilities of brain tissues. Current pharmaceuticals for prevention and treatment display 
considerable overlap. Anti-thrombotic therapy is primarily employed as a treatment modality, 
whereas neuroprotective strategies may be beneficial in both prevention and treatment. 
Despite the potential benefits of neuroprotective therapies, it is currently considered a 
secondary modality due to the nature of ischaemic stroke and emergency priorities. Stroke 
rehabilitation is focused not on prevention or treatment but, rather, on recovery of motor 
and cognitive function and subsequent quality of life. Despite the variety of available 
pharmaceuticals and treatment plans, there are significant shortfalls with each of the 
therapeutic domains that have yet to be overcome (Patel & McMullen, 2017; Ringleb et al., 
2007; van der Worp & van Gijn, 2007). 
2.4.1 Anti-thrombotic therapy 
General treatment usually occurs in a hospital setting after the onset of stroke. Treatment 
method varies depending on the severity and the time of treatment after onset. The primary 
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therapeutic aims are to minimise the cerebral necrosis that is usually caused by arterial 
occlusion or thrombosis and to prevent reoccurrence of ischaemic attack (Patel & McMullen, 
2017; Ringleb et al., 2007). 
Acute management, such as intravenous thrombolysis with intravenous tissue 
plasminogen activator (rtPA), is given within the first six hours of onset of ischaemic stroke to 
dissolve thrombotic embolisms (Ringleb et al., 2007). This therapy has been found to decrease 
post-stroke dependency. However, a review by Wardlaw et al. (Wardlaw et al., 2009) 
evaluating the benefit-to-death ratio suggests that thrombolysis therapy significantly 
increases the death rate due to a high incidence of cerebral haemorrhage. 
Anti-platelet treatment is considered as a valuable primary treatment and secondary 
preventative modality for ischaemic stroke (Ringleb et al., 2007). However, evidence suggests 
the use of anti-platelet therapy could increase the risk of fatal or disabling intracranial 
haemorrhage (Sandercock et al., 2008). While there are numerous anti-platelet 
pharmaceuticals available, aspirin is the most common anti-platelet agent employed for 
ischaemic stroke (Mohr et al., 2001; NSF, 2013; Sandercock et al., 2008). Evidence from two 
large randomised, non-blinded intervention studies indicates that aspirin is safe and effective 
when started within 48 hours post- stroke and is beneficial for acute ischaemic stroke (Z. Chen 
et al., 2000; Sandercock et al., 2008).  
As anti-platelet therapies such as aspirin also increase the risk of intracranial haemorrhage, 
studies have shown that its use in combination with thrombolysis treatment significantly 
increases death rate from all causes, including neurological or intracranial haemorrhage 
(Sandercock et al., 2008). Furthermore, studies suggest that long-term use of aspirin increases 
the risk of gastrointestinal bleeding and irritation and that this adverse effect is likely to be 
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more apparent in elderly individuals (Guazzi, Brambilla, Reina, Tumminello, & Guazzi, 2003; 
Silagy et al., 1993).  
Anti-coagulants such as heparin and warfarin are another strategy for treatment and 
prevention of ischaemic stroke. This therapy is typically employed in patients with existing 
emboli such as deep-vein thrombosis. According to a review by Gubitz et al. (2008), anti-
coagulants do not produce any significant overall short- or long-term reduction in death and 
disability. Despite this, anti-coagulants appear to result in fewer recurrent ischaemic stroke 
incidents; however, this benefit is entirely offset by a similarly-sized increase in intracranial 
haemorrhage (Gubitz et al., 2008; Ringleb et al., 2007). 
2.4.2 Neuroprotection therapy 
The primary goal of neuroprotective therapy is to salvage the ischaemic penumbra (Dirnagl 
et al., 1999). It has been well documented that abrupt deprivation of oxygen and glucose to 
neuronal tissues elicits a series of pathological cascades leading to the spread of neuronal 
death. However, neuroprotective treatment has yet to be implemented in conventional 
treatment guidelines due to a lack of solid clinical evidence (Patel & McMullen, 2017; Ringleb 
et al., 2007). 
For the past two decades, neuroprotective agents designed to block these cascades – 
including glutamate receptor antagonist, calcium channel blockers, anti-inflammatory agents 
and free radical scavengers – have been investigated in animal models of cerebral ischaemia. 
Numerous agents have been found to reduce infarct size in rodents, rabbits, and primate 
stroke models (Gorelick et al., 1999; Osuntokun, Bademosi, Akinkugbe, Oyediran, & Carlisle, 
1979) However, translation of neuroprotective benefits from laboratory experiments to 
clinical trials was not successful (Cheng et al., 2004; Patel & McMullen, 2017).  
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While blocking glutamate receptors can protect against neurological excitotoxicity, these 
glutamate receptor antagonists exhibit serious adverse effects, such as psychotomimesis, 
respiratory depression and cardiovascular dysregulation. The benefits found in clinical trials 
have been outweighed by these effects and long-term preventative use is discouraged 
(Dirnagl et al., 1999; Patel & McMullen, 2017).  
Glutamate receptor antagonists such as Selfotel act on various glutamate receptor sites 
throughout the central nervous system (Grotta et al., 1995; Q. J. Wu & Tymianski, 2018). A 
phase III trial with Selfotel was terminated because of a substantial increase in the adverse 
event-to-benefit ratio. Eliprodil is a strong antagonist that acts on the polyamine modulator 
site; however phase III trials showed no efficacy upon futility analysis and the trials were 
stopped prematurely (Gotti et al., 1988; O'Neill, Hicks, & Ward, 1996; Patat, Molinier, 
Hergueta, & Brohier, 1994). Aptiganel (Cerestat, CNS 1102) is a non-competitive NMDA 
glutamate receptor blocker with a relatively short half-life. Although it reached phase III trial 
status, Aptiganel was similarly found to be ineffective for acute stroke therapy (Aronowski et 
al., 1994; Cohen, Hasegawa, & Fisher, 1994) due to poor tolerance of the drug and a short 
therapeutic window (Q. J. Wu & Tymianski, 2018). 
Clinical trials employing ion channel modulators – including calcium channel antagonists, 
potassium channel activator and sodium channel blocker – were all terminated prematurely 
due to lack of sufficient benefits (Cheng et al., 2004; Patel & McMullen, 2017).  
Free radical-trapping agents such as Citicoline (cytidyl diphosphocholine) were studied in 
preclinical and clinical trials. Citicoline is a phosphatidylcholine precursor that has membrane 
stabilisation properties but may also have other neuroprotective properties. Preclinical 
studies in animal stroke models showed that Citicoline improved neurological outcomes and 
reduced infarct size (D'Orlando & Sandage Jr, 1995; Schäbitz et al., 1999). However, the 
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clinical phase III trials did not show efficacy despite employing a variety of dosing schedules 
(W. Clark, Warach, Pettigrew, Gammans, & Sabounjian, 1997; W. M. Clark et al., 1999)  
Other free radical-trapping agents, such as NXY-059 and magnesium sulphate, have not 
shown significant clinical benefits (Ringleb et al., 2007). Research into the use of thrombolysis 
rtPA followed by uric acid-based anti-oxidant therapy is currently in phase II study (Amaro et 
al., 2007). While researchers continue to investigate the potential discrepancies between the 
preclinical and clinical outcomes of these neuroprotective agents, pre-existing agents such as 
hydroxymethylglutaryl co-enzyme A reductase inhibitors, known as statins, have been 
recommended in the current acute ischaemic stroke management guidelines. Eighty-nine 
patients treated chronically with statin were evaluated under withdrawal of statin for three 
days and immediate administration of 20mg of atorvastatin per day. Results indicated a 
significant association of statin withdrawal with death rate and dependency level. This may 
indicate the potential neurological protection possessed by statin (Blanco et al., 2007).This 
was supported by a small retrospective study demonstrating that statin may potentially 
decrease the infarct volumes in those who suffered acute stroke (Nicholas et al., 2008). 
However, both studies include patients with chronic pre-treatment with statin; whether acute 
administration of statin provides neuroprotective benefits remains unclear. 
2.4.3 Post-stroke rehabilitation 
Even with optimal stroke unit care, including thrombolysis, less than one-third of patients 
recover fully from stroke (Hacke et al., 2004). Rehabilitation aims to assist people with 
disabilities to reach and maintain optimal physical, intellectual, psychological and social 
function. It is a fundamental goal of post-stroke treatment to increase independency and 
functional improvements. Current available rehabilitation modalities such as physiotherapy, 
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occupational therapy and nursing can help to reduce bed days for selected stroke patients 
(Feigenson, 1979). A meta-analysis concluded that continuous rehabilitation within the first 
year after discharge from hospital can reduce the risk of functional deterioration and improve 
activities of daily living (Legg, 2004). However, this improvement is largely associated with the 
quality of the rehabilitation as opposed to the duration. 
Despite these benefits, cognitive deficits are common following stroke and have a 
significant impact on quality of life of stroke patients. There is currently no evidence 
supporting the efficacy of specific memory and cognitive rehabilitation (Das Nair & Lincoln, 
2007). This cognitive aspect of post-stroke rehabilitation is particularly important, as 
cerebrovascular incidences have been shown to correlate with increased risks of severe 
cognitive deficits such as dementia (Ivan et al., 2004; Tatemichi et al., 1994). 
In summary, current conventional management of stroke is limited as it narrowly focuses on 
survival principles by dissolving/preventing emboli formation. The majority of the therapeutic 
benefits of anti-platelets and anti-coagulants are offset by dangerous adverse effect.  
While neuroprotection is important to reduce dependency rates, no standardised 
neuroprotective treatment is currently recommended in the clinical guidelines. Consequently, 
there is an urgent need to identify effective therapies that are not only safer but also can treat 
the underlying pathological conditions associated with stroke. Natural and traditional 
medicine typically retains insights for strategies in health preservations. It has made valuable 















Chinese herbal medicine (CHM) is the most widely practiced form of herbalism in Asia. CHM is 
based on a sophisticated medical theory and practice that is distinctly different from orthodox 
Western medicine (Sucher, 2006). It is most appreciated for its individualistic application to 
cases and application in conjunction with other modalities, such as acupuncture, for debilitating 
diseases affecting neurological activities such as stroke (X. Zhang, Liu, & Kang, 2016). 
Most traditional therapeutic formulations of CHM consist of a combination of several 
herbs. The combination of herbs is thought to maximise therapeutic efficacy by targeting 
multiple therapeutic areas and facilitating synergistic actions, and to ameliorate or prevent 
potential adverse effects (Bensky, Gamble, & Kaptchuk, 2004; Gong & Sucher, 1999). 
Orthodox drug therapy has been subject to critical analysis by the evidence-based medicine 
movement, and it is desirable that herbal medicine should be subject to the same kind of 
scrutiny for safety and efficacy (Barrett, Kiefer, & Rabago, 1999; Sucher, 2006). However, a 
number of issues make the evaluation of herbal medicine a very challenging task. For example, 
the active components of many medicinal herbs are still poorly understood; scientific data on 
the efficacy and mechanism of action of single herbs are lacking; rigorous quality control 
measures for these herbs have not been well-established; and interactions between multiple 
bioactive components and multiple herbs are largely unknown (E. Chan, Tan, Xin, Sudarsanam, 
& Johnson, 2010). 
The application of CHM is not used based solely on its pharmacological principles but also 
on Chinese medicinal theories and principles (X. Zhang et al., 2016). A large number of CHM 
products included in the Chinese pharmacopoeia are based on empirical evidence rather than 
the best evidence in the systematic hierarchy. It is important to note that TCM has played a 
unique role in Chinese culture and influenced its use within the Chinese population. Chinese 
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medicine has been the medicinal mainstream for the Chinese people for more than 3000 
years. The empirical evidence documented throughout its history influences therapeutic 
strategies for many diseases and ailments even today. While Western medicine dominates 
mainstream practices globally, Chinese medicine still plays a significant role aligned with its 
historical developments and clinical evidences. 
Research on Chinese medicine has grown substantially over recent decades in an attempt 
to understand the effectiveness and efficacy of its interventions. Significant progress has been 
made in defining, evaluating and standardising CHM in China. An increasing number of CHM 
products in China have adopted standardisation and patent strategies to control the quality 
and efficacy of medicinal sources. These medicines have been used for a broad range of 
clinical indications, including some common diseases such as stroke. In recent decades, 
hospitals in China have adopted TCM treatment, in particular herbal medicine, for the 
management of stroke (Feigin, 2007; M. Liu et al., 2007).  
Preclinical studies suggest that the use of herbal medicines can increase neurological 
recovery and enhance functional outcomes in stroke patient and, thus, may be beneficial in 
post-stroke rehabilitation (I. Lee, Lee, Chang, Chien, & Lin, 2005; M. Liu et al., 2007; FL Shi, 
Hart, Sherman, & Tegeler, 1989). According to Chen et al. (Z. Chen et al., 1997), over 66% of 
physicians in China incorporate some form of TCM treatment for acute management of 
ischaemic stroke. It is estimated that 10-20% of all healthcare services is solely provided by 
the TCM sector in China (Jiang, Zhang, Cao, Chan, & Lu, 2011).  
 
Nao Xin Qing (NXQ) is a standardised and patented herbal extract from the leaves of 
Diospyros kaki that has been used for many years in China for the treatment of apoplexy 
syndrome, coronary artery disease and ischaemic stroke (Bei, Peng, Ma, & Xu, 2004; Bei, Zang, 
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et al., 2009; Y. Cai & Yang, 2001). The key bioactive components of D. kaki have been 
identified as flavonoids (particularly quercetin and kaempferol) (Bei, Peng, Ma, & Xu, 2005b). 
Data from previous studies have shown D. kaki has several therapeutic effects including anti-
thrombotic, neuroprotective, haemostatic, anti-oxidative, cholesterol-lowering, and anti-
hypertensive effects, thereby presenting a potential therapeutic option for both treatment 
and prevention of ischaemic stroke (Y. Cai & Yang, 2001; Y. Yu, Yu, & Guo, 1988). The 
preliminary evidence suggests there are potential therapeutic benefits of NXQ for ischaemic 
stroke; however, the mechanisms remain unclear.  
The current chapter aims to provide an overview of the current status of CHM (both 
traditional and patented forms) for the treatment of ischaemic stroke, including their use, 
efficacy and effectiveness and safety profile. In addition, an overview of the current evidence 
of NXQ use for ischaemic stroke will be discussed. 
3.2 Perspective of TCM 
TCM originated in China over 3000 years ago and is a form of medicine that integrates 
philosophical concepts and empirical experiences into clinical practice (Deadman, 2006). The 
concept of health in TCM has been described as a holistic therapeutic intervention, in which 
the balance between the mind, body and spirit is involved. Disease prevention is considered 
in the fundamentals of TCM, emphasising body’s self-healing mechanisms; when balance 
within the body is achieved, diseases will fade and good health be maintained. To achieve this, 
TCM offers a complex framework comprising numerous integrated theoretical components 
that describe various aspects of human physiology and pathophysiology (H.-z. Wu & Fang, 
2013).  
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These theoretical components can be categorised into acupuncture and meridian theory 
(Jing Luo); visceral theory (Zangfu); and qi, blood, jing and body fluids (Jinye). All these 
theoretical approaches have yet to be sufficiently explained using biomedical medicine and 
modern science (Lu, Jia, Xiao, & Lu, 2004). Despite the inadequate scientific explanation of 
these theoretical concepts, TCM provides a comprehensive framework that allows for the 
integration of every possible ‘symptom’ and consequently, a diagnostic model that 
encompasses individual physiological systems (e.g. respiratory or cardiovascular) as well as 
the body and mind in its entirety (H.-z. Wu & Fang, 2013). While biomedical science employs 
the same fundamental concepts in diagnostics, the symptomology and pathological diagnoses 
employable in biomedicine are considerably narrower and more focused. This is one of the 
distinguishing characteristics of TCM; from symptomology to diagnosis to treatment, the 
therapeutic scope approaches the body and mind in a holistic fashion, thereby allowing 
individualised diagnoses and treatment for a specific set of symptoms (B. Zhu & Wang, 2011). 
In comparison to the more restricted perspective of biomedicine, this holistic paradigm is 
difficult to replicate and challenging to adequately combine with the ‘gold standard’ model 
of randomised control trials (Y. Liu, 1988; Wiseman, 1996). 
3.2.1 TCM nomenclature 
While it is beyond the scope of this review to discuss each aspect of TCM theory, an important 
distinguishing feature of TCM is the nomenclature employed to describe various physiological 
process or systems. The term ‘meridian’ and collaterals in TCM can be interpreted as the 
passageways of energy. Energy travelling within these passageways interconnects with 
viscera to maintain healthy function and life. When the flow of energy within these 
passageways is disturbed, illness may present (Y. Liu, 1988; Lu et al., 2004). Terms such as the 
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‘liver’, ‘kidney’ or ‘heart’ do not describe the physiological organ within the human body, but 
rather a system of physiological processes (Lu et al., 2004). An example of this would be the 
‘liver’, a label that encompasses aspects of circulation and emotion. Herbal medicines used in 
stroke treatment are often associated with two vital components in TCM, Qi and ‘blood’. Qi 
is typically explained as energy, a vital source that is not visible to the naked eye, while ‘blood’ 
typically refers to the biomedical perspective of blood. Thus, the TCM terminology does not 
equate to the common understanding of the system or the substances themselves. The terms 
should not be confused with the common definitions or biomedical definitions.  
3.2.2 Ischaemic stroke in TCM perspective 
TCM possesses its own diagnostic system and disease patterns. In the classical literature, 
ischaemic stroke as a disease name was not mentioned; however, clinical terms such as Cu 
Zhong and Zhong Feng were used to describe symptoms such as sudden collapse, weakness 
or numbness or paralysis of the face, arm or leg; difficulty speaking and understanding; 
dizziness, loss of balance or an unexplained fall. These symptoms correspond well with those 
of a stroke with a ischaemic or haemorrhagic cause (Tsai, 2011). The diagnosis in Chinese 
medicine is ‘syndrome’ (Zheng)-based. For instance, a particular syndrome (Zheng) is 
characterised by a patient’s signs and symptoms, the location of the underlying ‘lesion’, its 
aetiology, and the specific relationship between the patient’s resistance and the pathological 
agents (Lu et al., 2004). Thus, a syndrome is the concrete (physical) manifestation of a 
fundamental pathological process combined with the incidental aspects such as the patient’s 
physical and psychological constitution and the physical and social environment. As such, 
these ’syndromes’ do not, in general, correspond to the disease classification of Western 
medicine (Sucher, 2006). Moreover, TCM is individualised medicine, in the sense that each 
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patient is treated with a specific but varying combination of drugs chosen on the basis of the 
particular presenting syndrome (symptom complex) observed at a given point in time, rather 
than a nosologically defined disease. 
TCM diagnostic theory was constructed based on four major diagnostic methods: 
observation, auscultation/olfaction, questioning and palpation. Before the advanced 
magnetic resonance imaging system and other advanced diagnostic tool existed, TCM 
practitioners were making disease judgement based on these four methods. All of these 
methods are equally important, as they provide important indicators to help practitioners 
categorise and subcategorise the cause of disease as well as evaluating the patient’s current 
bodily constitution. This evaluation directly affects the practitioner’s therapeutic strategy 
plan, with medicine prescribed accordingly.  
With time and evolution of the TCM itself, several patterns were identified as contributing 
to ischaemic stroke. In the recent years, some countries with Chinese medicine regulatory 
boards haves systematically categorised several constitutional and pathological patterns that 
can lead to ischaemic stroke (Table 1). 
Table 1: Clinical symptoms categorised based on Chinese medicine syndromes differentiation of stroke 




Main clinical Symptoms Associated clinical symptoms 
Main Stroke 
characteristics 
Wind Pattern  Paralysis of face and tongue, 
slurred speech, slowed reaction, 
dull and dark complexion, blurry 
vision, body paralysis 
Uncontrolled drooling, 
somnolence, acute onset, 
thick tongue coating 
Category 1 Phlegm pattern Uncontrollable bowel and 
urination, difficulty in speech, 
nausea and vomiting 
Difficult swallowing, stiff 
tongue 
Category 2  
(pattern 
translatable 
between I and II) 
I. Blood stasis 
pattern 
Dark dull tongue body, and 
purplish blue vein underneath 
the tongue 
Chopping and knot pulse 
II. Yin deficiency 
pattern 
Irritation, easily angry, sudden 
severe headache 
Fixed continuous headache, 
numb face, sudden numbness 
of the tongue 
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Category 3 Qi deficiency 
pattern 
Lassitude, tiredness, minimal 
speech 
Dizziness, drowsiness, uneven 
pulse, dull tongue body 
Category 4 Fire -heat pattern Bitter taste, dry throat, 
numbness of limbs, dry mouth 
and lip 
Red complexion, half body 
numbness, weakness of the 
limbs, vertigo 
 
The major principle of ischaemic stroke refers to obstruction and stagnation. A study 
conducted by a Taiwanese research group looking at the occurrence rates of acute ischaemic 
stroke cases based on pattern differentiation noted that 98.4% of the cases belong to the 
stagnation pattern, followed by the wind pattern, phlegm pattern, deficiency pattern, heat 
pattern and yin deficiency with hyperactive yang pattern (Tsai, 2011). Depending on the 
causal factors, cases are typically further sub-categorised into more precise pattern diagnosis; 
in many cases, syndromes may overlap. For instance, Tsai et al. (2011) report that of the 253 
studied acute ischaemic cases, 99.6 % had more than one pattern at the time of onset. On 
average, 30% of the studied cases had four overlapping syndromes. This indicates the 
complexity of the ischaemic disease itself; therefore, the therapeutic strategies are typically 
individualised. Nevertheless, the patterns of ischaemic stroke were mostly associated with 
the above six types, particularly the stagnation type. Hence, the majority of the research 
focuses on blood-regulating herbs such as Panax notoginseng, known as Sanchi, and Salvia 
miltiorrhiza, known as Danshen. Because TCM theory visualises broader aspects involving 
more than body physiology (for example, emotional mediators, acute or chronic, can be an 
aetiology themselves), the therapeutic strategies are diverse. For example, the treatment 
approach for ischaemic stroke typically incorporates blood regulation and stasis resolution. It 
is either ‘excess’ that obstructs the flow of the blood, or ‘insufficiencies’ that lead to other 
ischaemic changes. The blood itself in TCM can be cross-referenced with multiple body 
systems; in contrast to the cardiovascular system in Western medicine, in TCM, ‘heart’ and 
‘liver’ is also considered to encompass metabolic systems (the spleen and stomach) and 
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immune systems (the kidneys and bladder). Although the treatment approach for ischaemic 
stroke in TCM varies between individuals, the treatment principles typically incorporate blood 
regulation and stasis resolution.  
3.2.3 Chinese herbal medicine for ischaemic stroke 
3.2.3.1Complexity of CHM and its use 
Chinese herbal pharmacotherapy is as old as TCM itself (S. Yang, 1998). The Chinese Materia 
Medica has grown substantially over the last 2000 years, from a few hundred documented 
herbs to more than ten thousand including substances from animal, mineral and plant sources. 
For example, an authoritative 10-volume compendium of Chinese Materia Medica lists more 
than 11,228 plant species, 1150 animal species, and 74 minerals as sources of drugs and 
interactions for their use (Sucher, 2006). The official pharmacopoeia of the People’s Republic 
of China lists information on some 530 traditional drugs, including some 460 herbal drugs, 
more than 40 drugs of animal origin, human hair and placenta, and some 30 minerals (hui, 
2000). Individual herbal drugs can be derived from more than one species.  
The drug a patient take home from the pharmacy based on a doctor’s prescription is not 
‘fresh’, but ‘processed’. Herbs and other natural materials become drugs only after processing. 
The specific possessing procedures play an important role in Chinese medicine (K. Chen, Xu, 
Hao., 2003). Processing can prevent or abate adverse effects of some drugs that would be 
toxic in unprocessed form. It can enhance or reduce the potency of drugs and even change 
their therapeutic effect. Processing is also used to make drugs easier to store and prepare 
and to make them more palatable and more convenient to take. There are various method of 
processing, including cutting, cleaning, rinsing, grinding, softening, parching, roasting, 
steaming and boiling (K. Chen, Xu, Hao., 2003). 
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Most CHM formulations consist of a combination of up to 20 herbs. In fact, combination 
therapy is a fundamental principle of Chinese medicine. The combination of multiple herbs in 
complex formulations (and the presence of multiple active compounds even in single herbs) 
is thought to maximise therapeutic efficacy by facilitating synergistic actions (mutual 
reinforcement) among the herbs and ameliorating (mutual restraint) or preventing (mutual 
detoxification) potential adverse effects at the same time as targeting one or several 
pathophysiological mechanisms (mutual assistance) (Gong & Sucher, 1999). Some herbs may 
be weakened (mutual inhibition) in their therapeutic effects when they are combined; others 
may become outright poisonous or cause serious adverse effects in combination, which must 
be avoided (K. Chen, Xu, Hao., 2003). While herb–herb interactions have been explored since 
the origins of TCM, the treatment effects and efficacy continue to exhibit strong discrepancies 
between practitioners. Because TCM emphasises individualised therapy, on the basis of the 
particular presenting syndrome (symptom complex) observed at a given point in time, rather 
than a nosologically defined disease, standardisation becomes impossible. This creates 
potential safety risks, particularly with time-sensitive diseases such as stroke. Therefore, in 
modern times TCM therapy has been used mostly as an adjunct therapy to Western medicine, 
particularly with diseases requiring surgical attention. However, TCM may be able to 
contribute to the management of major systemic disorders if more scientific validation and 
development is conducted to modernise these medicines.  
3.2.3.2 Current evidence on CHM for ischaemic stroke 
To better validate the efficacy and effectiveness of CHM for its various clinical applications, it 
is important to standardise herbal medicines’ resources and chemical composition. A series 
of scientific methods, including chemical characterisation, preclinical in vitro and in vivo 
testing and clinical evaluation have been commonly used in evaluation of CHM products.  
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Many TCM herbs that can be potentially used in stroke therapy have been investigated 
and some key bioactive components characterised. Chinese herbs that possess blood-
regulating properties have been most investigated, as they have traditionally been used for 
the blood stagnation pattern, which is related to ischaemic stroke pathology. For example, 
Danshen (Salvia miltiorrhiza) and Sanchi (Panax notoginseng) were investigated intensively 
and the bioactive constituents of these herbs were found to improve microcirculation in the 
brain, protect against reperfusion injury, possess neuroprotective and/or anti-inflammatory 
properties, and inhibit apoptosis (X. Chen et al., 2008a; B Wu, M Liu, & S Zhang, 2007; Yuan, 
Zeng, Luo, Li, & Wu, 2008). A number of herbs or herbal formulations that have been used 
clinically for treating ischaemic stroke are discussed below.  
3.2.3.3 Single herbs and herbal formulations for ischaemic stroke 
3.2.3.3.1	Salvia	miltiorrhiza	(Danshen)	
Danshen is one of the herbs that have been used as single extract or in complex herbal 
formulations either orally or intravenously for the treatment of ischaemic stroke in modern 
China. It is a dried root of S. miltorrhiza Bunge of the Labiatae family and contains several 
important bioactive components, contributing to its therapeutic effects. Tanshinone, 
isotanshinone and hydroxytanshinone are the important ingredients. Pharmacological 
studies indicate that Danshen can be used for dilating the cardiocerebral vessels, suppressing 
the aggregation of platelets, improving circulation, removing blood stasis, protecting against 
ischaemic reperfusion injury and enhancing the tolerance of ischaemic tissue to hypoxia 
(CMMCC 1998; Li 2000). Danshen was found to protect against cerebral injury from cerebral 
ischaemia reperfusion in rats. The model was designed to induce cerebral reperfusion injury 
by occlusion of the middle cerebral artery for two hours and then by reperfusion (X.-Y. Liang 
et al., 2013). The author reports that Danshen significantly protects against ischaemic 
46 
reperfusion injury by decreasing pro-inflammatory factors such as CRP, IL-8, IL-10, NSE and 
TNF-a, suggesting a strong anti-inflammatory property of the herb. The same group of 
researchers further demonstrated protection of cerebral damage by upregulating angiogenic 
mechanism TGF-B1 positive expression, which promotes blood circulation to the infarcted 
brain (X.-Y. Liang et al., 2013). 
Furthermore, the main active components found in Danshen, tanshinones, have been 
shown to exert neuro-protective effects in rat models with transient focal cerebral ischaemia. 
Lam et al. (B. Lam et al., 2003) demonstrated that 16mg/kg of tanshinones reduced the 
infarction size by approximately 30% and significantly improved the neurological functions in 
MCAO-induced ischaemia stroke models in mice. The authors did not elaborate the potential 
mechanism of actions underlying this observation. However, it was believed that tanshinones 
could potentially inhibit platelet aggregation and lessen the inflammatory response by 
reducing both neutrophil phagocytosis and leukocyte infiltration in the infarct region (J. D. 
Adams, Wang, Yang, & Lien, 2006). Further, Danshen has found to inhibit angiotensin-
converting enzyme (ACE) to lower the blood pressure and dilate arteries (Gao, Xu, Deng, & 
Zhang, 2004; Kang, Oh, Chung, & Lee, 2003).  
Despite the preliminary evidence from preclinical studies, the efficacy and safety profile 
for Danshen’s use for acute ischaemic stroke remains inconclusive. While no clear evidence 
of the efficacy of Danshen for acute ischaemic stroke was identified, it has been widely used 
in both Western medicine hospitals and traditional Chinese medicine hospitals in China (Bo 
Wu, Ming Liu, & Shihong Zhang, 2007). Danshen and its patent form are considered a standard 
treatment in clinical practice and used as a standard control intervention in clinical trials (Bo 
Wu et al., 2007). A limited quality-controlled trial was conducted to evaluate the clinical 
efficacy and safety profile of Danshen. Wu et al. (2007) evaluated six randomised controlled 
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trials of Danshen for acute ischaemic stroke, with a total of 494 participants involved. Meta­
analysis of these six trials showed that Danshen agents may improve neurological and 
functional outcome after acute ischaemic stroke, but this result should be interpreted with 
caution because of the poor methodological quality of the included trials and the small 
numbers of participants. Overall, the findings remain inconclusive due to methodological 
problems such as inadequate concealment and reporting of concealment, safety profile, and 
adverse events. No detailed evaluation was conducted to review the potential drug–herb 
interaction against standard orthodox treatments such as anti-coagulant or anti-platelet 
agents.  
3.2.3.3.2	Panax	notoginseng	(Sanchi)	
Sanchi (Panax notoginseng; also known by other names include Jinbuhuan, Tianqi, Panlongqi, 
Xueshen, Tiansanqi and Shensanqi) is a Chinese medicinal herb used for promoting blood 
circulation and is commonly used for the treatment of acute ischaemic stroke. Sanchi is the 
dry root of the Araliaceae plant, and its main active component attribute to its therapeutic 
function was known as Panax notoginseng saponins (PNS). Sanchi has been commercialised 
for patent medicine, known as Xuesetong, Xuesaitong Xueshuantong Lulutong, 
Zhengkangnaoming, Sanchitongshu, and Xinaotai, all of which are used for cardio- and 
cerebrovascular diseases (X. Chen et al., 2008a). Sanchi is known as an expensive and precious 
herb, as are P. ginseng (Renshen) and P. quinquefolius (Huaqisheng). Many of the saponines 
found in Sanchi are similar to those in Renshen, but most notoginsenosides are dammarane-
type tetracyclic triterpene saponins (Matsuura et al., 1983). Other saponins, such as 
notogisenosides R1 and R2, are found in Sanchi but not Renshen or Huaqishen (Ng, 2006). 
Apart from PNS, Sanchi also contains active component such as dencichine, amylose, flavanol 
glycosides, flavanones and naphtha (T. Wang et al., 2016). Previous studies demonstrate that 
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PNS is likely to dilate cerebral blood vessels, promote cerebral blood contribution (Ma, 1998; 
J. X. Wu, Sun, J. J., 1992), inhibit thrombosis and platelet aggregation (J. Xu, 2003), decrease 
serum lipid (Lv 2004), restrain atherosclerosis (A. Liu, 2005), reduce oxygen free radicals (E. 
Dong, Peng, LF., Gao, GL. , 1990) and inflammatory response (N. Li, Sun, J., Wang, Y., Li, XH. , 
1999), relieve cerebral oedema (Yao & Li, 2002) and improve cerebral cell proliferation and 
decrease infarction quantity after ischaemic reperfusion damage (X. Hu, Zhou, D., Zhou, DM. , 
2004; X. Hu, Zhou, DM., Zhou, D. , 2004). In addition, PNS is also reported to alleviate pain, 
promote calm and increase intelligence and memory (Guo, 2004; H. Yang, Zhang, J. , 2005). 
Although Sanchi has been shown to have promising effects in preliminary studies, clinical trial 
translation was somewhat inconclusive.  
A systematic review conducted by Chen and colleague (X. Chen et al., 2008b) evaluated 
eight randomised controlled trials with a total of 660 cases of acute ischaemic stroke cases, 
administering Sanchi or its patent extract as an co-intervention in addition to the standardised 
anti-platelets agent. The total administrating dose was between 200 and 525mg per day over 
14, 20 and 28 days. Subgroup analysis suggests that Sanchi capsules (200mg/day) given within 
one month of stroke onset (RR 0.22, 95% CI 0.11 to 0.45) were more efficacious in improving 
neurological deficit than Sanchi injection (200mg/day) given within 72 hours of stroke onset 
(RR 0.40, 95% CI 0.20 to 0.80). Further to this, the funnel plot presented asymmetrically, 
suggesting a high risk of bias in assessing the treatment effects. The mortality rate was 
extremely low in the studies, indicating that these researchers tended to choose patients with 
mild stroke. 
3.2.3.3.3	Classical	Chinese	medicine	formula	for	ischaemic	stroke	
In addition to Danshen and Sanchi, several formulas were commonly used for ischaemic 
stroke associated conditions. These include Xue Fu Zhu Yu decoction, which consists of 11 
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herbs: Danggui (Angelica sinensis), Shendihuan (Rehmannia glutinosa Libosch), Taoren 
(Prunus persica L. Batsch), Honghua (Carthamus tinctorius L), Zhiqiao (Citrus aurantium L), 
Chishao (Paeonia lactiflora Pall), Chaihu (Bupleurum chinensis), Gancao (Glycyrrhiza uralensis 
Fisch), Jiegeng (Platycodon grandiflorum), Chuanxiong (Ligusticum chuanxiong) and Niuxi 
(Achyranthes bidentate) (Scheid & Scheid, 2009). Xue Fu Zhu Yu decoction has been used 
traditionally to regulate the blood and remove stasis, and has a strong analgesic effects. It has 
been used in cases of coronary artery diseases, hypertension, hyperlipidaemia, 
atherosclerosis, epilepsy and stroke with patterns correlating to blood stasis. While it is 
difficult to evaluate the mechanism of action, synergism and antagonisms between the herbs 
of the formula, some preliminary data have demonstrated its potential pharmacological 
actions (Scheid & Scheid, 2009).  
Song et al. (2013) used an NMR-based plasma metabolomic method to evaluate the effects 
of Xue Fu Zhu Yu decoction on hyperlipidemic rats, suggesting that the decoction can 
ameliorate hyperlipidaemia by decreasing the accumulation of ketone body (β-
hydroxybutyrate) and acetyl-glycoproteins, enhancing glutathione (GSH) biosynthesis, 
partially reversing energy and lipid metabolism disturbance (Song et al., 2013). β-
hydroxybutyrate, as a ketone body, is produced by the oxidation of fatty acids, primarily in 
liver. β-hydroxybutyrate is normally exported to peripheral tissues, particularly brain tissues, 
that have no other non-glucose-derived source of energy (Newman & Verdin, 2014). The 
continuous accumulation of β-hydroxybutyrate causes ketoacidosis, which can lead to a 
potentially life-threatening condition known as metabolic acidosis (Daum et al., 1973). GSH is 
the major natural anti-oxidant that can combat oxidative injury by reducing H2O2. Depletion 
of GSH leads to increased levels of ROS, causing lipid peroxidation, e.g. the oxidation of LDL 
to ox-LDL (oxidised low-density lipoprotein). Exposure to ox-LDL inhibits the release of NO 
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(nitric oxide) in endothelial cells, facilitates the production and release of endothelin (ET) and, 
consequently, promotes vasoconstriction and proliferation of smooth muscle cell, which are 
key steps in the pathogenesis of atherosclerosis (Song et al., 2013). This finding indicates that 
the anti-oxidative effects and lipid-lowering effects of the formula may contribute to its 
clinical use to treat atherosclerosis and dyslipidaemia. 
Bu Yang Huan Wu decoction is another traditional formula used for post-stroke recovery. 
The formula consist of seven herbs: Huangqi (Astragalus membranaceus Fisch.), Danggui wei 
(Angelica sinensis (Oliv.) Diels), Chishao (Paeonia lactiflora Pall), Dilong (Pheretima 
aspergillum), Chuanxiong (Ligusticum chuanxiong), Taoren (Prunus persica) and Honghua 
(Carthamus tinctorius L.) (Scheid & Scheid, 2009). 
Pharmacologically, the main chemical constituents of Bu Yang Huan Wu decoction include 
C-glycosyl quinochalcones, flavonoid O-glycosides, isoflavones, monoterpene glycosides, 
saponins, organic acids and amino acids (E. H. Liu et al., 2009). All these constituents play 
roles in anti-apoplexy (Jingfen et al., 2002), and some have been demonstrated to prevent 
injury and apoptosis of neurons (C. Deng, He, Fuyang., Tang, Yinghong., Deng, Yihui., Wan, 
Ming., 2000) through the reduction of glutamate and aspartic acid in brain tissue (C.-Q. Deng, 
Deng, Y.-H., Xiang, H.-L. , 2001).  
Bu Yang Huan Wu decoction has been reported to possess neuroprotective effects in 
cerebral ischaemic reperfusion injury rat models (L.-D. Zhao, Wang, Jin, Zhao, & Zhang, 2012). 
It is suggested that the formula is involved in the inhibition of excessive release of glutamate 
resulting from cerebral ischaemia and the down-regulation of mGluR-1 mRNA. Cerebral 
ischaemia or brain injury has been shown to cause marked elevation in glutamate 
concentrations (Parelkar, 2008), resulting in neuronal injury or death owing to excitotoxicity 
(Bonde, Noraberg, Noer, & Zimmer, 2005). Sustained intracranial pressure elevations and 
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poor patient outcome are significantly associated with high levels of central nervous system 
glutamate in humans (Bullock et al., 1998). Activation of mGluR-1 promotes the post-
ischaemic injury of neurons (Meli et al., 2002). Therefore, maintaining a normal extracellular 
glutamate concentration is a key to preventing glutamate neurotoxicity. 
Further to this, Bu Yang Huan Wu decoction also demonstrates anti-inflammatory effects 
against ROS-induced oxidative stress. It is reported that the decoction modulates the gene 
expression of the pro-inflammatory cytokines/chemokines and suppresses the genes 
promoting cell death, such as IL6, CCL11, CXCL2, CXCL3, CD163, CD24a, caspase 8, Tlr4 (toll-
like receptor 4), thrombospondin 1, Bmp7, Mmp8 and Mmp9 (H.-W. Wang et al., 2011).  
Of particular interest, the key herb in Bu Yang Huang Wu Tang is Huangqi (A. 
membranaceus), which is the main source of astragalin (Shaw, Lin, & Tsai, 2012). Astragalin 
has been shown to involved in re-vasculature and angiogenic factor regulation (Ke, Hu, 
Ouyang, Dai, & Xu, 2012). Angiogenic genes such as vascular endothelial growth factor (VEGF) 
and its receptor Flk1 is reported to be upregulated by Bu Yang Huang Wu decoction during 
stroke protection in rats on days 7–14 after stroke (G. Cai et al., 2007). However, Wang et al. 
(2011) report various angiogenic genes were less active in Bu Yang Huan Wu decoction-
treated mice. It has been reported that upregulation of VEGF increases BBB permeability 
(Vandenbroucke, Mehta, Minshall, & Malik, 2008), possibly by enhancing VEGF-mediated 
activation of Rac-1, which causes ROS generation (Monaghan-Benson & Burridge, 2009). In 
addition, the anti-VEGF receptor antagonist VGA1155 has been demonstrated to reduce 
infarction in rat permanent focal brain ischaemia (Chiba et al., 2008). Based on these 
observations, Wang et al. propose that suppression of angiogenesis by Bu Yang Huan Wu 
decoction may be due to the time point of investigated in their study, which was day one after 
stroke when they harvested brain RNA for transcriptome for analysis. The CI/R-induced 
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ischaemic response, especially BBB leakage, may have been ameliorated by Bu Yang Huan Wu 
decoction in vivo so that blood vessel formation was no longer active in vivo (H.-W. Wang et 
al., 2011). 
While the preliminary benefits of the use of Bu Yang Huan Wu decoction was evident, the 
effects and safety profile in clinical use remain inconclusive. Hao et al. (Hao et al., 2012) 
reviewed nineteen randomised clinical trials including a total of 1580 individuals for the 
efficacy and safety of Bu Yang Huang Wu decoction for acute ischaemic stroke. The findings 
are inconclusive as methodological bias was considerable. While the effective rates of 
neurological deficit improvements favour Bu Yang Huan Wu Tang, Hao et al. (2012) report a 
publication bias in the funnel plot analysis. Further, all studies failed to provide randomised 
allocation concealments and 14 studies did not report adverse events. Therefore, more 
rigorous methodological trials are required to support clinical efficacy and safety of Bu Yang 
Huan Wu decoction as a routine treatment in clinical practise. Nevertheless, the decoction 
itself has been used for hundreds of years by Chinese medicine practitioners and is still used 
in cases of post-stroke management of neurological deficits and after-effects of ischaemic 
stroke (Chang et al., 2016). 
3.2.3.4 Patented herbal medicine for ischaemic stroke 
Traditional Chinese patent medicine (TCPM) has been widely used and accepted in China for 
several decades for the management of stroke in both Western medicine and Chinese 
medicine hospitals (Z. Chen et al., 1997). The Chinese National Essential Drug (CNED) 2012 
edition, the Pharmacopoeia of People’s Republic of China (PPRC) 2010 edition, and the China 
Food and Drug Administration (CFDA) list a variety of CHM preparations (mixtures of multiple 
herbs) that have been subjected to a relatively strict drug evaluation process and are widely 
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used in current clinical practice for stroke in China and these TCM preparations are defined 
as TCPMs. TCPMs represent some potentially important therapies in addition to the standard 
use of aspirin and thrombolytic and recombinant tissue plasminogen activator for the 
treatment of ischaemic stroke.  
Clinical effectiveness and safety of TCPMs are yet to be fully investigated. One systematic 
review conducted by Wu et al. (2007) evaluated the efficacy and safety of 22 TCPMs listed in 
the CNED (2004 edition) as potential drugs for ischaemic stroke patient. Although the pooled 
analysis of the existing randomised and nonrandomised trials showed significant positive 
effects in lowering mortality rates and improving neurological impairments, highlighting the 
potential benefits in stroke treatment, over 97% of the included clinical trials were noted as 
having poor methodological quality (B Wu, M Liu, H Liu, et al., 2007). The main 
methodological weaknesses of these trials were lack of bias control (such as double blinding 
and placebo control, concealment and randomised allocation reporting) and lack of adverse 
event reporting.  
A recent systematic review evaluated nine TCMPs, including Danshen agents, Mailuoning, 
Ginkgo biloba, Denzhanhua, Acathopanax, Chuanxion-type preparations, Puerarin, Huangqi 
and Qing Kai Ling, attempting using the GRADE approach to assess the outcome of the RCTs. 
The results showed that the quality of the scientific evidence to support these nine TCPMs 
ranged from low to very low, due to small sample sizes and various methodological issues in 
the primary studies including inadequate reporting of allocation concealment, randomisation 
methods, and lack of blinding and inconsistency. This highlights the need for high-quality 
research to validate these TCPMs before being used as standard treatment in clinical practice. 
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3.2.4 Summary 
In short, early evidence exists to support the use of CHM products in the treatment of 
ischaemic stroke. However, the efficacy of these CHM interventions needs to be validated in 
well-designed quality-controlled trials. Standardisation of CHM products is particularly 
important to replicate the results of clinical trials. There is also an urgent need to understand 
the mechanisms underlying the observed clinical effects of these medicines. Given these 
medicines consist of multiple bioactive components, research is needed to understand the 
interactions among these herbs (synergistic effects) and their interactions with 
pharmaceutical medications. The latter is critical in clinical practice, as therapeutic windows 
for some Western pharmaceutical medicines are narrow and their effects can be either 
enhanced (increased toxicity) or reduced (decreased efficacy) when used together with 
herbal medicines with which they may interact.  
3.3 Nao Xin Qing (NXQ) 
Nao Xin Qing (NXQ) is a patented CHM product made from the standardised extract of D. kaki 
leaves (D. kaki L.). NXQ has been clinically used in China for numerous years in the treatment 
of apoplexy, coronary heart disease, and ischaemic stroke recovery. Previous clinical and 
preclinical studies have suggested that NXQ has potential therapeutic effects for cerebral 
atherosclerosis, transitory ischaemic syndromes, cerebral thrombogenesis, cerebral 
thrombosis sequelae, apoplexy sequelae, and cerebral embolism, with minimal adverse 
effects (Bei et al., 2007; Y. Cai & Yang, 2001).  
3.3.1 NXQ bioactive profile 
D. kaki is a traditional herb that has been used in Asia for hundreds of years. In 1436, it was 
documented in Chinese herbal Materia Medica (the Dian Nan Bencao) that the leaves of 
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persimmon can be used to alleviate chronic shank ulcers, which was typically a result of 
varicose veins in the lower limbs and traditionally caused by ‘stasis of the collaterals’. In 1841, 
the Bencao Zaixin further elaborated on the use of D. kaki L. for chronic cough, bloody vomit, 
and thirst. Clinically, the application of D. kaki L. has been reported to stop bleeding, 
particularly internal bleeding due to tuberculosis, peptic ulcers, haemoptysis, uterine 
bleeding, haemorrhoids, and epistaxis. The use of D. kaki L. was not exclusive to Chinese 
culture; it was also used in Japan as a traditional medicine under the name of kaki-yo for 
several clinical indications, including homeostatic, diuretic, laxative, and hypotensive 
properties, with no appreciable side effects. 
NXQ is a standardised, patented herbal extract developed by Hutchison Whampoa 
Guangzhou Baiyunshan Chinese Medicine Co. Ltd (HGB), China. It was listed in China 
Pharmacopoeia 2015 as an approved therapeutic drug and has been active in the Chinese 
market for several years. The permissible clinical indications of NXQ include cerebral 
atherosclerosis and coronary heart diseases with particular symptoms such as shortness of 
breath, palpitations, dizziness, vertigo, numbness in the limbs, chest stuffiness, and chest 
pain. From a TCM viewpoint, NXQ is used to treat a particular Chinese medical pattern of 
‘blood stagnation and dampness obstruction of the collaterals that are typically related to 
conditions with an apoplexy origin’. NXQ is publicly accessible in China from online stores and 
by prescription from TCM practitioners. 
Also, several patented herbal formulations include D. kaki leaves. These products – 
primarily available in mainland China – include NXQ tablets, Shiye Su Rong drinks, Fu Yan Jing 
capsules, Fen Shang pills, and Shingshuning Pian. They target a range of ailments including 
coronary artery disease, cerebral atherosclerosis, cough, proteinuria, and inflammatory 
gynaecological disorders. Most patented CHM products contain a mixture of herbal extracts, 
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however, NXQ is a product that only contains D. kaki L. extract. Whilst patented herbal 
medicines are commonly used in clinical practice throughout China, the evaluation of their 
efficacy, safety, and mechanisms of action remain a high priority in matching the modern 
standards of an evidence-based portfolio. 
Among the varieties of persimmon species, D. kaki is one of the most investigated herbal 
resources in recent literature. It is traditionally used in Asian countries for alleviating multiple 
ailments, which can involve the fruit itself (D. kaki), the sepal of the fruit (D. kaki thund.), or 
the leaf of the plant (D. kaki L.). More than 30 potentially bioactive compounds have been 
isolated from the leaves of the Diospyros species, which can be divided into five main chemical 
groups: acids, biphenyls, flavonoids, polyphenols, and triterpenoids (Bei et al., 2004, 2005b). 
The D. kaki L. extract used to produce NXQ is standardised. NXQ is chemically comprised of 
more than 50% organic acids (including protocatcchuic acid, benzoic acid, and scopoletin) and 
26.56% flavonoids, including quercetin and its glucosides (hyperin, isoquercetin, kaempferol, 
and astragalin) (Bei et al., 2004). Quercetin and kaempferol are known to be the two most 
important and abundant compounds found within NXQ. Zhang and colleagues (2019) 
conducted HPLC/MS evaluation of NXQ and identified eight effective constituents, including 
quercetin (100.0 mg/g), kaempferol (33.3 mg/g), kaempferol-3O-B-D-glucopyranoside (28.7 
mg/g), kaempferol-3-O-B-galactopyranoside (76.5 mg/g), protocatechuate (66.2 mg/g), 
hyperoside (97.9 mg/g), myricetin (5.6 mg/g), and naringenin (0.8 mg/g), in crude drug (P. 
Zhang et al., 2019). Liang and colleagues, who evaluated the consistency of quercetin and 
kaempferol content in 10 batches of NXQ tablets using HPLC (J. Liang et al., 2012), confirmed 
that the two compounds were consistently detected with an average range of 3.850 – 5.578 
mg/g of quercetin and 5.095 – 7.947 mg/g of kaempferol. Qin et al. further confirmed that 
quercetin and kaempferol are the two most abundant compounds found within the NXQ 
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formula responsible for the protection of cerebral infarct in cerebral ischaemic mice (Qin et 
al., 2011).   
Flavonoids, particularly kaempferol and quercetin, are the main compounds thought to be 
responsible for the therapeutic action of NXQ; however, glycosides, such as astragalin, rutin, 
isoquercetin, and hyperin, have also been identified. Flavonoids are thought to have several 
pharmacological effects that benefit human health. It is reported that flavonoids possess anti-
atherosclerotic effects, mainly due to their anti-oxidative properties, by preventing oxidation 
of low-density lipoprotein (LDL) and endothelial wall injury (Holiman, Hertog, & Katan, 1996). 
In addition, anti-inflammatory effects have also been reported (Hertog, Feskens, Kromhout, 
Hollman, & Katan, 1993; Holiman et al., 1996). Quercetin, for example, can inhibit 
cyclooxygenase and lipoxygenase activities, thus, diminishing the formation of inflammatory 
metabolites, such as arachidonic acids (Robak & Gryglewski, 1996). Other effects, such as anti-
tumour, anti-thrombogenic, anti-viral, and anti-bacterial effects, have also been reported 
(Agrawal, 2011). 
3.3.1.1 Quercetin 
Quercetin (3,3’,4’,5,7-pentahydroxyflavone), a polyphenolic compound found abundantly 
in dietary resources, is known for its health benefits as a natural flavonoid. It is one of the 
main bioactive compounds found in NXQ that contributes to its therapeutic effects. Quercetin 
is potent as a dietary supplement; in fact, 10 mg of quercetin accounts for ~50% of the total 
flavanols in an individual’s dietary intake recommendation (Kawabata, Mukai, & Ishisaka, 
2015).  
Research has shown that quercetin has beneficial effects on CVDs and diabetes through 
numerous mechanisms such as antioxidant and anti-inflammatory signalling pathways (Costa, 
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Garrick, Roquè, & Pellacani, 2016; Formica & Regelson, 1995). In a clinical trial, quercetin 
supplementation (150 mg/day; 6 weeks) reduced systolic blood pressure and serum oxidised 
LDL in overweight subjects with a high CVD risk phenotype (Egert et al., 2009). Similarly, 
quercetin reduced blood pressure, serum glucose, LDL, and total cholesterol in high-salt, diet-
induced, hypertensive rats (Olaleye, Crown, Akinmoladun, & Akindahunsi, 2014). In a meta-
analysis, quercetin was found to be effective in reducing blood pressure in both diastolic and 
systolic figures and induced superior effects on diabetic subjects (Serban et al., 2016). In 
addition, quercetin was found to have anti-inflammatory effects by inhibiting cyclooxygenase 
and lipoxygenase activities, thus, diminishing the formation of inflammatory metabolites, 
such as arachidonic acids (Robak & Gryglewski, 1996).  
3.3.1.2 Kaempferol 
Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a polyphenolic 
compound that naturally occurs in dietary resources like tea, vegetables, and fruits. 
Kaempferol possesses multiple therapeutic benefits similar to quercetin, including 
antioxidant and anti-inflammation (A. Y. Chen & Chen, 2013; Seifried, Anderson, Fisher, & 
Milner, 2007). Studies have found that kaempferol decreases lipopolysaccharide (LPS)-
induced tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) expression by 
increasing the number of macrophages that suppresses TNF-α-mediated translocation of NF-
κB p65 to the nucleus (Lin et al., 2011). Kaempferol has shown some promising effects on 
various chronic inflammatory diseases, such as intravertebral disc degeneration, 
osteoarthritis, colitis, mastitis, and rheumatoid arthritis (Ren et al., 2019). It is believed that 
kaempferol maintains a relatively important role during chronic inflammation by inhibiting 
LPS-induced decreases in chondrogenic markers, such as SOX-9, collagen II, and aggrecan, 
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thereby, preventing tissue breakdown (Jun Zhu et al., 2017). In addition, kaempferol also 
reduces the IL-1B-stimulated formation of PGE2 and NO in a concentration-dependent 
manner and upregulates the expression of iNOS and COX-2 (H. Zhao et al., 2014). These 
cellular actions inhibit the NF-κB pathway and achieve an anti-arthritis effect by retarding the 
progression of osteoarthritis. 
Furthermore, kaempferol also prevents the development of mastitis by decreasing 
myeloperoxidase (MPO), IL-6, and ANGPTL2 expression. Kaempferol has also shown effects 
in inhibiting TNF-α-induced mitogen-activated protein kinase (MAPK) activation and blocking 
the MAPK pathway without affecting the expression of TNF-α receptor (Xiao, Sui, Lu, & Sun, 
2018).  
Kaempferol has been reported for its anti-cancer effects by inhibiting angiogenesis. Li et al. 
reported that kaempferol inhibited the invasion of breast cancer cells by blocking protein 
kinase C (PKC/MAPL/activator protein-1AP-1 cascade and subsequent expression and activity 
of MMPs) (2017). Kaempferol can also significantly inhibit vascular endothelial growth factor 
(VEGF)-induced HUVEC proliferation (Xu, Zhao, Peng, Xie, & Liu, 2017). Li et al. further 
indicated that kaempferol reduces the expression of estrogen receptor, IGF-1, and VEGF 
precursor at the mRNA and protein level by inhibiting the proliferation of human uterine 
fibroid cells in vitro (Y. Li, Ding, & Wu, 2016).  
The anti-inflammatory and anti-oxidative effects of kaempferol also benefit vascular 
protection. Kaempferol can inhibit pro-inflammatory response mediated by LPS or high 
mobility group box 1 (HMGB1) by increasing barrier integrity and inhibiting the expression of 
cell adhesion molecules (Kim, Ku, & Bae, 2012). Kaempferol can lower plasma LDL and reduce 
the risk of CVD, as well as protect cells from apoptosis (J. Che et al., 2017). 
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Synergism between flavanones 
Besides the widely known benefits of quercetin and kaempferol, studies have suggested 
that interactions exist between flavonoids, which may lead to a synergistic reaction (Hidalgo, 
Sánchez-Moreno, & de Pascual-Teresa, 2010; Lila, 2008; Sonam & Guleria, 2017). While many 
believe that consuming quercetin and kaempferol individually may impart health benefits, 
few studies have looked into the synergistic ratio of the two compounds that may be present 
in a single herbal substance. Such a ratio from natural sources may be valuable for 
understanding the potential of additive or synergistic effects of the two bioactive compounds. 
The effects of natural flavanones on human health are complex. While most studies have 
examined the potential bioactive compounds responsible for the effects of a natural product, 
few have studied the synergisms between the bioactive compounds found within the same 
herbal source. Quercetin and kaempferol each possess strong effects in ROS scavenging and 
anti-inflammatory effects, however, varied outcomes have been observed between different 
flavonoid compounds. Hidalgo et al. investigated the flavonoid-flavonoid interaction on 
antioxidant activities using a DPPH assay and found that when kaempferol was paired with 
myricetin, quercetin, or quercetin-3-glucoside, a significant increase in antioxidant activity 
was observed. While the ratio of quercetin and kaempferol used in their study was 1:1, it 
provided insight that flavonoids synergistically interact, which may yield improved 
therapeutic outcomes (2010).  
In summary, synergism is observed between flavonoid interactions. However, the ratio 




3.3.2 Clinical evidence 
Several clinical trials have been conducted in China recently assessing the clinical effects of 
NXQ. One study assessed NXQ as an adjunct therapy to standard dehydration, anti-
hyperglycaemic and anti-lipidaemic treatment for acute ischaemic stroke in 35 Type 2 
diabetic participants (B. Tang et al., 2012). The results of this study showed that NXQ 
positively improved blood rheology by acting on C-reactive protein (C-RP) and blood lipids. 
Lipids and lipoproteins modulate haemostasis by altering rheological factors. Increasing the 
cholesterol concentration in human erythrocyte membranes in vitro increases erythrocyte 
rigidity and blood viscosity, and loading of cholesterol into erythrocytes in vitro increases their 
surface area and decreases their deformability (Machida et al., 2010; Yagi et al., 2016). 
Elevation of C-RP typically indicates that pro-inflammatory factors, including tumour necrosis 
factor (TNF)-α and interleukin-1β, are in excessive quantities, which can be deleterious to 
neurons. (TNF)-α stimulates the production of fibrinogen, which affects blood rheology and 
viscosity (Marioni et al., 2009). The authors suggested that the active component flavonoids 
from D. kaki L. extract possess anti-ischaemic effects through promoting cerebral and cardiac 
blood flow and neuroprotective effects through radical scavenging and lipid lowering 
(Machida et al., 2010).  
Another study conducted by Wang et al. (2012) assessed NXQ in combination with acute 
management therapy (mannitol and glycerol fructose dehydration) in comparison to acute 
management therapies alone in patients with cerebro-cardiac syndrome caused by acute 
stroke. A total of 204 participants were included; 130 suffered from ischaemic stroke, 61 from 
intracranial haemorrhages and 13 from sub-cranial arachnoid haemorrhages. A standard dose 
of NXQ was given at the acute phase in addition to acute management therapy protocols for 
a continuous four-week period. The results suggested that the NXQ group had superior results 
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in improving cardiac function recovery, including arrhythmia, changes in ST-T wave and 
abnormal cardiac enzymes in comparison to the control group (A. Wang et al., 2012).  
Chen, Shao and Cheng (2012) conducted a clinical trial assessing NXQ as an adjunct to low-
molecular weight heparin in comparison to heparin alone in 160 patients with cerebral 
transient ischaemic attack. Results suggested that both groups had prolonged partial 
thromboplastin time (PTT) and active partial thromboplastin time (APTT); however, NXQ 
treatment showed a significantly longer duration in both outcome measures when compared 
to the control group. In addition, no significant adverse events were identified. 
Although few clinical studies focused directly on cerebral ischaemic stroke, a number of 
clinical trials were conducted assessing the benefits of NXQ for ischaemic heart disease and 
angina, which share a similar underlying pathological process to ischaemic stroke, namely 
atherosclerosis. A study conducted by Cai and Yang (2001) assessed the effects of NXQ in 60 
participants (48 with atherosclerosis and 12 with coronary artery disease-induced angina). 
The study showed that NXQ significantly lowered blood lipids and improved symptoms such 
as vertigo and headaches. A recent study by Wu, Wu and Zheng (2013) comparing NXQ 
against a standard vasodilator in 90 patients with coronary artery disease reveals similar 
positive results. The authors find that NXQ treatment significantly decreased blood lipid levels 
and reduced cardiac stress and cardiac oxygen consumption, and improved oxygen supply to 
cardiac muscle through aorta dilation. In another study, clinical effects of NXQ as an adjunct 
treatment were compared to a standard angina treatment (including nitrates, aspirin, beta 
blockers, angiotensin-converting enzyme inhibitors and lipid-lowering drugs) alone in 120 
elderly patients with unstable angina. The results suggested that the NXQ group had 
significant improvements in symptoms of angina and a reduction in blood lipid levels 
compared to standard treatment alone (Xiong, Tang, & Zhou, 2013). 
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In summary, the preliminary clinical evidence suggests that NXQ is effective for lipid 
reduction and may also improve cardiac blood flow as well as relieving clinical symptoms such 
as angina. No severe adverse events were identified in study conducted by Xiong et al. (2013). 
However, the methodology of these trials did not appear to be rigorous or precise and the 
samples in these studies were small. Of all the trials, only Tang et al. (2012) reported a 
randomisation method and statistical power calculation. Apart from Wang et al. (2012), no 
study reported the treatment duration for either intervention or control groups. Furthermore, 
adverse events were not reported in the studies by Cai and Yang (2001), Wu et al. (2013) and 
Wang et al. (2012). At present, there are no trials that have evaluated the neuroprotective 
effects of NXQ with standardised outcome measures.  
3.3.3 Preclinical evidence 
Previous research has demonstrated numerous pharmacological effects of D. kaki L. extract, 
such as improved cardiac and cerebral blood flow, anti-hypertensive, lipid-lowering and 
radical-salvaging capabilities (S. Cao, Zhang, Bai, Wang, & Miao, 2012). A study conducted by 
Xin, Feng and Yao (2007) investigated the effects of intravenous injections of D. kaki L. 
flavonoids in rabbits and found a 30–40 % increase in aortic circulation as well as significant 
dilation of the veins of the ears. These results were also supported by the findings of Zhang, 
Wang and Xiao (2004), which showed that the leaves of D. kaki can improve overall circulation 
in anaesthetised dogs and can reduce oxygen consumption of cardiac muscles. Ou, Bei and 
Lai (2003) found that the total flavonoid count can significantly inhibit reperfusion-induced 
cell apoptosis. Furthermore, Ou, Liu and Bei (2004) suggested that D. kaki L. can inhibit fibrin 
adhesion (scar tissues) on the adventitia stimulated by factors such as advanced glycation 
end-products (AGEs) and advanced oxidation protein products (AOPPs).  
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In relation to the cerebrovascular system, Cao et al. (2012) studied the fibrinolytic function 
in an ischaemic brain injury model and found that D. kaki L. flavonoids can increase tissue 
plasminogen activator (t-PA) which is involved in the breakdown of blood clots and reduction 
of plasminogen activator inhibitor-1 (PAI-1) levels, thereby improving the outcome of 
thrombotic-related cerebral ischaemia. Cao et al. (2012) further demonstrated that the von 
Willebrand Factor (vWF), a blood glycoprotein involved in haemostasis, is reduced in 
ischaemic brain injury rats subjected to treatment with D. kaki L. flavonoids. Reduction of 
vWF has been associated with the resolution of thrombosis during an ischaemic attack and 
restoration of damaged endothelial cells. Cao et al. (2012) propose that D. kaki L. flavonoids 
could reduce positive signalling of Intercellular Adhesion Molecule-1 (ICAM-1), a 
immunoglobulin molecule associated with the release of inflammatory factors, and thereby 
act against atherosclerosis and reduce sustained haemostasis. 
Additionally, Bei, Li et al. (2009) propose that the potential neuroprotective effects of NXQ 
and D. kaki L. flavonoids could activate L-type Ca2+ channels, thus modulating intracellular 
Ca2+ level to protect neurons in the hippocampus. This action is complemented by the anti-
oxidative ability of NXQ and D. kaki L., which positively inhibits ROS (including hydrogen 
peroxide) and therefore could reduce neuron damage. 
Kameda et al. (1987) first demonstrated the anti-hypertensive effects of D. kaki L. in 
hypertensive rats. The mechanism is thought be through inhibition of angiotensin-converting 
enzyme activity. Tan, Lin and Zhang (2009) further investigated these anti-hypertensive 
effects and observed an increase in plasma nitric oxide (NO) and reduced over-production of 
platelets by essential thrombocytosis (ET) and reduced angiotensin II in rats. The results 
suggested that D. kaki L. flavonoids have potential to enhance endogenous vasodilators and 
modulate endogenous vasoconstrictors.  
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The preliminary evidence suggests there are potential therapeutic benefits of NXQ for 
ischaemic stroke; however, the precise mechanism remain unclear.  
3.4 Summary 
In summary, over the past few decades, there has been a growing body of literature reporting 
on the phytochemistry and pharmacological activities of constituents isolated from D. kaki 
leaves. However, the benefits for human health are still unclear due to lack of well-designed 
randomised control trials. There is some available Chinese-language literature, but its content 
typically relates to traditional Chinese medicine with lack of scientific interpretation. 
NXQ, a single standardised patent extract of D. kaki L., possesses potential therapeutic 
benefit for ischaemic stroke. Early evidence suggests that the bioactive components of D. kaki 
L., such as flavonoids, could benefit ischaemic conditions such as ischaemic stroke. However, 
the exact role and mechanisms of action of NXQ on stroke are not fully understood. 
Therefore, more research is needed to evaluate the potential vascular and neurological 














4.1 Introduction  
4.1.1 Standardisation and quality control of herbal medicine 
Herbal medicine (HM) in general refers to medicinal products containing botanical, animal or 
mineral materials obtained or processed from their original form (Loew & Kaszkin, 2002). HMs 
can be used in single form or in combinations. In Chinese herbal medicine (CHM), herbal 
preparations are typically prescribed and prepared in combination following the traditional 
Chinese medicine synergistic and antagonistic principles known as Jun Chen Zuo Shi. In 
contrast to chemically defined pharmaceutical drugs, HMs typically contain complex mixtures 
of chemicals that may have active, synergistic, complementary, antagonistic or even toxic 
effects. This also applies to single herbs, which contain complex mixtures of chemicals. For 
example, NXQ, a patented extract from Diospyros kaki L. contains a variety of flavonoids such 
as quercetin and kaemferol, glucosides such as astragalin, rutin and hyperin, and some 
phenolic acids including protocatechuic, benzoic, salicylic and syringic acids (K. Zhang et al., 
1983).  
The active components of most HMs are secondary plant metabolites, which are 
compounds that may not be essential for plant growth but are thought to play a role in plant 
defence and survival (Stamp, 2003). The amount of secondary metabolites in HMs can vary 
depending on growing conditions (such as soil and climate), harvest season and post-harvest 
treatment (Y. Liang, Xie, P. Chan, K., 2004; H. Wagner, 1999). Once ingested, some secondary 
plant metabolites may be metabolised into active compounds, a process called bioactivation 
(Fang et al., 2011). The complex chemical composition and potential interactions of bioactive 
components in herbal preparations create challenges in evaluating and assessing their 
chemical consistency and clinical efficacy. 
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Quality control is a critical process for standardising a medicine and ensuring batch-to-
batch consistency of its active component(s). Unlike pharmaceutical medicines, which contain 
a simple chemical entity, HM preparations often contain a large number of bioactive 
components. This has made standardisation of herbal extracts a very challenging task.  
Standardisation is the process whereby a medicine is prepared in a way that ensures a 
consistent concentration of one or more analytes (usually a bioactive compound found in high 
concentration) regardless of variation in the concentration of these substances in the raw 
material from which the extract is prepared. In HM, it is a common practice to select several 
representative compounds that are either unique in the herb or appear in abundance. This 
approach is problematic, as the compounds selected for standardisation/quality control 
purposes may not be consistent with those bioactive components responsible for the 
therapeutic effects of the herbal medicine (Ong, 2004; Yadav, 2008).  
NXQ has already been previously standardised by the herbal manufacturer. In the present 
research, the objective was not to full development and validation of analytical methods for 
key bioactive compounds for quality control purposes. Instead, the aim is to identify and 
quantify the key bioactive components, especially quercetin and kaempferol, in the extract 
used for the studies described in Chapters 5 and 6 to determine the quercetin:keaempferol 
ratio.  
4.1.2 Physical description of D. kaki leaf 
D. kaki belongs to the family Ebenaceae. Native to China, where it has been cultivated for 
centuries and from where it spread to Korea and Japan, it was introduced into Europe in 1789 
and into the USA in the 1800s. It is typically known as Japanese or Chinese persimmon and 
the leaves have been documented for their medicinal effects as early as the fifteenth century 
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in China (Xie, Xie, Xu, & Yang, 2015). The deciduous tree is 5–10 metres tall, similar in width, 
and has drooping branches and upright to round-headed leaves. The appearance of the leaves 
varies from simple elliptic-ovate to oblong or obovate, averaging 6–18 cm in length. The base 
of the leaf is usually broad or wedge shaped, leathery, glossy dark green above and lighter 
green and pubescent below. During autumn, the leaves are coloured a vivid yellow-orange 
and red (Celik & Ercisli, 2008; Xie et al., 2015).  
D. kaki is well known by its fruit, an ovoid to slightly flattened sphere 3.5–7 cm long with 
orange and bright yellow colours (Xie et al., 2015). 
  




Figure 4.2: Persimmon tree (Celik & Ercisli, 2008) 
4.1.3 Traditional uses of D. kaki leaf 
The traditional use of persimmon leaves was first recorded in the Chinese ancient medical 
book Dinnan Bencao, which was written by Lan Mao in 1436 in the Ming Dynasty. The first 
recorded use of persimmon leaves as medicine is for chronic ulceration of the lower legs 
(Lan,1436). In 1841, during the Qing Dynasty, the book of Chinese Materia Medica named 
Bencao Zaixin stated that persimmon leaves could be used to treat cough and haematemesis, 
increase salivation and slake thirst (Ye, 1933). Later it was stated in Fei Lei Cao Yao Xing, a 
medical book written in the late Qing Dynasty, that persimmon leaf could be used to treat the 
disease fei zhang, also known as lung distension in traditional Chinese medicine (Anon, 1911). 
It was not until the early 1990s that the effects of persimmon leaves were identified through 
pharmacological analysis. The report of Chinese herbal medicines, Guangxi Standards 
(published in 1990), suggests that the persimmon leaves were effective for cough, internal 
haemorrhage, hypertension, cerebral arteriosclerosis and coronary disease. In addition, it is 
also used traditionally to promote maternal health (Han, 2002). The standardised patent 
extract of persimmon leaf named NXQ was recorded in Chinese Pharmacopoeia 2010 as a 
patented and approved TCM drug for the use of atherosclerosis (Chinese Pharmacopoeia 
Commission, 2012).  
In Japan and Korea, persimmon leaf also has been used in health beverages for centuries 
(Funayama & Hikino, 1979; Sakanaka, Tachibana, & Okada, 2005). It has often been made as 
tea and is popular among Chinese and Japanese for its potential to reduce blood pressure, 
eliminate cholesterol and prevent melanin accumulation. In Japan, it was also regarded as an 
anti-ageing tea as it is rich in vitamin C and active nutrients (Sakanaka et al., 2005).  
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4.1.4 Chemical substances in D. kaki leaf 
To date, numerous chemical constituents have been identified in the extract of D. kaki. L, 
including flavonoids, terpenoids, naphthoquinine, naphothol, coumarin, sterol, organic acids, 
fatty acids and volatile components. 
4.1.4.1 Flavonoids 
Flavonoids are the main compounds thought to be responsible for the therapeutic action of 
D. kaki L., with kaempferol and quercetin the main flavonoids. Glycosides such as astragalin, 
rutin, isoquercetin and hyperin have also been identified. The structures of different 
flavonoids identified in D. kaki L. are shown in Figure 4.3 and Table 2.  
 
 
Figure 4.3: Nucleus structures and substituents of flavonoids 
 
Table 2: Main flavonoids in Diospyros kaki L (Zhou, 2014) 
 Compounds Nucleus 
structure 
Substitutes References 
   R1 R2 R3 R4 R5  




OH   (G Chen, Xue, Xu, & Zhang, 2007) 
2 kaempferol A H H H   (G Chen et al., 2007) 
3 quercetin A H H OH   (G Chen et al., 2007) 
4 annulatin A OH CH3 OH   (G Chen et al., 2007) 
5 isoquercitrin A OH Glc H   (G. Chen, 2003; G Chen et al., 
2007; Kameda et al., 1987; Xue et 
al., 2011) 








A OH Rha OH   (Guang Chen et al., 2009) 
9 myricetin-3-O-β-D-
glucopyranoside 
A OH Glc OH   (Guang Chen et al., 2009) 
10 quercitrin A H Arab OH   (Gafner, Chapuis, Msonthi, & 
Hostettmann, 1987) 
11 astragalin B H OH H H H (Kameda et al., 1987) 
12 kaempferol-3-O-(2ʺ-
galloyl) -glucoside 








B H H OH H H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, 
Meng, et al., 2002; G Chen et al., 
2007; Xue et al., 2011) 
15 kaempferol-3-O-β-D-
glucopyranoside 
B H OH H H H (Guang Chen, Lu, Wang, 
Yamashita, Manabe, Meng, et al., 
2002; G Chen et al., 2007; 




B OCH3 H H H H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, 
Meng, et al., 2002; Guang Chen, 
Xu, Wang, & Zhang, 2005) 
17 quercetin-3-O-β-D-
galactopyranoside 
B OH OH OH H H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, 
Meng, et al., 2002; G Chen et al., 




B OH OH H Rha H (Guang Chen, Lu, Wang, 
Yamashita, Manabe, Meng, et al., 
2002) 
19 hyperoside B OH H OH H H (Xue et al., 2011) 
20 vitexin C Glc     (G. Chen, 2003; Guang Chen et 
al., 2005) 
21 2ʺ-O-rhamnosyl-vitexin C Glc 
(2→1) 
Rha 
    (G. Chen, 2003; Guang Chen et 









    (Guang Chen et al., 2009) 
 
Flavonoids are reported to have several pharmacological effects that benefit human health 
in a number of ways. It is reported that flavonoids possess anti-atherosclerotic effects, mainly 
due to their anti-oxidative properties that likely prevent oxidation of low-density lipids and 
endothelial wall injury, thereby ameliorating atherosclerotic changes. In addition, anti-
inflammatory effects are also reported (Hertog et al., 1993; Holiman et al., 1996). Quercetin, 
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for example, can inhibit cyclooxygenase and lipoxygenase activities, thus diminishing the 
formation of inflammatory metabolites (Robak & Gryglewski, 1996). Other effects, such as 
anti-tumour, anti-thrombogenic, anti-viral and anti-bacterial effects, have also been reported 
(Agrawal, 2011). 
Chrysontemin is another compound isolated from D. kaki L. (Xie et al., 2015). It has showed 
a moderate inhibitory effect on tyrosinase, a copper-containing enzyme that catalyses the 
production of melanin and other pigments from tyrosine. Chrysotemin has also been shown 
to inhibit tumour promoter-induced carcinogenesis and tumour metastasis (Xie et al., 2015). 
Other components found in D. kaki leaves, such as trifolin and hyperoside, demonstrate anti-
fungal properties. Astragalin demonstrates anti-allergic activities and inhibits angiotensin-
converting enzymes, thereby regulating blood pressure by preventing vasoconstriction (Xue 
et al., 2011).  
4.1.4.2 Terpenoids 
Triterpenoid compounds are also found in abundance in D. kaki L. Most of these terpenoids 
present in oleanane, lupine and ursan (see Figure 4.4 and Table 3). Terpenoids possess 
multiple pharmacological properties; for instance, ursolic acid, 19-hydroxy ursolic acid and 19, 
24-dihydroxy ursolic acid isolated from D. kaki L. have been shown to suppress stimulus-
induced superoxide generation and tyrosyl phosphorylation, which regulates the 
transduction of the enzymatic activity of tyrosin kinase (Guang Chen, Lu, Wang, Yamashita, 




Figure 4.4: Nucleus structures of triterpenes 
 
Table 3: Main triterpenes in Diospyros kaki leaves (Zhou, 2014) 
 Compounds Nucleus 
structure 
Substitutes References 
   R1 R2 R3 R4 R5  
1 β-amyrin A CH3      (G. Chen, 2003; HIGA, Ogihara, & 
Yogi, 1998) 
2 oleanolic acid A COOH     (G. Chen, 2003; G. Chen, Sha, 
Ching., 2000; HIGA et al., 1998) 




A CHO     (Uc-Cachón et al., 2013) 
5 betulinic acid  B COOH     (G. Chen, 2003; G. Chen, Sha, 
Ching., 2000; Guang Chen et al., 
2005; HIGA et al., 1998) 
6 lupeol B CH3     (G. Chen, 2003; HIGA et al., 1998; 
Uc-Cachón et al., 2013) 
7 α-amyrin  C H OH (β) CH3 CH3 H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, Xu, et 
al., 2002; HIGA et al., 1998) 
8 uvaol  C  OH (β) CH3 Ch2OH H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, Xu, et 
al., 2002) 
9 ursolic acid  C  OH (β) CH3 COOH H (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, Xu, et 
al., 2002) 
10 pomolic acid  C  OH (β) CH3 COOH OH (α) (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, Xu, et 




ursolic acid  
C  OH (β) CH2OH COOH OH (α) (G. Chen, 2003; Guang Chen, Lu, 
Wang, Yamashita, Manabe, Xu, et 




C  OH (α) CH2OH COOH OH (α) (G. Chen, 2003)  
13 rosamutin C OH (α)  OH (β) CH3 COOGlc  (G. Chen, 2003) 
14 kakisaponin A  C  OH (α) CH2OH (β) COOGlc OH (α) (G Chen et al., 2007) 
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4.1.4.3 Other compounds 
Other compounds, such as naphthoquinone and naphthol, coumarin, sterol, organic acids, 
fatty acids, and volatile oils, were also identified in D. kaki L. extracts (Zhou, 2014) along with 
resins, polysaccharides, chlorophyll, carotene, kryptoanthin, cellulose, hemicelluloses, lignin, 
and trace elements of amino acids (Xie et al., 2015).  
4.2 Aims 
This study aims to evaluate the key bioactive components (especially flavonoids) of the 
standardised patent extracts of D. kaki L. 
The study aims to:  
— identify and quantify the key bioactive constituents of the NXQ commercial extract 
— determine the ratio of quercetin and kaempferol in the extract. 
4.3 Methods 
4.3.1Materials 
4.3.1.1 Standards availability 
For an analytical method to be useful and have wide applicability, the analytes selected for 
quality control should be commercially available as well as being of reasonable cost. The 
selection of analytes is therefore a balance of commercial practicality and the desire to 
characterise as many analytes as possible to be more confident that the analytical results 
accurately reflect the functional quality of the herb.  
Though the flavonoids are believed to be the key bioactive components of NXQ extract (W. 
Li et al., 2011), other components may also contribute to NXQ’s therapeutic effects. Given 
the main purpose of this study was to determine the ratio of two most prominent flavonoids, 
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quercetin and kaempferol, in the standardised D. kaki L. extract, only five other bioactive 
compounds – for which the reference standard could be commercially obtained and analytical 
methods had previously been developed by Kazzem (2012) – were selected 
The standards and reagents used were obtained from reputable sources with claimed 
purity. Kaempferol (99%), quercetin (99%), 2-furic acid (98%) and protocatechuic acid (98%) 
were purchased from Sigma (Sydney, Australia). Astragalin (98%), hyperin (98%) and 
isoquercetin (98%) were purchased from Biopurify (Chengdu, China). 
4.3.1.2 Source of the D. kaki L. extract 
The NXQ extract of D. kaki L. was supplied by Hutchison Whampoa Guangzhou Baiyunshan 
Chinese Medicine Co. Ltd. (China).  
4.3.2 Sample stock and standards preparation 
The NXQ extract was prepared in triplicate and dissolved by sonication in methanol for 60 
minutes at 10mg/mL. The stock solutions of standards, quercetin, kaempferol, astragalin, 
isoquercetin, hyperin, protocatechuic acid and 2-furic acid were prepared to 1mg/10mL in 
methanol. For all in one stock of standards, a mixture standard was produced containing 
10mg of each of the 7 compounds in a 100 mL methanol. 
The sample and mixed standard were filtered with 0.45µm PTFE. The standard mixture was 
diluted to 100%, 75%, 50%, 25%, 20%, 5%, 1%, 0.1% and 0.01%.  
4.3.3 HPLC system 
High-performance liquid chromatography photodiode array detection (HPLC-PDA) was used 
to profile the phytochemical composition of the D. kaki L. extracts. The HPLC-PDA analysis 
was performed on a Shimadzu UFLC system (Shimadzu, Australia) comprising a LC-30AD pump, 
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SIL-30ACHT auto sampler, SPD-M20A PDA detector and DGU-20A5 inline solvent degasser. 
The system was controlled using Class-VP 7.4SP4 software.  
4.3.4 HPLC analysis of extracts 
The HPLC-PDA analysis of the extracts was performed using a Phenomenex Luna 
(Phenomenex, Australia) reverse-phase C18 column (46mm × 150mm I.D., 3µm) with a 
Phenomenex (California, USA) Security C18 guard column (20mm × 4mm, 3μm).  
HPLC-PDA profiles were generated by 5µl injection. The mobile phase consisted of 0.1% 
(v/v) aqueous formic acid (mobile phase A) and 0.1 % (v/v) formic acid in methanol (mobile 
phase B). The gradient program was 16% B for 15 min with a linear increase: to 25% B at 21 
min, then to 38 %B 23 minutes, then to 60% B at 35 min followed by a 7min wash at 95% B 
and 8 min re-equilibration at 16% B. Mobile phase flow rate was maintained at 0.8mL/min. 
The PDA was set to acquire absorbance data from 200 to 500nm.  
4.4 Results and discussion 
4.4.1 Method development 
The chemical characterisation of D. kaki L. extract has been previously published (YIN et al., 
2013; Zhou, 2014). It is outside the scope of this project to repeat the work and identify all 
peaks present in the NXQ extract. Instead, we focus on seven analytes, including quercetin 
and kaempferol, for which analytical methods were previously established in our lab. A 
mixture of the seven standards was composed to assess whether the known components of 
D. kaki L. were detectable in the commercial NXQ extract using the HPLC-PDA system. A 





Figure 4.5: HPLC chromatogram retention times for the seven analytes analysed in NXQ at 254nm. 
 
Figure 4.5 shows the chromatogram of the standardised patent D. kaki L. extract NXQ at 
254nm. The two largest peaks detected was quercetin (retention time 30 min) and 
kaempferol (retention time 32.5 min), with other compounds also present.  
Compounds have different absorption peaks (λmax) and molar absorptivities (ε) at different 
wavelengths, depending on the chromophore in the molecule. As the patent extract of D. kaki 
L. contains different compounds with different structures, a wavelength of 254nm that 
detects most of the compounds was selected based on previous studies (Kazzem, 2012). 
4.4.2 Accuracy 
The accuracy of the analytical methods was validated by comparing the retention times and 
UV spectrum of the peaks in the sample to certified reference standards.  
Accuracy refers to the ability of the method to produce results that are in agreement with 
the true values of the analyte concentration. The commonly used method to determine 
accuracy is by spiking the sample with known concentrations of the analyte(s) of interest. The 
spiking levels are usually 0 (unspiked), 50, 100 and 200 percent of the mean expected 
λdetection = 254 
nm 
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concentration. Results from the spiked sample can be compared to the expected 
concentration, which indicates for both the linearity of the method and its ability to produce 
an accurate result. Figure 4.6 is a chromatogram of the patent standard extract of D. kaki L. 
(NXQ) overlaid with the mixed standards. Comparison of the UV spectrum of the sample and 
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Figure 4.12: UV spectrum comparison between protocatcheuic acid and peaks tentatively identified as 
corresponding peaks in patent standardised D. kaki extract (NXQ). The protocatcheuic acid peak was Rt 3.8 min 




Figure 4.13: UV spectrum comparison between 2-furic acid and peaks tentatively identified as corresponding 
peaks in patent standardised	D. kaki extract (NXQ). The 2-furic acid peak was Rt 5.2 min in the mixed standard 
and 5.3 min in NXQ (pink). 
 
As shown in Figures 4.7–4.13, the peaks with the matching retention times to the mixed 
standards have similar UV spectrum. The lower concentration of compounds such as 2-furic 
acid and hyperin in the patent standardised D. kaki L. extract (NXQ) make it more difficult to 
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compare the UV spectrum, as at low absorbances the absorbance of the mobile phase 
dominates. In any case, there is a good retention time match between sample and standard 
peaks and a fair match between their UV spectra. The identification of the small peaks is 
considered tentative as some are close to detection limit.  
4.4.3 Linearity 
Linearity is the range over which the analytical method is able to produce results that are 
proportional to the concentration of analyte(s) in the sample. The linearity of a standard curve 
is determined by a series of injections of standard solutions of different concentrations, 
covering the expected concentration range in the test solution. The equation fitted to the 
standard curve should have an intercept close to 0 and R2 of >0.99. 
Figure 4.14 shows the linear relationship between the peak area versus concentration 
produced by a range of known concentration standards. The calibration curve of all tested 
standards was at R2=0.999 or above, showing a good linearity for the experimental data for 
the analytical method. 
  
A. concentration standards curve of protocatcheuic 
acid. The calibration curve is linear (R2=0.9995) 
(n=3). 
B. concentration standards curve of 2-fuoric acid. 
The calibration curve is linear (R2=0.9995) (n=3).  
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C. concentration standards curve of hyperin. The 
calibration curve is linear (R2=0.9991) (n=3). 
 
D. concentration standards curve of isoquercetin. 
The calibration curve is linear (R2=0.9998) (n=3). 
  
E. concentration standards curve of astragalin. The 
calibration curve is linear (R2=0.9998) (n=3). 
F. concentration standards curve of quercetin. The 
calibration curve is linear (R2=0.9997) (n=3). 
 
 
G. concentration standards curve of kaempferol. The 
calibration curve is linear (R2=0.9997) (n=3). 
 











































































Figure 4.14: Regression data for the seven analytes in the mix standard determined by HPLC. 
4.4.4 Precision 
Precision is the degree of agreement between a set of results produced by the same analytical 
method in several replicated extractions and analyses. The agreement is usually expressed 
and calculated from the standard deviation (SD) and relative standard deviation (RSD).  
Precision is divided into two categories: repeatability and reproducibility. Repeatability is 
the agreement between the test results produced using the same operating conditions in a 
short period of time by the same analyst. This is typically referred to as intra-day precision. 
Reproducibility is the standard deviation between a set number of samples run using the 
same operating conditions but over a long period of time, two weeks or more. This is typically 
referred to as inter-day precision. The precision that can be expected of the analytical method 
depends on the concentration of the selected analyte(s), where the lower the analyte 
concentration, the higher the expected standard deviation. 
Instrumental precision is determined by injecting a standard solution multiple times within 
a short period of time and determining the RSD of the peak area. The sample treatment 
contribution to total RSD can be estimated by subtracting the total RSD (calculated from the 
replicate extraction and measurement determinations) from the instrument RSD contribution. 
The general expectation is that the sample treatment will make the greater contribution to 
the total RSD. 
Table 4 shows the instrumental precision and total precision. The instrumental precision 
of the method was determined by six repeat injections of the mixed standard. The total 
precision of the method was determined by preparing seven replicates of the sample. The 
instrumental precision was determined to be acceptable at <2 % method precision was 
determined to be acceptable at <5% for all analyte. As shown in Table 4, the RSD for the 
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instrumental precision and total precision ranged from 0.08–0.68% and 0.82–3.41%, 
respectively. 
Table 4: Instrumental precision and total precision of the seven analytes of the mix standard  
Analyte Instrumental Precision (RSD)% Total Precision (RSD) % 
protocatcheuic acid 0.11 0.82 
2-furic acid 0.16 1.40 
hyperin 0.68 1.24 
isoquercetin 0.37 1.20 
astragalin 0.29 1.17 
quercetin 0.46 3.41 
kaempferol 0.08 0.85 
 
4.4.4.1 Inter-day precision 
The experiment was repeated on three separate days a week apart. Table 5 shows the SD 
between the results obtained on separate days. The RSD for the inter-day precision ranged 
from 0.5–5.7%. The inter-day RSD of <10% suggests adequate repeatability for the method.  
 
Table 5: Regression data and precision data for the seven analytes determined in mix standard 
Analyte Regression equation R2 Average 
mg/mL 
SD mg/mL RSD % 
Protocatcheuic acid y=21282x - 1.2616 0.9995 0.496 0.014 2.8 
2-furic acid y=44203x - 0.8459 0.9995 0.073 0.002 3.2 
Hyperin y=13579x +12.669 0.9991 5.451 0.198 3.6 
Isoquercetin y= 14221x + 9.9997 0.9998 9.874 0.279 2.8 
Astragalin y= 11821x + 1.6871 0.9998 11.624 0.059 0.5 
Quercetin y= 21629x +10.712 0.9997 5.867 0.337 5.7 
Kaempferol y= 185888x – 9.9448 0.9997 6.969 0.073 1.0 
n=3; RSD (%)=100 x SD/mean; y, peak area; x, the concentration of each compound (mg/mL); R, correlation 
coefficient of regression equations.  
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4.4.4.2 Limit of detection and limit of quantification 
To determine the LOD and LOQ of the analytical method, the samples were analysed seven 
times on the same day. This determines the SD of the analytical method. Three times the SD 
gives LOD while ten times the SD gives the LOQ. The LODs and LOQs of the seven analytes 
ranged from 0.003–0.647 mg/g and 0.010–2.158 mg/g, respectively. The method was found 
to be valid and used to quantify the main bioactive constituents and quercetin and 
kaempferol found in NXQ (Table 6).  
Table 6: Detection and quantification limits for the seven analytes determined in mix standard 
Compound LOQ (mg/g) LOD (mg/g) 
Protocatcheuic acid 0.038 0.012 
2-furic acid 0.010 0.003 
Hyperin 0.705 0.211 
Isoquercetin 1.227 0.368 
Astragalin 1.354 0.406 
Quercetin 2.158 0.647 
Kaempferol 0.598 0.179 
LOQ: limit of quantification (10x[SD of y-intercept/mean of slope]; LOD, limit of detection (3.33 x [SD of y – 
intercept/mean of slope]). 
 4.4.4.3 Quantification of active components in NXQ 
The concentration of each of the seven analytes in NXQ was determined by HPLC and the 
results presented in Table 7. Protocachueic acid and 2-furic acid were identified in the extract 
but with a very low concentration (0.58±0.01 and 0.08±0.01 mg/g respectively). The 
concentrations of the other five analytes including hyperin, isquercetin, astragalin, quercetin 
and kaempferol were found to be 5.27±0.07, 9.18±0.02, 12.93±0.08, 6.23±0.04, and 
8.10±0.02 mg/g respectively. Based on these results, ratio of quercetin to kaempferol was 
found to be ~3:4. 
Table 7: Concentration of analyte in NXQ determined by HPLC. SD calculated from seven replicates 
Compound Concentration (mg/g) ±SD  
Protocatcheuic acid 0.58±0.01  
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2-furic acid 0.08±0.01  
Hyperin 5.27±0.07  
Isoquercetin 9.18±0.02  
Astragalin 12.93±0.08  
Quercetin 6.23±0.04  
Kaempferol 8.10±0.02  
4.5 Conclusion 
The method was found to be valid for the quantification of the seven analytes in NXQ. The 
method was used to quantify the main bioactive constituents in the NXQ commercial extract 
and determine the ratio of kaempferol to quercetin. The ratio of quercetin to kaempferol was 















Vascular protection is known to be an important aspect of prevention and treatment of stroke. 
Neural damage can be initiated by acute ischaemia and exacerbated by reperfusion injury 
after the ischaemic attack (Hausenloy & Yellon, 2013). Reperfusion of ischaemic tissues is 
often associated with microvascular injury, particularly due to increased permeability of the 
capillaries and arterioles leading to increased diffusion and fluid filtration across the tissues 
(Kalogeris, Baines, Krenz, & Korthuis, 2012). Activated endothelial cells release excessive 
reactive oxygen species (ROS) following the reperfusion and the imbalance results in a 
subsequent inflammatory response and, ultimately, cell apoptosis (Go et al., 2010; Kalogeris 
et al., 2012).  
Living organisms produce ROS during normal and abnormal cellular metabolism. ROS are 
highly reactive molecules that can damage the cell structures, including carbohydrates, 
nucleic acids, lipids and proteins, and alter their functions (Go et al., 2010; Ray, Huang, & Tsuji, 
2012). Oxidative stress refers to an increased concentration of cellular oxidant and 
insufficiency of oxidant-scavenging agents to combat the change in intracellular environment. 
Oxidative stress is known to be one of the leading mediators of tissue injury in post-stroke 
reperfusion due to overwhelming of the ROS and loss of combating ability, which contributes 
to a variety of pathological changes such as cellular necrosis and apoptosis of affected tissues 
(Dorweiler et al., 2007). Regulation of the reducing and oxidising states, or ‘redox’, is critical 
for cell viability, activation, proliferation and organ function (Birben, Sahiner, Sackesen, 
Erzurum, & Kalayci, 2012). 
H2O2 is the major source of endogenous ROS responsible for oxidative stress and is mainly 
generated during hypoxia and ischaemic reperfusion injury (Ballinger et al., 2000). It was 
confirmed that H2O2 arose from the dismutation of superoxide generated within 
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mitochondria (Forman & Kennedy, 1974; Loschen, Azzi, Richter, & Flohé, 1974; Murphy, 2009). 
Accumulation of these ROS can lead to oxidative damage to mitochondrial proteins, 
membranes and DNA, impairing the ability of mitochondria to synthesis ATP and to carry out 
their metabolic functions (Murphy, 2009). 
Pervious study has shown that low concentrations of H2O2 (>200μmol/L) may induce 
endothelial apoptosis, which makes H2O2 a typical agent for studies of oxidative stress injury 
in in vitro models (C. H. Coyle et al., 2006).  
Previous studies have demonstrated that NXQ protects against H2O2-induced NG108-15 
neuron cell injury (Bei et al., 2004; Bei, Peng, Ma, & Xu, 2005a). It has been shown that NXQ 
attenuates the reduction of activities of intracellular endogenous anti-oxidant, glutathione 
and glutathione peroxidase by catalasing and decreasing lactate dehydrogenase (LDH) 
leakage, suggesting significant protection for NG108-15 cells against H2O2 insults by 
improving redox imbalance and inhibiting apoptosis (Bei et al., 2004, 2005a). However, the 
role of NXQ’s vascular protection property was not evaluated.  
In this study, we aim to evaluate the potential vascular protective effects of NXQ against 
H2O2-induced oxidative stress in human umbilical vascular endothelial cells (HUVEC). In vitro 
studies of cell viability, ROS scavenging and LDH leakage were tested using EA.hy926 cells. In 
addition, we evaluated the effects of the two main bioactive components of NXQ, kaempferol 
and quercetin, in an attempt to evaluate their contribution to NXQ’s therapeutic actions and 
their potential synergistic effects. 
In addition to the in vitro model described above, we also endeavour to develop an in vivo 
hypoxia model using adult zebrafish to evaluate the neuroprotective and vascular protective 
effects of NXQ. The model development is based on a published protocol (X. Yu & Li, 2011); 
however, we have not been able to replicate the published results despite investment of 
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substantial efforts and time. Our results are presented and discussed below to shed light on 
the issues and challenges associated with this model.  
5.2 Methods 
5.2.1 Chemicals and reagents 
The chemicals used are summarised in Table 5.1 
Table 8: Chemicals and reagents used for in vitro study 
Chemical Source 
Culture medium Dulbecco’s Modified Eagle’s Medium 
(DMEM/Ham’s F12 containing 15mM HEPES and L-glutamine, 
with phenol red) 
Life Technologies (Australia) 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich (Australia) 
Fetal bovine serum (FBS) Life Technologies (Australia) 
Hydrogen Peroxide  Sigma-Aldrich (Australia) 




NXQ Powder extracts Diospyros kaki. L Guangzhou Baiyunshan 
Pharmaceutical Co. Ltd. (PRC) 
Phenol red absence culture medium (DMEM/Ham’s F12 
containing 15mM HEPES and L-glutamine) 
Gibco™ (Australia) 
Phosphate-buffered saline (PBS) tablets Sigma-Aldrich (Australia) 
Penstrep (penicillin and streptomycin) Gibco™ (Australia) 
Quercetin Sigma-Aldrich (Australia) 
Trypsin (10x) solution Sigma-Aldrich (Australia) 
VEGF receptor tyrosine kinase inhibitor II (VRI) Calbiochem (Merck KGaA, Germany) 
5.2.2 NXQ extracts stock preparation 
To prepare the aqueous stock extract, the NXQ extract was weighed and dissolved in 99.9% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and mixed thoroughly with Vortex until fully 
dissolved. A serial dilution was made of concentrations 10, 50, 100, 250 and 500 (mg/mL). To 
prepare the dosing solution, the stock extract was diluted into serum-free culture mediums, 
93 
mixed thoroughly and filtered with Millex syringe filters (0.22µm pore size) to eliminate 
remaining precipitants.  
Table 9: NXQ extract stock measurements.Final testing concentrations are labelled in data figures for comparison 
purpose. Volume stock dissolved in serum-free culture medium are the concentration add into 
96 well micro-plate containing 200µL of serum-free medium. 
NXQ stock preparation Final testing concentration Volume stock dissolved in 
serum-free culture medium  
A. 250 mg/mL 500 µg/mL 4 µL of 250 mg/mL 
 250 µg/mL 2 µL/mL of 250 mg/mL 
B. 100 mg/mL 100 µg/mL 2 µL/mL of100 mg/mL 
C. 50 mg/mL 50 µg/mL 2 µL/mL of 50mg/mL 
D. 10 mg/mL 10 µg/mL 2 µL/mL of 10mg/mL 
5.2.3 Quercetin and kaempferol stock preparation 
Pure extracts of Q and K were purchased from Sigma-Aldrich. To prepare quercetin and 
kaempferol aqueous stock solution, the powdered compound was weighed based on 
molecular weight and dissolved in 99.9% DMSO (Sigma-Aldrich) and mixed thoroughly with 
Vortex until fully dissolved. A serial dilution was made of concentrations 10, 50, 100, 250 and 
500 (mmol/mL). To prepare the dosing solution, the stock extract was diluted into serum-free 
culture mediums. 
Table 10: Quercetin and kaempferol stock measurements. Final testing concentrations are labelled in data figures 
for comparison purpose. Volume stock dissolved in serum-free culture medium are the 
concentration add into 96 well micro-plate containing 200µL of serum-free medium. 
Stock preparation Final testing concentration Volume stock dissolved in 
serum-free culture medium  
A. 100 mmol/mL 500 µmol/mL 10 µL of 100 mmol/mL 
 250 µmol/mL 5 µL/mL of 100 mmol/mL 
 100 µmol/mL 2 µL/mL of 100 mmol/mL 
B. 50 mmol/mL 50 µmol/mL 2 µL/mL of 50 mmol/mL 
C. 10 mmol/mL 10 µmol/mL 2 µL/mL of 10 mmol/mL 
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5.2.4 Quercetin and kaempferol (3:4) combination stock preparation 
The ratio of Q and K combination was obtained as detailed in Chapter 4. Pure extract of Q and 
K was purchased from Sigma-Aldrich (Australia). To prepare Q and K aqueous stock solution, 
the powdered compound was weighed based on the ratio 3:4 respectively. The stock solution 
was weighed in mg/mL at concentrations of 3, 15, 30, 75 and 150 mg/mL, which is equal to 
the concentrations of 10, 50, 100, 250 and 500 mmol/mL respectively. Stock solution was 
dissolved in 99.9% DMSO (Sigma-Aldrich) and mixed thoroughly with Vortex until fully 
dissolved. To prepare the dosing solution, the stock solution was diluted into serum-free 
culture mediums and mixed thoroughly. 
Table 11: Quercetin and kaempferol (3:4) combination stock measurements. Final testing concentrations are 
labelled in data figures for comparison purpose. Volume stock dissolved in serum-free culture 
medium are the concentration add into 96 well micro-plate containing 200µL of serum-free 
medium. 
Stock preparation Final testing concentration Volume stock dissolved in 
serum-free culture medium  
A. 150 mg/mL  500 µmol/mL (150 µg/mL) 2 µL of 500 mmol/mL 
B. 75 mg/mL 250 µmol/mL (75 µg/mL) 2 µL/mL of 250 mmol/mL 
C. 30 mg/mL 100 µmol/mL (30 µg/mL) 2 µL/mL of 100 mmol/mL 
D. 15 mg/mL 50 µmol/mL (15 µg/mL) 2 µL/mL of 50 mmol/mL 
E. 3 mg/mL 10 µmol/mL (3 µg/mL) 2 µL/mL of 10 mmol/mL 
5.3 In vitro cell survival bioassays – experiment methodology 
5.3.1 Cell culture 
Human umbilical vein cell line (EA.hy926) was kindly provided by Dr Phoebe Zhou from the 
NICM research institute. The cell line was cultured in DMEM Hams’s F-12 containing 15 mM 
HEPES and L-glutamine and supplemented with 10% FBS, 100U/mL of penicillin and 
streptomycin (Gibco BRL, Australia). The cell line was grown in a 5% CO2- humidified incubator 
at 37°C and 95% humidity.  
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5.3.2 Cell viability determined by MTT dye reduction bioassays 
The MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), tetrazolium 
reduction assay was the first homogenous cell viability assay developed for a 96-well format 
that regarded fitting for high throughput screenings. The MTT assay has been widely adopted 
and has retained its popularity in academic labs. The MTT substrate was prepared in a 
physiologically balanced solution, added to cells in culture, usually at a final concentration of 
0.2–0.5mg/mL, and incubated for 1–4 hours. The quantity of formazan was measured by 
recording the changes in absorbance at 570nm using a plate-reading spectrophotometer (Riss 
et al., 2016). 
Viable cells with active metabolism convert MTT into a purple-coloured formazan product 
with an absorbance maximum near 570nm. When cells die, they lose the ability to convert 
MTT into formazan. Hence, colour formation is a convenient marker for viable cells. The cell 
viability of the tested sample is calculated based on the equation of cell viability percentage 
equals absorbance of treated cells divided by absorbance of untreated cells (control) 
multiplied by 100%. 
5.3.2.1 Experimental procedure 
EA.hy926 cell passage numbers 26–35 were seeded on a 96-well cell culture plate with culture 
medium (DMEM Hams’s F-12, containing 15mM HEPES and L-glutamine) and supplemented 
with 10% FBS, 100U/mL of penicillin and streptomycin (Gibco BRL, Australia) at a 
concentration of 1x105 cells/mL and allowed to confluence overnight. 
NXQ solution was prepared according to Sections 5.2.2 to 5.2.4 above. The cells were 
treated for 24 hours. 
After the treatment period, 100µl of supernatant was removed and an MTT solution with 
a final concentration of 0.5mg/mL in PBS was added to the cells and incubated for four hours 
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at 37°C and 5% CO2. After incubation, MTT solutions were removed and 50µL of DMSO (99.9%) 
added to dissolve the insoluble formazan crystal. The absorbance was measured at 570nm 
using a microplate reader (BMG Labtech Fluostar Optima, Mount Eliza, Victoria, Australia). 
The intensity of formazan formed in control (medium with vehicle DMSO) cells was taken as 
100% cell viability. Each experiment was repeated three times. 
5.3.3 Cytotoxicity induced by hydrogen peroxide (H2O2) 
Hydrogen peroxide (H2O2) is a reactive oxygen metabolic by-product that serves as a key 
regulator for some oxidative stress-related conditions such as cancer, neurological disorders 
(Jenner, 2003; Lyras, Cairns, Jenner, Jenner, & Halliwell, 1997; Sayre, Smith, & Perry, 2001; 
Toshniwal & Zarling, 1992), atherosclerosis, hypertension, ischaemic reperfusion (Dhalla, 
Temsah, & Netticadan, 2000; Kašparová et al., 2005; Kerr et al., 1999; Kukreja & Hess, 1992) 
and metabolic disorders (Asami et al., 1997; Pick & Keisari, 1980). The oxidative burst is 
characterised by a sharp increase in oxygen uptake followed by the channelling of the bulk of 
the oxygen from a biochemical pathway initiated by the one-electron reduction of oxygen 
towards a biochemical pathway using nicotinamide adenine dinucleotide phosphate (NADPH 
or NADH), a cofactor in anabolic reaction, as the electron donor (Pick & Keisari, 1980). Also, 
while superoxide can be directly toxic (Fridovich, 1998), its reactivity is mostly through 
superoxide dismutase to H2O2. Therefore, H2O2 almost always is formed under the 
circumstances in which superoxide is produced, acting as an electron donor.  
H2O2 diffuses freely into cells to produce several biochemical perturbations, including 
several metabolic pathways such as activation of hexose monophosphate shunt (Miller, 
Buettner, & Aust, 1990); introducing glycolysis and generating NADPH (Birben et al., 2012; 
Dupuy et al., 1991); oxidation of intracellular sulfhydryls (Ray et al., 2012); depression of 
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intracellular ATP (D. N. Granger, 1988); DNA damage (Ballinger et al., 2000; Halliwell & 
Gutteridge, 2015); loss of intracellular beta-NADH; activation of poly(ADP-ribose) polymerase; 
fast rise of intracellular calcium; gross perturbations to the cytoskeleton and plasma 
membrane; and depression in glycolytic flux (Birben et al., 2012; Sies, 2017). All of these 
processes occur before the loss of membrane integrity as measured by vital stains or before 
the loss of preloaded chromium (Sies, 2017). 
5.3.3.1 Experiment procedure 
To investigate the protective effect of NXQ against endothelial cell toxicity caused by H2O2, 
EA.hy926 cells were pre-treated for 30 minutes with NXQ at concentrations of 10, 50, 100, 
250 and 500μg/mL, quercetin, kaempferol, or quercetin and kaempferol (3:4) combination at 
concentrations of 10, 50, 100, 250 and 500 mmol/mL. H2O2 (0.5mmol) was then dosed and 
incubated for 24 hours. The cell viability was measured by MTT assay as described in Section 
5.3.2.1. Each experiment was repeated three times. 
5.3.4 Cytotoxicity induced by ROS 
ROS has been regarded as an essential source of oxidative stress leading to endothelial 
dysfunction. ROS are baneful to all aerobic species, and these molecules are typically 
generated as byproducts during the mitochondrial electron transport of aerobic respiration 
or by oxidoreductase enzyme and metal-catalysed oxidation (Murphy, 2009). Excess 
accumulation of ROS can induce endothelial cellular injury by modulating a series of 
intracellular signalling pathways. For example, it can directly quench the production of eNOS 
and upregulate the degradation of existing eNO, which onsets and exacerbates endothelium 
dysfunction (Förstermann, 2010).  
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Intracellular ROS is an important indicator in responding to cellular damage models 
induced by oxidative stress. In the Cellular Reactive Oxygen Species Detection Assay Kit 
(ab113851), a cell-permeant reagent 2’,7’–dichlorofluorescein diacetate (DCFDA) (a 
fluorogenic dye) is used to detect ROS within the cells through a series of chemical reactions. 
After DCFDA is diffused into the cells, it is deacetylated by cellular esterases to a non-
fluorescent compound, which is later oxidised by ROS into 2’, 7’–dichlorofluorescein (DCF). 
DCF is a highly fluorescent compound that can be detected by fluorescence spectroscopy with 
maximum excitation and emission spectra of 495nm and 529nm, respectively. The amount of 
ROS is proportional to the DCF that is measured. 
5.3.4.1 Experimental procedure 
The assay was conducted based on the protocol from the cellular ROS detection assay kit 
manufacturer (Abcam, Australia). EA.hy 926 cells were seeded on a 96-well cell culture plate 
with culture medium (DMEM Hams’s F-12 without phenol red), containing 15mmol HEPES 
and L-glutamine, and supplemented with 10% FBS, 100 U/mL of penicillin and streptomycin 
(Gibco BRL, Australia). Cells were seeded at 1x105 cells/mL and allowed to confluence 
overnight. The medium was then removed and the cells were washed once with 1X assay 
buffer (from the kit). The cells were then stained with DCFDA (20 μmol) at 100μL per well. 
The plate was incubated with a staining solution for 45 min at 37°C in the dark. After 
incubation, the DCFDA staining was removed and the plate immediately read under a 
microplate reader to get the initial absorbance (A0). The cells were then washed again with 
PBS and tested drugs were added at concentrations 10–500 μg/mL and treated for one hour. 
Finally, the absorbance at the endpoint (A1) was measured in the presence of the treatments 
under the same microplate reader. The wavelength was set up with excitation at 455nm and 
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emission 535nm in fluoresce mode. The final absorbance was calculated as A1 normalised 
with its corresponsive A0 (A1/A0). Each experiment was repeated three times. 
5.3.5 Cytotoxicity – lactate dehydrogenase leakage (LDH) measurement 
Apoptosis and necrosis are the two major forms of cell death observed in normal and disease 
pathologies. Necrosis is a type of cell death that is morphologically characterised by swelling 
and rupture of intracellular organelles, leading to permeabilisation of the plasma membrane 
(Challa & Chan, 2010; Schweichel & Merker, 1973). Plasma membrane leakage from necrotic 
cells causes the release of intracellular contents into extracellular milieu, which evokes 
inflammatory responses and is closely associated with inflammatory diseases (Kono & Rock, 
2008).  
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme that presents in majority of 
cells and is released through damaged plasma membranes (Burd & Usategui-Gomez, 1973; F. 
K.-M. Chan, Moriwaki, & De Rosa, 2013). Thus, LDH leakage measurement has been widely 
used to evaluate the presence of damage, toxicity or necrotic tissues and cells. Released LDH 
in culture supernatants is quite stable and can be quantitatively measured with a 30-minute 
coupled enzymatic assay through a series of chemical reactions (Promega, 2016).  
To detect the leakage of LDH into cell culture medium, a tetrazolium salt 
(iodonitrotetrazolium violet) is used in this assay. LDH released from leaky cells reacts with 
lactate and forms pyruvate via catalysing the oxidation of nicotinamide adenine dinucleotide 
(NADH), then converting the tetrazolium salt into a red formazan product (Korzeniewski & 
Callewaert, 1983). The amount of colour formed by formazan is proportional to the number 
of lysed cells (Promega, 2016). Absorbance for the optimal colour density can be measured 
using a microplate reader under the wavelength of 540nm.  
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5.3.5.1 Experimental procedure 
EA.hy926 cells were pre-treated for 30 min with NXQ at various concentrations of between 
10 and 500μg/mL quercetin, 10–500μg/mL kaempferol, or quercetin and kaempferol 
combination (3:4) at various concentrations between 10 and 500μg/mL. H2O2 (0.mM) was 
then dosed and incubated for 24 hours.  
After the treatment period, the supernatants from the cells were subjected to LDH 
measurement using a commercial kit (Promega, Australia) according to the manufacturer’s 
instructions. Briefly, the cells in the 96-well cell culture plate with supernatant after the 
treatment period were centrifuged at 250 X g for 4 min. Then 50μl of the supernatant was 
transferred from each test well to a fresh 96-well flat-bottom plate. Prepared CytoTox 96 
substrate mix (50μl) obtained from the kit was added to each well of the new 96-well plate, 
containing samples transferred from the original cytotoxicity assay plate. The plate was then 
covered with aluminium foil to avoid light and incubated for 30 min at room temperature. 
Finally, 50μl of stop solution (from the kit) was added to each well, and the absorbance was 
monitored at 490nm.  
The readings from the untreated and test wells are subtracted from the readings from the 
medium-only control wells. The reading from volume correction control wells are subtracted 
from the reading of maximum LDH release wells (H2O2 treatment only). Lastly, the percentage 
of cytotoxicity is calculated via the equation 1 (F. K.-M. Chan et al., 2013): 
 





	x100	 [Eq. 1] 
Each experiment was repeated three times. 
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5.3.6 Statistical analysis 
All statistic comparisons were performed using GraphPad Version 5.02(US). The statistical 
significance was analysed by one-way ANOVA test. Data were expressed as mean±SEM. 
Statistical significance was regarded when P <0.05 was obtained. 
5. 4 Results of cellular protective effects of NXQ on EA.hy926 cells  
5.4.1 Cytotoxicity of NXQ on EA.hy926 cells detected by MTT assay 
Cytotoxicity of NXQ (10–1000µg/mL; n=3) on EA.hy926 cells was examined using MTT assay 
to determine the safe dosage range. NXQ did not show any significant cytotoxic effects up to 
500 µg/mL. NXQ caused a significant reduction (~25%) in cell viability at 1000 µg/mL when 
compared to vehicle control. Therefore, all the subsequent experiments were conducted at 


































Figure 5.1: Endothelial cell death induced by NXQ (10–1000 µg/mL). Cell viability, as determined by MTT dye 
reduction assay in EA.hy926 endothelial cells for 24 hrs. Cell viability was expressed as a percentage of various 
concentrations of NXQ pure extract compared to control (0.1% DMSO). All results were expressed as mean±SEM 
from three separate experiments** p<0.01 vs control. 
5.4.2 Effects of NXQ, quercetin, kaempferol and quercetin and kaempferol (3:4) combination 
on cell survival against H2O2 on EA.hy926 cells 
To evaluate whether NXQ could protect against H2O2-induced cell damage, cells were pre-
treated with NXQ for 30 minutes, then tested on H2O2 (0.5mM) for 24 hours; cell viability was 
measured by MTT assay. EA.hy926 cell viability was markedly reduced (30%) by H2O2 (0.5mM; 
24 h) (p<0.05, n=3). Pre-treatment of NXQ (10–500µg/mL) protected cells against H2O2-
induced cell death (p<0.05 at 50, 250 and 500 µg/mL; n=3) (Figure 5.2A).  
The cell viability with pre-treatment of quercetin and kaempferol (3:4) combination 
followed by H2O2 (0.5mM) is shown in Figure 5.2D. Quercetin and kaempferol (3:4) 
combination also protected the EA.hy926 cell from H2O2-induced damage in a concentration-
dependent manner (p<0.001; n=3). 
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Figure 5.2: Protective effects of NXQ on EA.hy926 cells against H2O2 (0.5mM)-induced cell injury by restoring 
reduced cell viability at various concentrations of NXQ extract, quercetin, kaempferol, and quercetin–kaempferol 
(3:4) combination. (A): Protective effects of NXQ on EA.hy926 cells against H2O2 (0.5mM) induced cell injury by 
restoring reduced cell viability at various concentrations of NXQ extract. Cell viability was determined by the MTT 
method in EA.hy926 cells for four hrs. Cell viability was expressed as a percentage vs H2O2 treatment only. NXQ 
extract at 10, 250 and 500 µg/mL showed statistical significance. All results were expressed as mean±SEM from 
three separate experiments. * p<0.05 vs H2O2 treatment only. (B): Protective effects of kaempferol on EA.hy926 
cells against H2O2 (0.5mM)-induced cell injury by restoring reduced cell viability at various concentrations of 
kaempferol. Cell viability was determined by the MTT method in EA.hy926 cells for four hrs. Cell viability was 
expressed as a percentage vs H2O2 treatment only. (C): Protective effect of quercetin on EA.hy926 cells against 
H2O2 (0.5mM). (D): Protective effects on Q3:K4 (quercetin and kaempferol 3:4 combination) on EA.hy926 cells 
against H2O2 (0.5mM)-induced cell injury by restoring reduced cell viability at various concentration. Cell viability 
was determined by the MTT method in EA.hy926 cells for four hrs. Cell viability was expressed as a percentage 
vs H2O2 treatment only. Q3:K4 combinations at 50, 100, 250 and 500 mmol/mL showed statistical significance. 
All results were expressed as mean±SEM from three separate experiments. * p<0.05 compared to H2O2. ** 
p<0.001 vs H2O2 treatment only. V:p<0.05 compared to control. *** p<0.001 compared to H2O2. 
 
In addition, Figure 5.3 provides a comparison for specific concentrations between the active 
components and their combination in the ratio detected from NXQ. Based on the results 
shown in Figure 5.3, kaempferol failed to protect against H2O2 damage (p>0.05) in all 
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concentrations (10, 50, 100, 250 and 500mmol/mL). Interestingly, quercetin showed 
protection at concentration 10mmol/mL (p<0.05). However, at higher concentrations 
quercetin failed to restore cell viability (50, 100, 250 and 500mmol/mL) (p>0.05). This 
observation suggests that quercetin and kaempferol alone do not protect cell death caused 
by H2O2. In contrast, a potential effect on cell survival against H2O2 of the quercetin–
kaempferol combination (3:4) is observed at concentrations 50, 100, 250 and 500mmol/mL. 
The quercetin–kaempferol combination (3:4) significantly restored cell viability against H2O2 
damage (p<0.05) in comparison to quercetin and kaempferol alone at their specific 
concentration. This suggests that when quercetin and kaempferol are combined at a ratio of 
3:4, a cellular protective effect against H2O2 was enhanced. These results suggest a potential 
synergistic or additive effect which requires further investigation.  
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Figure 5.3: Restoring cell viability against H2O2, effects determined between groups based on single 
concentration. Q3:K4 (quercetin–kaempferol 3:4 combination) compared with quercetin and kaempferol at 
concentration 10 mmol/mL (A), 50 mmol/mL (B), 100 mmol/mL(C), 250 mmollmL (D) and 500 mmol/mL (E) on 
EA.hy926 cells (p<0.05; n=3). v:p<0.05 compared to control. *** p<0.001 compared with H2O2. 
5.4.3 Effects of NXQ on H2O2-induced ROS generation in EA.hy926 cells 
As shown in Figure 5.4A, EA.hy926 cells incubated with H2O2 exhibited a significant increase 
in ROS production compared to the control group (p<0.05; n=3). Pre-treatment of NXQ (10-
106 
500µg/mL) significantly attenuated ROS generation by H2O2 (p<0.05: n=3) in a concentration-
dependent manner. 
Similarly, pre-treatment of quercetin (10–500 mmol/mL) significantly attenuated the ROS 
generation induced by H2O2 (p<0.05; n=3) (2.4C). The ROS attenuation effects are relatively 
linear between concentrations 50, 100, 250 and 500 (mmol/mL) with no significant dose 
dependency curve. In Figure 5.4B, pre-treatment with kaempferol showed significant 
attenuation of H2O2-induced ROS level in a concentration-dependent manner. However, a 
statistical significance was only observed at 250 and 500 mmol/mL (p<0.05; n=3). In Figure 
5.4D, pre-treatment with the quercetin and kaempferol combination (10–500 µg/mL) 
significantly attenuated the ROS generation induced by H2O2 (p<0.05; n=3).  
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Figure 5.4: ROS inhibition by NXQ extracts. (A), kaempferol (B), quercetin (C), and Q3:K4 (quercetin and 
kaempferol combination 3:4)(D) on H2O2 (0.5mM)-induced ROS production in EA.hy926 endothelial cells. ROS 
was determined using DCFDA Cellular ROS Detection Assay. ROS inhibition was expressed as O.D. compared to 
H2O2 treatment only. All results were expressed as mean±SEM from three separate experiments. V: p<0.001 
compared to control. ***p<0.001 vs H2O2 treatment only. 
 
We further compared the analytes quercetin, kaempferol and their combination (3:4) for its 
attenuation effects on ROS induced by H2O2 (Figure 5.5). The quercetin–kaempferol 
combination shows a better attenuation of ROS generation at 100, 250 and 500 mmol/mL 
(p<0.001) compared to quercetin and kaempferol at concentrations between 100, 250 and 
500 mmol/mL. Quercetin seems to be responsible for its ROS attenuation property against 
H2O2-induced ROS generation, which is significantly inhibited at concentrations 100, 250 and 
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500 mmol/mL. Kaempferol, in contrast, only showed inhibition of ROS generation at a higher 
concentration, 250 and 500 mmol/mL (Figures 5.5 D and E). The effects of the quercetin–
kaempferol combination and quercetin and kaempferol alone may not show a significant 
difference among themselves; however, the ROS attenuation effects does seem to be more 
prominent in the quercetin–kaempferol combination (Figure 5.5E). While quercetin may be 
the main compound responsible for its ROS attenuation effects, kaempferol may also provide 
a protective effect against H2O2 at a higher concentration. The possible reason for the big 
inter-experimental variations on the baseline presented in Figure 5.4A and Figure 5.4 B,C&D 
is that the data presented in Figure 5.4A were collected at the early stage of the experimental 
study before further examination of individual components. The variation shown in the 
control bar may be due to the lack of experimental skills at the early stage of the candidature. 
The control baselines were relatively similar in Figure 5.4 B, C and D following improved 
experimental skills. Nevertheless, the data presented in Figure 5.4A provided preliminary 
evidence suggesting NXQ extract significantly restore cell viability by attenuating ROS. 
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Figure 5.5: ROS inhibition induced by H2O2, effects determined between groups based on single concentration.	
Q3:K4 (quercetin–kaempferol 3:4 combination) compared with quercetin and kaempferol at concentration 10 
mmol/mL (A), 50 mmol/mL (B), 100 mmol/mL (C), 250 mmol/mL (D) and 500 mmol/mL (E) on EA.hy926 cells. v: 
p<0.001 compared to control. ***: p<0.001 compared to H2O2. 
5.4.4 Effects of NXQ on H2O2-induced LDH leakage in EA.hy926 Cells 
As presented in Figure 5.6A, EA.hy926 cells incubated with H2O2 significantly increased LDH 
leakage compared to the control group. Cells pre-treated with NXQ (10, 50, 100, 250 and 500 
µg/mL) significantly attenuated H2O2-induced LDH leakage in a concentration-dependent 
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manner (p<0.001, n=3) (Figure 5.6A). Similarly, in Figure 5.6B, kaempferol significantly 
reduced LDH leakage induced by H2O2 at concentrations 50–500 mmol/mL (p<0.001, n=3). In 
contrast, cells pre-treated with quercetin showed a dose-dependent manner 50 mmol/mL 
(p<0.05), 100 mmol/mL (p<0.01), 250 and 500 mmol/mL (p<0.001) in inhibiting LDH 
production respectively (n=3) (Figure 2.6C). 
Cells pre-treated with quercetin and kaempferol (3:4) combination (10–500 mmol/mL) 
significantly attenuated the increased LDH leakage induced by H2O2 (p<0.001, n=3) as shown 
in Figure 5.6D. 
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Figure 5.6: LDH leakage induced by H2O2 (0.5mM) in EA.hy926 endothelial cells. LDH leakage was determined 
using LDH cytotoxic kit mixing the supernatant with the reaction mixture. LDH leakage was expressed as a 
percentage compared to H2O2 treatment only. NXQ with concentrations between 10 and 500 µg/mL was tested 
(A). Q3:K4 (quercetin–kaempferol (3:4) combination) (B) with concentrations between 10 and 500 mmol/mL 
were tested. Quercetin (C) and kaempferol (D) with concentrations from 10 to 500 mmol/mL were tested 
retrospectively. All results were expressed as mean±SEM from three separate experiments. *p<0.05, **p<0.01 
and ***p<0.001 vs H2O2 treatment only (n=3). 
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Figure 5.7: LDH inhibition induced by H2O2, effects determined between groups based on single concentration.	
Q3:K4 (quercetin–kaempferol combination 3:4) compared with quercetin and kaempferol at concentration 10 
mmol/mL (A), 50 mmol/mL (B), 100 mmol/mL (C), 250 mmol/mL (D) and 500 mmol/mL (E) on EA.hy926 cells 
(p<0.001; n=3).***: p<0.001 compared to H2O2. 
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The comparison of quercetin, kaempferol and quercetin–kaempferol combination responses 
to the LDH attenuation induced by H2O2 is shown in Figure 5.7. Quercetin, kaempferol and 
quercetin–kaempferol (3:4) combination appear to significantly attenuate LDH leakage at 
concentrations of 50, 100, 250 and 500 mmol/mL. However, quercetin at 250 mmol/mL 
seems to have the strongest effect in attenuating LDH leakage compared to kaempferol and 
the quercetin–kaempferol combination. The quercetin–kaempferol combination does not 
appear to be better at inhibiting LDH leakage than quercetin alone.  
5.5 Discussion of the protective activity of NXQ in cell survival 
Endothelial dysfunction caused by elevated cerebrovascular oxidative stress is one of the 
main features of reperfusion injury and the consequent loss of BBB causes irreversible neural 
damage (Alfieri et al., 2013; Nour, Scalzo, & Liebeskind, 2012; Poon et al., 2010). Therefore, 
interventions that can protect endothelial cells from ROS-induced damage would be 
beneficial in ischaemic cerebral injuries. In the present study, we demonstrated that NXQ 
could protect EA.hy926 cells from oxidative stress and cell damage caused by H2O2. 
NXQ, a standardised, patent herbal extract, has been used clinically as part of traditional 
Chinese medicine to improve cerebral atherosclerosis, transitory ischaemia syndromes, 
cerebral thrombogenesis, cerebral thrombosis sequelae, apoplexy sequelae and cerebral 
embolism, with minimal adverse effects (Bei et al., 2007; Y. Cai & Yang, 2001). Previous 
studies suggest that NXQ has potential lipid-lowering, oxidant-scavenging, anti-inflammatory 
and anti-hypertensive effects. It has been reported that NXQ possesses neuroprotective 
properties against ischaemia-related cerebral injuries (Bei et al., 2007). However, its role in 
vascular protection was not clearly defined. Microvascular injuries after reperfusion are 
regarded as the main cause of major neuron damage (Khatri, McKinney, Swenson, & 
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Janardhan, 2012; Nour et al., 2012). In this study, we evaluated the effects of NXQ on H2O2-
induced microvascular injury to further understand the mechanisms underlying neuro- and 
cerebrovascular-protective effects of NXQ in ischaemic stroke. 
First, we conducted a toxicity test of NXQ with various concentrations from 10 to 1000 
µg/mL on EA.hy926 cells. We found that NXQ at concentrations over 500 µg/mL showed a 
toxicity effect on cell viability (p<0.01; n=3) in comparison to controls. This result was similar 
to that of Bei et al. (2004), who reported that NXQ markedly decreased cell viability in a dose-
dependent manner when NXQ concentrations reached 500 μg/mL. 
Additionally, we evaluated the protective effect of NXQ on H2O2-induced cell injury in 
EA.hy926. Our results showed that NXQ (10–500 µg/mL) significantly suppressed the elevated 
ROS production induced by H2O2.	 However, NXQ only restored cell viability at higher 
concentrations, from 250 to 500 µg/mL. This suggests NXQ is capable of protecting cells 
against oxidative stress by altering the ROS level, but not strong enough to protect EA.hy926 
cells from apoptosis at concentrations less than 100 μg/mL.	 
In contrast, Bei et al. evaluated NXQ at concentrations between 2 and 30 μg/mL and 
reported that at 30 μg/mL NXQ significantly restored cell viability against H2O2 insult. 
However, in the current study NXQ did not show any significant protection at concentrations 
from 2 to 10 μg/mL. This discrepancy between the two studies may be due to the variation of 
cell lines and their susceptibility to NXQ treatment, and incubation time. In the latter case, 
Bei et al. (Bei et al., 2004) pre-treated the cells with NXQ for two hours, compared to 30 
minutes in the present study, suggesting the dose and treatment time play a critical role in 
NXQ’s effects on cell viability in response to H2O2 insults. 
In addition, our study also showed that NXQ (10–500 µg/mL) significantly suppressed the 
release of LDH leakage via restoring damaged plasma permeability induced by H2O2 (p<0.001, 
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n=3). This result is consistent with the findings of Bei et al. In their study, NXQ attenuated LDH 
leakage in a dose-dependent manner even though the effective concentration range (2–30 
µg/mL) was lower. 
In another study, Bei et al. (Bei et al., 2005a) reported the potential neuroprotective effects 
of NXQ using an H2O2-induced oxidative stress injury model in NG108-15 cells. The results of 
the study confirmed that NXQ reduced elevation of malondialdehyde in cells, increased 
release of intracellular lactate dehydrogenase into culture medium, and increased activity of 
intracellular anti-oxidant enzymes including catalase (CAT), glutathione peroxidase (GSH-Px) 
and the amount of the intracellular anti-oxidant glutathione (GSH). 
The same group of researchers further evaluated neuroprotective effects against CI/R 
damage, excitotoxic injury and hypoxia–reoxygen injury (Bei et al., 2007) and showed that 
NXQ also exhibited significant neuroprotective effects against H2O2-induced oxidative stress 
injury by improving redox balance in a concentration-dependent fashion and enhancing the 
expression of anti-apoptosis gene BCL2. BCL2 is a key anti-apoptosis gene and a mitochondrial 
protein involved in delaying neuron death and cerebral ischaemic injury through inhibiting 
the formation of reactive oxygen molecules, increasing ischaemic tolerance and resistance to 
oxidative stress and scavenging free radicals directly (Kane et al., 1993, Martinou et al., 1994; 
Chen & Simon, 1997). 
In answering the question of whether the main bioactive compounds of NXQ, quercetin 
and kaempferol, play a role in the observed effect of NXQ, the current demonstrated that 
both quercetin and kaempferol significantly reduced elevated ROS. Quercetin, in particular, 
inhibited the generation of ROS-induced by H2O2 at all concentrations 50–500 mmol/mL 
(p<0.001, n=3), whereas kaempferol significantly inhibits the elevation of ROS only at higher 
concentrations (250 and 500 mmol/mL) (p<0.001, n=3). However, quercetin and kaempferol 
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alone do not improve cell viability (p>0.05, n=3) at all concentrations, suggesting that these 
compounds when acting alone did not protect the cell from apoptosis. NXQ, on the other 
hand, significantly restored cell viability at 250–500 µg/mL, suggesting possible synergistic or 
additive effects among the individual bioactive compounds in the mixture. To further clarify 
whether the two bioactive compounds have an additive or synergistic effect, we tested a 
combination of quercetin and kaempferol at the same ratio (3:4) detected in NXQ extract. 
The quercetin–kaempferol combination significantly improves cell viability at concentrations 
of 50, 100, 250 and 500 mmol/mL (p<0.001, n=3). This suggests that quercetin and 
kaempferol when used together may have a synergistic effect in restoring cell viability caused 
by H2O2.  
Quercetin and kaempferol also show an ability to markedly inhibit LDH release. Quercetin 
most significantly inhibited LDH release at concentrations 50–500 mmol/mL in a 
concentration-dependent manner (p<0.001, n=3). Kaempferol, on the other hand, inhibited 
LDH release at concentrations 50–500 mmol/mL (p<0.001,n=3). The effects of a combination 
of quercetin and kaempferol at a ratio of 3:4 was also investigated. Although the combination 
demonstrated a significant inhibition of LDH leakage, its effect does not appears to be better 
than that of quercetin alone, suggesting that quercetin may play a greater role in suppressing 
LDH leakage in the mixture. 
Soobrattee and colleagues (Soobrattee, Neergheen, Luximon-Ramma, Aruoma, & Bahorun, 
2005) evaluated the anti-oxidant effects of quercetin and kaempferol and reported that 
kaempferol had a weaker oxidant-scavenging property compared to other flavanol aglycones 
such as quercetin and myricetin. The authors suggest that the low anti-oxidant activity of 
kaempferol could be attributed to the presence of a single hydroxyl group in the B ring which 
apparently makes little contribution even in the presence of the conjugated double-bond 
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system and the 3-OH group (Soobrattee et al., 2005). Further to this, our results showed that 
the combination of quercetin and kaempferol (3:4) produced a greater effect in reducing ROS 
elevation (p<0.05) than quercetin and kaempferol alone at all concentrations. This 
observation further supports the hypothesis that quercetin and kaempferol exert an additive 
or synergistic effect on cell viability at a ratio detected in NXQ extracts. This conclusion is 
consistent with that of Hidalgo et al. (2010), who propose that flavonoids present in a mixture 
can interact and that their interactions can affect the total anti-oxidant capacity of the 
mixture. 
In their study, Hidalgo et al. report that pelargonidin-3-glucoside and kaempferol, with only 
one hydroxyl group in the B ring, individually possessed the lowest anti-oxidant capacity. 
However, when kaempferol was paired with myricetin, quercetin or quercetin-3-glucoside, a 
statistically significant increase in anti-oxidant activity was observed. While the ratio of the 
compounds in their combination was not clearly defined, the results suggest that flavonoids 
could interact when mixed together, leading to synergistic and/or antagonistic effects.  
Put together, the results of this study demonstrate that NXQ possesses cell-protective 
properties against H2O2-induced cytotoxicity and demonstrates significant effects on 
restoring cell viability, reducing ROS elevation and inhibiting LDH leakage. In addition, 
preliminary evidence supports the synergistic/addictive interactions between the two key 
bioactive flavanols of NXQ, quercetin and kaempferol. Based on these results, more research 
is warranted to understand the nature of and mechanisms underlying the synergistic effects 
between quercetin and kaempferol and their potential role in the observed clinical effect of 
NXQ. 
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5.6 Development of an in vivo hypoxia model in zebrafish 
In this study, we have attempted to establish a zebrafish hypoxia model to be used for the in 
vivo evaluation of the neuroprotective effect of NXQ. This model development was based on 
the previously published results of Yu et al. (X. Yu & Li, 2011, 2013) and Braga et al. (Braga et 
al., 2013). After several attempts, a model was established. However, the results from the 
hypoxia and normoxia groups were not significantly different, in contrast to previous reports. 
Hence, the test of NXQ using this model did not proceed. This section describes the model 
development details, the preliminary data collected, and the problems identified and 
potential troubleshooting strategies for future studies. 
5.6.1 Zebrafish as an in vivo model for drug screening 
Zebrafish (Danio rerio) is a freshwater fish that originated in northern India and adjacent 
countries. They are usually found in shallow water or streams and are a widely used 
vertebrate model organism in biological and biomedical research (Kari, Rodeck, & Dicker, 
2007; Langheinrich, 2003). Zebrafish exhibit unique characteristics that are desirable in an 
animal model, including having a short reproductive cycle and being easily bred in large 
numbers (100–150 embryos per mating). In addition, the availability of genetically 
manipulated zebrafish strains, functional knockdown of specific genes by Morpholino 
technology and easy and low-cost maintenance provide zebrafish an advantage over other 
existing disease models. Furthermore, their ex utero development and optical clarity during 
embryogenesis allow for visual analysis of early developmental process and organ 
morphology (Kimmel, Ballard, Kimmel, Ullmann, & Schilling, 1995).  
Zebrafish develop relative quickly, with the entire body structure plan established and all 
the precursor cells and tissues of the brain, eyes and heart easily visualised using light 
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microscopy at 24 hours post fertilisation (hpf). At 72 hpf, embryogenesis is complete, and the 
internal organs, including cardiovascular system, gut, liver and kidney, are fully matured by 
96 hpf. This rapid development is comparable to three months of development in human 
embryos (Y. Sun, Fang, Xu, Lu, & Chen, 2015). In comparison to other organisms, such as fruit 
flies and worms, there are numerous symmetries between zebrafish and humans that make 
zebrafish a desirable model organism for studying complex biological processes, including 
generation of the nervous system, kidney, heart, hematopoietic system, and notochord (Kari 
et al., 2007; Kimmel et al., 1995; Parng, Seng, Semino, & McGrath, 2002).  
5.6.2. Acute hypoxia-induced brain damage model in zebrafish 
Recently, large-scale genetic screens have generated hundreds of zebrafish mutants, many of 
which show phenotypes resembling human disease states such as congenital heart disease, 
Alzheimer’s disease and stroke. Moreover, the ectopic expression of transgenes can be used 
not only to study ‘gain of function’ phenotypes in zebrafish, but also to generate chimeric 
animal models to study specific human proteins such as receptors or signalling effectors 
(Langheinrich, 2003; Parng et al., 2002).  
Currently, there are few established models to simulate the various types of ischaemic 
stroke. As ischaemic damage is primarily associated with deprivation of oxygen, hypoxia 
models were introduced as the most comparable model for the acute ischaemic condition (X. 
Yu & Li, 2011). A hypoxic environment was created by pumping nitrogen into a concealed 
container to ensure an anoxic environment where oxygen saturation is below a specified level. 
Zebrafish are then transferred into the chamber, triggering the onset of hypoxic brain damage. 
This model allows for a relatively quick induction of ischaemic stroke and is therefore a viable 
model for the assessment of both preventative measures (pre-treated) and therapeutic 
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measures (post-treated) of neuroprotection (infarct size) for an intervention. Yu and Li (2013) 
have further adapted this model to assess the neuroprotective effects of zinc chelation for 
acute ischaemic stroke. Their study was able to identify differences in infarct sizes between 
treatment and control groups; however, 60% of zebrafish died during hypoxic treatment 
before intervention was given (X. Yu & Li, 2013). Cao et al. (Z. Cao et al., 2010), who published 
a protocol for creating a chronic hypoxic model in zebra fish, assessed angiogenesis due to 
oxygen deprivation and pointed out that the oxygen saturation needed to be monitored and 
gradually decreased in order to reduce death rates in the fish. In this study, we aimed to 
develop a hypoxic model in zebrafish based on the above studies as a reliable in vivo model 
to evaluate the neuro- and cerebrovascular-protective effects of NXQ in ischaemic stroke. 
6.6.2.1 Ethics statement  
All animal experiments were conducted according to the ethical guidelines of Western Sydney 
University. The protocol was approved by Animal Ethics Committee, Western Sydney 
University (ethics approved protocol number A10378). 
5.6.2.2 Animal 
Adult zebrafish (D. rerio) ~6 months old were procured from the School of Medicine Zebrafish 
Research Facility and were kept in aquaria under a 12h light/12h dark photoperiod with half 
deionised water plus half dechlorinated water (made with fresh tap water with sodium 
thiosulfate, a dechlorinating agent, 10–15mg/L) at room temperature (X. Yu & Li, 2013).  
5.6.2.3 Maintenance of zebrafish  
Zebrafish were maintained in a controlled environment at a temperature of 28˚C on a 
12h/12h light/dark cycle according to the zebrafish handbook (Westerfield, 1993) within the 
zebrafish lab facility in School of Medicine in Western Sydney University. Zebrafish were 
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stored in 3.5L or 5L Tecniplast tanks that complied with Australian and NSW standards, with 
automatic monitoring of environmental conditions such as water temperature, pH level (~pH 
6.73–6.75), and dissolved oxygen saturation. Each tank housed up to a maximum of 120 fish. 
Adult zebrafish were fed with dry food flakes or pellets, live artemia or shell-free artemia, 
three times daily from Monday to Friday and once daily during weekends and public holidays 
in compliance with School of Medicine Zebrafish Feeding Standard Operation Procedures. 
5.6.2.4 Establishment of hypoxia chamber 
An hypoxic environment was created using a hypoxia chamber similar to that previously 
reported by Yu and Li (X. Yu & Li, 2011). The hypoxia chamber was constructed using a one-
litre clear container filled with 800 mL of distilled water (Figure 5.8). A dissolved oxygen 
sensor (3) was placed inside the container and connected to an external readout to monitor 
the oxygen level of the chamber. The chamber has one port (4) which connects to a nitrogen 
tank, allowing for nitrogen to be perfused into the water, and a sealable lid (2) with another 
port (5) connecting the air space inside the chamber to the open air (1). The hypoxic 
environment was created by pumping pure nitrogen into the water until the dissolved oxygen 
level was less than 1mg/L (approximately 0.5~0.75mg/L). The time required to reach anoxia 
environment was recorded.  
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Figure 5.8: Hypoxia chamber. (1) Sealing cap for oxygen outlet port (2) Sealable lid (3) Dissolved oxygen sensor 
(4) Nitrogen inlet port (5) Oxygen outlet port.  
 
5.6.2.5 Validation of hypoxia chamber and hypoxia treatment 
The hypoxia model was validated to ensure the equipment and procedures produced a stable 
hypoxic environment similar to those previously reported. An hypoxic environment was 
generated by pumping pure nitrogen into the water until the desired dissolved oxygen level 
(<1mg/L) was reached. The chamber was repeatedly tested and oxygen levels measured in 
response to various rates and periods of nitrogen infusion. Once a hypoxic environment was 
established, a single zebrafish was transferred into the chamber. Once the lid had been 
resealed, nitrogen was continuously perfused for an additional period to ensure a hypoxic 
environment was maintained. Nitrogen was turned off and the port located on the lid was 
then immediately sealed. The time taken to re-establish an hypoxic environment during 
validation was recorded and averaged.  
5.6.2.6 Measurable parameters 
Several parameters were measured as the zebrafish underwent the hypoxic treatment, 



















chamber once the ideal oxygen level was achieved and was observed closely to detect the 
representative behaviours in response to hypoxia as described by Braga et al. (2013) (Table 
12). Once the third level of behaviour sequence (i.e., maintenance of opercular beats with 
brief movements) was observed as the end point of global ischaemia, the time to reach this 
endpoint was recorded and the zebrafish was removed and transferred to a recovery 
chamber with oxygen level approximately 7mg/L. Death and survival rate was recorded. 
For the zebrafish that survived the hypoxic treatment, duration to full recovery was 
assessed by recording the time between post-hypoxia treatment and fish swimming normally 
again in the recovery chamber. They were kept in the recovery chamber for 24 hours. 
Table 12: Summary of representative behaviours reported by (Braga et al., 2013)  
 Behaviour sequence Description 
1st Swimming at the top 
2nd Loss of posture 
3rd Maintenance of opercular beats with brief movements 
4th Death 
 
5.6.2.7 Brain Extraction, TTC Staining and Measurement 
After 24 hours of recovery time, the fish were euthanised with 8 mg/mL tricaine (ms222) 
(Sigma, Australia). The brain was then extracted via tissue dissection performed in cold 
artificial cerebral spinal fluid before staining. The average time for brain extraction was kept 
as minimal as possible at an average of two minutes.  
Ischaemic brain damage was evaluated using 2,3,5-triphenyltetrazolium chloride (TTC) 
staining as described by Yu and Li (2013). The staining was performed at 24 hours after the 
hypoxia treatment. The entire brain was extracted immediately after dissection and 
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incubated in TTC solution (2% by weight) in darkness for 40 minutes. After staining, the TTC 
solution was discarded and the brain tissue was placed in an oven at 40°C for 4–6 hours to 
eliminate excess fluid. The dried brain tissue was then weighed and recorded. For dye 
extraction, the brain tissue was gently rinsed with two drops DMSO/ethanol (1:1) solution, 
and then placed individually inside a well of a 96 well plates with 100μL DMSO/ethanol (1:1) 
solution in darkness for extraction over six hours. The brain tissue was then removed and the 
supernatant of the dye was measured at 590nm with a microplate reader (Sabaeifard, Abdi-
Ali, Soudi, & Dinarvand, 2014). The readings were normalised by weight and calculated for 
the final absorbance result. The calculation for the percentage of TTC absorbance were 
measured using the equation 2. 
  
% TTC absorbance = >?/#$?)+"%	
@%*,A&	(.,)
 x100  [Eq. 2] 
5.6.3 Results 
5.6.3.1 Validation of hypoxic chamber and hypoxia condition 
Based on the above results, nitrogen was perfused for a minimum duration of five minutes, 
maintaining the oxygen level at 7mg/L according to validation averages plus 20% to ensure 
an anoxic environment.  
5.6.3.2 Results of zebrafish undergoing hypoxia treatment 
The survival rate for the hypoxia treatment was ~90%, with an average of one death in every 
10 hypoxia-treated fish.  
The average time to induce global ischaemia endpoint (maintenance of opercular beats 
with brief movements) was between 3.32 and 31.35 minutes (Table 13). The observed 
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recovery time (fish begin to swim after hypoxia treatment) was 11.56± 9.38 minutes on 
average. 
Table 13: Maximum, minimum and average hypoxia and recovery time collected (n=18)  
 Maximum Minimum Average 
Hypoxia time induced global 
ischaemia 
31.35 min 3.32 min 11.56±9.38 
Recovery time until normal 
swimming activity observed 
12.34 min 1 min 4.67±3.8 
 
As presented in Figure 5.9, no significant difference in the TTC absorbance was observed 
between the hypoxia and normoxia groups (p=0.1878). The average absorbance for the 
hypoxia group was 35.9% for the normoxia group (control) 40.77%.  
 
Figure 5.9: Absorbance % relative to weight (mg) of the brain sample. Control sample (n=16), hypoxia sample 


































The model developed was not suitable for evaluation of the neuroprotective effect of NXQ as 
none of parameters detected a significant difference between hypoxia and normoxia groups. 
However, some valuable results were obtained that may shed light on further development 
of this potentially useful model.  
Several issues were identified during the development process. The time for obtaining and 
preparing sliced brain tissue for staining was very long, which may lead to further tissue 
damage that is not purely induced by hypoxia. Initially, attempts were made to use the 
hypoxia end point as described by Yu and Li (X. Yu & Li, 2011, 2013), which was defined as 
zebrafish staying motionless for one minute. A very high fatality rate of 90% was experienced. 
Of a group of ten zebrafish, only one survived the hypoxia treatment, whereas Yu and Li 
reported a survival rate of 40%. As a result the end point was modified based on (Braga et al., 
2013), and defined as maintenance of opercular beats with brief movements. This led to a 
significant improvement in the survival rate.  
Initially the same oxygen cut-off level (0.6–0.8 mg/L) described by Yu and Li (2011) was 
used in the hypoxia chamber. However, this resulted in a significantly longer time to achieve 
the desired hypoxic condition than was reported by Yu and Li (2011). The hypoxia time 
needed was 3.32–31.35 min, as opposed to the 9–16 mins reported in Yu and Li’s study (2011). 
This observation may indicate that the hypoxia tolerance of zebrafish is affected by different 
strain used, environment, sex, age or other factors (Arslan-Ergul & Adams, 2014; Rees, 
Sudradjat, & Love, 2001). Roberson et al. (2014) were the first to report that gender 
differences in adult fish positively affected hypoxia tolerance. In their study, hypoxic tolerance 
was tested in the larval stage and adulthood of fish. The authors reported that populations of 
fish that mounted a HIF-1 response to low O2 during development had a higher proportion of 
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males as adults. Therefore, induction of the cellular hypoxia response during early 
development results in an improved hypoxia tolerance at the population level (Robertson et 
al., 2014). Further studies may be required to evaluate the potential physiological adaptability 
between sex in zebrafish to better design the zebrafish hypoxia model.  
In addition, the absorbance extraction of TTC dye described in Yu and Li’s study (2011) was 
not normalised by weight (eliminating water content), which introduced potential errors. In 
the current study, the protocol was modified by drying the brain tissue and normalising the 
weight of the tissue and the TTC dye absorbance. 
In the current study, fish of mixed sex aged 6–18 months were used. In contrast, in Yu and 
Li’s study (2011) fish with body size 30–49mm total length (mean: 41.56mm; median: 42.5mm) 
were used (X. Yu & Li, 2011, 2013). Zebrafish is a popular animal model used to study ageing 
and human diseases. Like humans, aged zebrafish demonstrate reduced exercise tolerance 
(Gilbert, Zerulla, & Tierney, 2014), degenerative changes in the spinal column (Hayes et al., 
2013), and cognitive decline (Arslan-Ergul & Adams, 2014; L. Yu, Tucci, Kishi, & Zhdanova, 
2006). And, like humans, differences in genetics have also been shown to contribute to 
differences in lifespan (Gerhard et al., 2002). Recently, mutations that affect atrial and 
ventricular development have been reported and age-related mitochondria have been 
identified (Almaida-Pagán, Lucas-Sanchez, & Tocher, 2014). A recent study by Sun et al (Y. Sun 
et al., 2015) evaluating the age-related functional modification and pathophysiological 
changes in zebrafish hearts positively identifies that impairment in cardiac performance in 
the older fish population and the cardiac ageing process in zebrafish are comparable to those 
in humans. Although a comparable study of zebrafish brains was not available, an 
investigation of cerebral pathophysiology and age-related difference would be useful in 
guiding future model development.  
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The underlying principle of TTC staining involves the formation of red formazan TTC 
products, predominantly in the mitochondrial compartment. This staining procedure enables 
delineation of cerebral infarct sizes, and thus reliably detects the amount of damaged brain 
tissue caused by the global ischaemia (Benedek et al., 2006; Popp et al., 2009). No statistical 
significance was detected between the hypoxia group and normoxia group, after eight 
separate experiments. This may be due to the fact that zebrafish have a high recovery capacity 
compared to other species (Braga et al., 2013; Krock, Skuli, & Simon, 2011). Similar to our 
result, the study conducted by Braga et al. (2013) investigated brain damage after hypoxia 
exposure at stage 1 to 4 and noticed complete recovery between 24 and 48 hours. Hypoxia is 
the principal regulator of VEGF expression, which elicits angiogenic responses to combat 
tissue ischaemia. It is also evident that the acute hypoxia insult can cause graduated damage 
to mitochondria activities (Braga et al., 2013; Murphy, 2009) at particular time-points; 
however, recovery was usually observed within 48 hours from introduction of the normoxic 
environment. Whether these reversal effects were due to the tolerance of fish to hypoxia, or 
to hypoxia-induced angiogenesis, was unclear.  
In summary, although the model development was not successful, several valuable lessons 
were learned. For future development of zebrafish hypoxia models, the complexity of age-
related pathophysiology and variation in sex-biased hypoxia tolerance should be considered. 
In addition, more sensitive parameters (such as metabolomics and/or proteomic measures) 
could be used to detect the differences between hypoxia and normoxia conditions. Due to 














Angiogenesis is the morphogenic process through which new blood vessels sprout from pre-
existing vessels. It plays a pivotal role in various physiological and pathological conditions and 
is coordinated by the endothelial cells and their niche (Kajdaniuk, Marek, Borgiel-Marek, & 
Kos-Kudła, 2011). Inadequate vasculature maintenance or insufficient vessel growth may lead 
to tissue ischaemia, while excessive vascular growth or abnormal remodelling may promote 
cancer, inflammatory disorders and retinopathies (Denekamp, 1993; Polverini, 1995). 
Angiogenesis is considered an essential physiological process for maintaining blood vessel 
homeostasis by facilitating nutrient transportation, as well as promoting tissue growth and 
repair (Potente, Gerhardt, & Carmeliet, 2011). In ischaemia, the injured tissue triggers an 
angiogenic response that helps the blood flow adjacent to the ischaemic core in order to 
rebuild the blood vessel and restore the delivery of oxygen. Lack of angiogenesis can 
complicate recovery from ischaemic conditions such as myocardial infarction and ischaemic 
stroke, which are associated with inadequate blood supply (Potente et al., 2011). Presently, 
therapeutic angiogenesis is a novel approach to improving the outcome of ischaemic vascular 
diseases (Losordo & Dimmeler, 2004a). In such conditions, the therapeutic goal is to stimulate 
angiogenesis, or allow generation of neovascularisation to improve perfusion, deliver survival 
factors to sites of tissue repair, mobilise regenerative stem cell populations and, ultimately, 
restore form and function to the tissue (Losordo & Dimmeler, 2004b). Early clinical evidence 
evaluating the effects of angiogenesis and vasculogenesis on ischaemic diseases with cell-
based therapy has shown promising results. For example, in a clinical study, bone marrow-
derived mononuclear cells were infused into patients 5–9 days after acute myocardial 
infarction and shown to enhance regional infarct region perfusion when compared to ten 
nonrandomised control patients, as assessed by thallium scintigraphy. Moreover, stroke 
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volume, end-systolic volume and contractility indices were improved after cell therapy 
(Yousef et al., 2009).  
The angiogenesis process typically consists of six major steps: (1) vasodilation of the 
parental vessels, reducing endothelial cell contact; (2) degradation of the basement 
membrane by a variety of proteolytic enzymes; (3) migration and proliferation of endothelial 
cells at the spearhead of new vessels; (4) production of capillary lumen and formation of tube-
like structures; (5) basement membrane synthesis; and (6) recruitment of vascular smooth 
muscle cells. The sequence of the molecular events resulting in angiogenesis requires precise 
fine-tuning of multiple signalling pathways, cell–cell and cell–matrix interactions. In these 
events, chemical stimulants such as vascular endothelial growth factor (VEGF), fibroblast 
growth factors (FGF) and various angiogenic proteins such as integrins and prostaglandins 
typically play an initiating role (Jain, 2003; Kelm et al., 2005). 
Therapeutic angiogenesis aims to induce, augment and control the host angiogenic 
response in order to revascularise ischaemic tissues, and often involves delivery of growth 
factors or stem/progenitor cells. Growth factors may be delivered in the form of proteins or 
genes encoding target proteins. The premise behind this approach is to apply well-studied 
growth factors such as VEGF to ischaemic tissues to guide angiogenic cellular and tissue 
behaviour. VEGF and bFGF are the two most well-studied growth factors and have reached 
human clinical trials (Deveza, Choi, & Yang, 2012). VEGF is the most important regulator of 
physiological angiogenesis during growth and healing in response to hypoxia (Carmeliet & 
Jain, 2011; Losordo & Dimmeler, 2004a). VEGF is upregulated 30-fold by hypoxia-inducible 
transcription factor, which is more than any other inducible angiogenic factors (Deveza et al., 
2012). To date, there have been several preclinical and clinical studies evaluating the safety 
and efficacy of growth factors for inducing angiogenesis in ischaemic disease in relation to 
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heart, brain and peripheral arteries. Numerous clinical trials applying gene therapy have 
mostly used adenovirus or plasmids to deliver VEGF or bFGF (Gupta, Tongers, & Losordo, 
2009). Early phase 1 and 2 human clinical trials support the safety of angiogenic gene delivery; 
however, efficacy has not yet been conclusively demonstrated. Moreover, one phase III trial 
investigating patients with critical limb ischaemia who received FGF-1 expressing plasmid 
failed to demonstrate benefits (Chu & Wang, 2012). Another phase III trial utilising an 
adenoviral vector to express FGF-4 in patients with angina also revealed no difference from 
the placebo group (Henry et al., 2007). The inconsistency of the trial outcomes may be caused 
by differences in patient selection criteria and assessment methods (Chu & Wang, 2012; 
Deveza et al., 2012). Despite of the complex mechanisms of neovascularisation, 
neurovascular remodelling is a key component of recovery after stroke. It is increasingly 
recognised that without vascular support, neuronal plasticity cannot be achieved (Navaratna, 
Guo, Arai, & Lo, 2009). Over the past few years, complex mechanisms are beginning to be 
dissected that underlie these endogenous responses in damaged brain parenchyma. As we 
understand more of these pathways, we may design better therapies to augment 
angiogenesis for promoting recovery. While augmentation of angiogenesis pathways is not 
the aim of this study, VEGF remains the prototypical growth factor involved (Navaratna et al., 
2009). Given that traditional herbal medicines are usually less invasive than conventional 
pharmaceutical treatment, they might provide the optimal approach for promoting 
angiogenesis in the brain. 
6.1.1 Vascular endothelial growth factor (VEGF)  
VEGF is one of the major mediators for angiogenesis process. VEGF is a major regulator of 
neovascularisation under physiological and pathological conditions (Gerber et al., 1999) and 
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is produced in five homodimeric isoforms (VEGF121, VEGF145, VEGF165, VEGF189 and 
VEGF206). The various isoforms of VEGF differ in their expression levels and localisation. They 
are involved in (a) the formation of immature vasculature (with VEGF receptor 2 (VEGFR-2) 
mediated signalling in angioblasts resulting in formation of the dorsal aorta and the cardinal 
vein; (Yancopoulos et al., 2000); (b) induction of migration and proliferation of endothelial 
cells (Conway, Collen, & Carmeliet, 2001); (c) vessel dilation and sprouting in the presence of 
angioprotein-2 (Tsigkos, Koutsilieris, & Papapetropoulos, 2003); (d) stabalisation of immature 
vasculature (VEGF-induced platelet-derived growth factor secretion of endothelial cells 
facilitates recruitment of mural cells; (Blau & Banfi, 2001); (e) sequestration of angioprotein-
2 which destabilises (Tsigkos et al., 2003); (f) suppression of apoptosis (Folkman, 2003); (g) 
branching, remodelling and pruning of vasculature (protease-mediated release of matrix-
sequestrated VEGF; (Peirce & Skalak, 2003); and (h) vessel specialisation (arterial growth 
promoted by VEGF–VEGFR2 neurophilin-1 signalling). Studies indicate that VEGF action goes 
beyond vascularisation and may be involved in neurogenesis (Jin et al., 2002) as well as 
growth- and survival-modulation of chondrocytes, a cell that secretes the matrix of cartilage 
and becomes embedded in it (Schipani et al., 2001). 
Several control circuits are at work to balance VEGF action. For example, in response to 
hypoxia, activation of hypoxia-inducible factor (HIF-)1 alpha results in induction of angiogenic 
factors such as VEGF which bind to their receptors on endothelial cells, leading to their 
activation (Gapizov et al., 2018). Another inducible factor is endostatin, a matrix-associated 
protease-mediated cleavage product of collagen XVIII that inhibits the VEGF-induced 
moblisation of endothelial cells (Gapizov et al., 2018).  
In recent years, the potential of angiogenesis as a therapeutic strategy for stroke recovery 
has been intensively studied (Navaratna et al., 2009). Many traditionally used herbal sources 
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contain potential pro-angiogenic substances that are usable in apoplexy conditions. For 
instance, Astragalus, Panax notoginseng (P. Chan, Thomas, & Tomlinson, 2002) and Angelica 
sinensis (J. Sun, Tan, Huang, Whiteman, & Zhu, 2002) have been used clinically for ischaemic 
heart diseases. NXQ has been clinically used for apoplexy diseases such as angina, ischaemic 
heart diseases, ischaemic stroke and atherosclerosis (Y. Cai & Yang, 2001). We hypothesise 
that the clinically observed beneficial effect of NXQ is at least partly mediated via its pro-
angiogenic properties. Hence, the aim of this chapter is to evaluate the angiogenic effect of 
NXQ using two cultured endothelial cell in vitro models and an in vivo model of angiogenesis 
using zebrafish. 
6.1.2 Evaluation of angiogenesis effects in in vitro bioassays  
Angiogenesis effects are commonly studied in vitro using vascular endothelial cells based on 
three essential characteristics of angiogenesis: cell proliferation, cell migration and tube 
formation (Staton, Reed, & Brown, 2009). Typically, endothelial cells start to proliferate 
before migration. At last, the cells outgrow, and form new, tubular structure with the 
assistance of adhesion molecules such as integrins, cadherins or selectins (Bischoff, 1997; Fan, 
Yeh, Leung, Yue, & Wong, 2006). The three bioassays described below are the most commonly 
used models to investigate the effects of pro-angiogenic and anti-angiogenic agents. Each of 
these assays mimics one of the major processes of angiogenesis.  
6.1.2.1 Cell proliferation assay 
Crystal violet staining was applied to determine the rate of cell proliferation. Crystal violet is 
frequently used as a histological stain for classifying bacteria based on Gram’s method, first 
published in 1954 (Bartholomew & Finkelstein, 1954). It is used also in cellular models to 
determine the number of cells, as crystal violet can bond to the DNA of both adherent and 
135 
non-adherent cells (Kueng, Silber, & Eppenberger, 1989). The density cell number based on 
the colour stained to the cell can then be quantified with a microplate reader with the 
wavelength at 590nm (Gillies, Didier, & Denton, 1986). The absorbance of the density is 
directly proportional to the total number of cells detected. 
In this study, we evaluated whether NXQ could induce cell proliferation using cultured 
human endothelial cell, EA.hy926, using the crystal violate assay. In brief, the cells were pre-
treated with testing compounds and compared with a vehicle (0.1% DMSO) and a positive 
control (VEGF 50 µg/mL). The vehicle control group was considered as the normal cell growth 
rate with a maximum cell number (100%). VEGF was used here as a positive control for model 
validity on proliferation. The % of proliferation was calculated using the following equation. 
 
% of proliferation in relation to vehicle control = >?/#$?)+"%	#-	/).C1%	&$%)&%'	"%11/
>?/#$?)+"%	#-	"#+&$#1	"%11/	
	x 100%      [Eq. 3] 
 
6.1.2.2 Cell migration (wound healing) assay 
Wound scratch assay is a simple and well-developed method for measuring the cell migration 
activity in vitro (C.-C. Liang, Park, & Guan, 2007). The measurement was obtained based on 
observing the gap-closing activity of the cells, which was either promoted or inhibited in the 
tested samples (Yarrow, Perlman, Westwood, & Mitchison, 2004). The change in gap area 
caused by the test compound can be observed under a microscope and recorded by a camera. 
Computer software such as Image J or Tscratch is frequently used to quantify and compare 
the open area of the cells before and after treatment period (Gebäck, Schulz, Koumoutsakos, 
& Detmar, 2009; Poujade et al., 2007).  
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6.1.3 Evaluation of angiogenesis effects in zebrafish model  
While in vitro assays are cheaper and simpler models that could provide basic information on 
the angiogenic properties and potential signalling mechanisms of drugs and bioactive 
compounds, it is not uncommon for in vitro studies to fail to translate effectively to a 
complete physiological system. Therefore, in vivo models are essential for the evaluation of 
new drugs and herbs.  
Aside from the numerous established applications of zebrafish and zebrafish embryos, 
they are also used to study angiogenesis, apoptosis, toxicity responses and preclinical drug 
screening (Parng et al., 2002). Transgenic zebrafish and their embryos are commonly 
employed in studies assessing vascular changes in angiogenesis and vasculogenesis 
(Langheinrich, 2003; Lawson & Weinstein, 2002). Tg(fli1:EGFP) is a common transgenic 
zebrafish model in which enhanced green fluorescent proteins are expressed in all endothelial 
cells of the vasculature, allowing for vascular changes to be detectable through fluorescent 
microscopy (Higashijima, Hotta, & Okamoto, 2000). Numerous studies have utilised this 
advantage to investigate vascular modifications of zebrafish embryos in both pathological 
conditions and pharmacologically induced changes due to the relatively quick embryonic 
development phase. For instance, Lam et al. (2008) successfully identified angiogenic changes 
in subintestinal vessels (SIV) of Tg(fli1:EGFP) embryos induced by a herbal extract of A. 
sinensis. Hong et al. (2009) adopted the same method to assess the angiogenic effects in 
zebrafish embryos of saponin extract from the herb P. notoginseng. Lam et al. (2008) and 
Hong et al. (2009) were both able to identify changes in embryo SIV at 72 hpf under 
fluorescent microscopy in three separated-dose variants of the herbal extracts when 
compared with positive and negative controls. Both studies observed gross vascular 
modifications using imaging software by comparing overall vasculature changes with controls; 
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however, modifications to the vasculature could not be quantified as no distinction could be 
made between normal physiological vasculogenesis and drug-induced angiogenesis. 
Addressing this issue, Tran et al. (2007) demonstrated an automated, quantitative 
screening assay for angiogenic compounds in zebrafish embryo models. The assay-adapted 
software could differentiate the normal vasculogenesis from drug-induced angiogenesis by 
identifying the width of arteries, the fluorescent intensity of endothelial cell body, and the 
outgrowth from the cell body. These features allowed for quantification and in-depth 
interpretation of vascular changes which were induced chemically rather than by normal 
progressive development.   
In summary, zebrafish provide a series of advantages as a model of study due to their rapid 
development, optical transparency, high number of offspring and straightforward strategies 
for forward and reverse genetic manipulation. Furthermore, the early development of a 
cardiovascular system in the transparent zebrafish embryo and larva translates into a unique 
opportunity for direct observation of blood flow and the development of the system’s related 
organs in both wild type and transgenic fish, without the need for complex instrumentation. 
Lastly, genetic studies have revealed conservation of the molecular pathways between fish 
and mammals, making research in vascular biology in teleosts directly translatable into 
potentially relevant information for human health. 
6.1.3.1 Vascular development in transgenic zebrafish 
Transgenic technology has enhanced the inherent in vivo imaging capabilities that zebrafish 
may offer the investigator. Though vessels and blood flow can easily be visualised with a 
simple dissecting scope, it was with introduction of tissue-specific expression of fluorescent 
protein that vascular and blood development could be examined in great detail. Confocal 
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microscopy and time-lapse imaging can both be carried out with live specimens, which allows 
detailed morphogenetic movements and cell shape changes to be followed directly. 
Thus, vascular development has been described in great detail, both from the anatomical 
and cellular point of view and with comprehensive examination of the molecular player 
involved (Gore, Monzo, Cha, Pan, & Weinstein, 2012; Schuermann, Helker, & Herzog, 2014).  
The development of the vascular anatomy of the zebrafish has been extensively described 
and has demonstrates a high similarity to that of other vertebrates. Many of the studies of 
vascular development have used molecular tracers during the early embryonic stages of 
zebrafish. One such strategy is the injection of fluorescent microspheres and their detection 
after lumenisation and anastomosis of the vascular network is complete. This strategy has 
also been used to compare the development of blood and lymphatic vasculature in zebrafish 
(Ellertsdóttir et al., 2010; Gore et al., 2012; Isogai, Horiguchi, & Weinstein, 2001). 
A remarkable feature of zebrafish compared to other vertebrates is that they rely on 
passive oxygen diffusion during the early embryonic stages, rather than oxygen perfusion, as 
the completion of vascular development takes place after hatching. Moreover, the generation 
and characterisation of zebrafish mutants has shown that embryos are able to sustain normal 
development even in absence of a functional vascular system or in the absence of blood. This 
attribute has made the analysis of late phenotypes related to circulatory system 
malformations possible (Chávez, Aedo, Fierro, Allende, & Egaña, 2016; Isogai, Lawson, 
Torrealday, Horiguchi, & Weinstein, 2003; Stainier, Weinstein, Detrich, Zon, & Fishman, 1995).  
6.1.3.2 Zebrafish angiogenic pre-inhibition model by VEGF receptor tyrosine kinase inhibitor II 
(VRI) 
Angiogenesis is one of the main focuses of vascular regeneration research; models for this 
type of vascular development and growth have been developed. In the embryo, the 
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intersegmental vessels form by angiogenic sprouting from the dorsal aorta and have been the 
target of studies using drugs or genetic perturbations. Angiogenic sprouting is inducible by 
recombinant VEGF (Q.-q. Xin et al., 2016; H. Zhao, Huang, & Lin, 2016). 
VEGF receptor tyrosine kinase inhibitor II (VRI) is a small molecule that strongly inhibits the 
kinase activity of VEGF receptors 1 and 2 (Furet et al., 2003). Visual analysis of zebrafish 
embryos from 24 hpf to 36 hpf, VRI can completely inhibit development of intersegmental 
blood vessels (ISV) (B.-r. Yang et al., 2016). After removing VRI by washing, these blood vessels 
remain largely inhibited until 72 hpf. During this period, pro-angiogenic compounds can be 
added to determine whether they induce more recovery of ISV, an indicator of angiogenesis, 
compared to a black control. VRI has been used as a valid angiogenesis-recovering model for 
evaluation of pro-angiogenic activities in vivo (H. Zhao et al., 2016). 
6.2 Angiogenesis in vitro bioassays (material and method) 
6.2.1 Chemical and reagent 
The chemicals used are summarised in Table 14 below: 
Table 14: Chemical and reagent used for angiogenesis in vitro bioassays 
Chemical Company and Country 
Crystal Violet  Sigma-Aldrich (Australia) 
Cultrex Basement Membrane Extract (BME) Trevigen (US) 
Culture medium Dulbecco’s Modified Eagle’s Medium (DMEM/Ham’s F12 
containing 15mM HEPES and L-glutamine, with phenol red) 
Life Technologies (Australia) 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich (Australia) 
Fetal bovine serum (FBS) Life Technologies (Australia) 
Hydrogen Peroxide  Sigma-Aldrich (Australia) 
Kaempferol Sigma-Aldrich (Australia) 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Sigma-Aldrich (Australia) 
NXQ Powder extracts Diospyros kaki. L Guangzhou Baiyunshan 
Pharmaceutical Co. Ltd. (PRC) 
Phenol red absence culture medium (DMEM/Ham’s F12 containing 15mM 
HEPES and L-glutamine) 
Gibco™ (Australia) 
Phosphate-buffered saline (PBS) tablets Sigma-Aldrich (Australia) 
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Penstrep (penicillin and streptomycin) Gibco™ (Australia) 
Quercetin Sigma-Aldrich (Australia) 
Trypsin (10x) solution Sigma-Aldrich (Australia) 




The herbal extract preparation was described in the previous chapter (Chapter 5 Section 5.2.2, 
NXQ Extracts Stock Preparation). 
6.2.1.2 Quercetin 
The stock preparation was described in the previous chapter (Chapter 5 Section 5.2.3, 
Quercetin and Kaempferol Stock Preparation). 
6.2.1.3 Kaempferol 
The stock preparation was described in the previous chapter (Chapter 5 Section 5.2.3, 
Quercetin and Kaempferol Stock Preparation). 
6.2.1.4 Quercetin and kaempferol combination 
The stock preparation was described in the previous chapter (Chapter 5 Section 5.2.4, 
Quercetin and Kaempferol (3:4) Combination Stock Preparation). 
6.2.3 Cell line and culture conditions 
EA.hy926 cells were used for the angiogenic in vitro experiments. The cells were cultured as 
described in Chapter 5 Section 5.3.1, Cell Culture.  
6.2.4 Crystal violet staining for cell proliferation assay 
6.2.4.1 Experimental procedure 
1 x 104 cells per well were seeded in a 96-well plate for 2 h, and then treated with samples 
(final dimethyl sulfoxide (DMSO) concentration 0.1%) in a serum-free medium. After a 72-h 
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incubation period, the cell supernatant was fixed with 3% buffered paraformaldehyde for 20 
min. The cells were then stained with 0.2% crystal violet in 20% methanol for 5 min. The 
excess crystal violet stain was rinsed 4–5 times with distilled water and air-dried. Glacial acetic 
acid (33%) in Milli-Q water was added to extract the crystal violet stain. Finally, the optical 
density was measured using a microplate reader (BMG Labtech Fluostar Optima, Mount Eliza, 
Victoria, Australia) at the wavelength of 595nm (A. Martin & Clynes, 1993). 
6.254 Cell migration (scratch wound healing) assay 
6.2.5.1 experimental procedure 
The wound scratch assay procedure was performed based on Gebäck’s protocol (Gebäck et 
al., 2009; C.-C. Liang et al., 2007). EA.hy926 cells were seeded at the concentration of 1 x 105 
EA.hy926 cells per well on a 24-well plate and growth allowed until 80–90% confluence. Then 
the cell monolayer was scratched using a 1000μL pipette tip and rinsed gently with 
phosphate-buffered saline (PBS) to remove cell debris. Cross-shaped gaps were scratched in 
each well and these were instantly centre-imaged at 4 × magnification, using a Motic AE20 
microscope and a Tucsen ISH500 digital camera with maximum contrast. The photo was 
viewed with ISCapture software, recorded as 0 h, and the cells were served with serum-free 
medium and incubation for 2 h for starvation. Tested samples were then administered to the 
cells and incubated for 24 h. The wound of the same well was photographed again and 
recorded at 24 h. The percentages of cell-free areas were then compared between 0 and 24 
h, and the data were analysed using TScratch software (Gebäck et al., 2009; C.-C. Liang et al., 
2007). The percentage of wound healing were calculated using the equation: 
 
Percentage of wound healing = >$%)(?)/%1*+%):>$%)	(DEA$)	
>$%)	(?)/%1*+%)	
	x 100%   [Eq. 4] 
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6.3 Western Blotting 
6.3.1 Background 
This study aimed to explore the mechanistic insight of NXQ for its observed effects on 
prevention of endothelial cell apoptosis and proliferation.  
Endothelial nitric oxide synthase (eNOS) is the nitric oxide synthase (NOS) isoform that 
produces endothelium-derived NO (Heiss, Rodriguez-Mateos, & Kelm, 2015). eNOS is found 
primarily in the endothelium of cerebral blood vessels. Nitric oxide generated by eNOS is 
crucial for vascular function, homeostasis prevent the cells from sheer stress (Fulton et al., 
1999; Jinqiang Zhu, Song, Li, & Fan, 2016). Treatment of endothelial cells with vascular 
endothelial growth factor or insulin stimulates the production of NO by a PI3K-akt dependent 
mechanism (C.-J. Li, Elsasser, & Kahl, 2009). 
The Akt proto-oncogene is an important regulator of the various cellular process, including 
glucose metabolism and cell survival. Activation of receptor tyrosine kinases and G-protein-
coupled receptors, and stimulation of cells by mechanical forces, can lead to the 
phosphorylation and activation of Akt (Fulton et al., 1999). Akt is a key mediator of eNOS 
activation and accounted for eNOS upregulation in vascular endothelial cells (C.-J. Li et al., 
2009). 
The mechanistic insight of NXQ on endothelial cell protection and proliferation were 
unclear, and we hypothesis that it may be mediated via Akt-eNOS pathway. 
 
6.3.2 Experimental procedure 
Cells were seeded in 6-well plates at a density of 1.0 x 106 cells/well and allowed to attach for 
24 hours. The cells were treated with vehicle, NXQ (10 and 50 µg/mL) or VEGF (100 ng/mL) 
for 24 hours. After the treatment, the cells were homogenised and lysed in a RIPA buffer 
(Thermo Scientific, USA) in the presence of protease inhibitors (Roche Applied Science, USA) 
and PhosSTOP (Sigma, USA) to obtain protein extracts. Protein concentrations were 
determined using the BSA protein assay kit (Pierce, USA). Samples (30 μg of protein per lane) 
were loaded onto a mini-PROTEAN TGXTM precast electrophoresis gel (BioRad, USA). After 
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electrophoresis (110 V, 90 min), the separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes using iBlot 2 gel transfer system (Thermofisher, USA). Non-
specific sites were blocked with 5% non-fat dry milk in PBSt for 60 min, and the blots were 
then incubated with anti-Akt, 1:1,000 (Cell Signalling, USA), anti-phospho-Akt, 1:1,000 (Cell 
Signalling, USA), anti-eNOS, 1:1,000 (Cell Signalling, USA) and anti-phospho-eNOS, 1:1,000 
(Cell Signalling, USA) in PBSt overnight at 4 °C. Anti-rabbit HRP conjugated IgG, 1:1000 
(DakoCytomation, Denmark) in PBSt (60 min, room temperature) was used to detect the 
binding of its correspondent antibody. The protein expression was detected with Western 
Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, USA) and quantified 
by ImageJ software (NIH, USA). 
 
6.4 Angiogenesis effects of NXQ in zebrafish embryos 
The experiments were conducted in collaboration with Institute of Chinese Medical Sciences, 
Macau University, where animals, maintenance of zebrafish and ethics approval complied 
with the University’s standard operations procedure and ethical guidelines.  
6.4.1 Ethics statement 
All animal experiments were conducted according to the ethical guidelines of Institute of 
Chinese Medical Sciences, University of Macau. The protocol was approved by Animal Ethics 
Committee Western Sydney University (ethics approved protocol number A10378). 
6.4.2 Animals  
Transgenic zebrafish Tg(fli1:EGFP) embryos were used in this study. The embryos were 
generated by natural pair-wise mating with 3–12-month-old zebrafish. Breeding boxes were 
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placed inside the tanks with light. Four to five pairs of zebrafish were set up in each tank for 
each mating and were left undisturbed for 15–30 minutes. Embryos were transferred using a 
fine fishing net into separate containers and maintained in embryo water (5g of instant ocean 
salt in 25L distilled water) at 28˚C. Embryos were then removed from their chorions at 19 hpf 
immediately prior to any treatment (Westerfield, 1995).  
6.4.3 Maintenance of zebrafish  
Zebrafish were maintained in a controlled environment at 28˚C on a 12/12h light/dark cycle 
according to the zebrafish handbook (Westerfield, 1995). Zebrafish were stored in 3.5L or 5L 
Tecniplast tanks with automatic monitoring of environmental conditions such as water 
temperature, pH level and dissolved oxygen saturation. Each tank housed up to a maximum 
of ten fish. Adult zebrafish were fed with dry food flakes or pellets, live artemia or shell-free 
artemia, three times daily from Monday to Friday and once daily during weekends and public 
holidays in compliance with Zebrafish Feeding Standard Operation Procedures. 
6.4.4 NXQ solution and control 
The NXQ extract was prepared by dissolving it in an aqueous solution of 10% DMSO with 
double-distilled water. This was then administered to the embryos by diluting the NXQ 10% 
to 0.1% DMSO in the embryos’ container water. An embryo container with 0.1% DMSO was 
used as negative control and microinjection of VEGF was used as positive control. VEGF was 
injected either into the yolk ball or into the perivitelline space between the yolk and periderm. 
These two sites for injection were chosen because proteins in the yolk are often taken up by 
the embryo, and the second location is in the path of venous return; therefore, after injection, 
proteins end up in the circulation of the embryo. 
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6.4.5 Experimental design and assessment 
Embryos were treated with the test agent 27 hpf for 24 h. Embryos were divided into five 
groups (n= 15 per group) as shown below:  
Group 1: NXQ extract low dose (25 µg/mL) 
Group 2: NXQ extract medium dose (50 µg/mL),  
Group 3: NXQ extract medium high dose (100 µg/mL) 
Group 4: NXQ extract high dose (300 µg/mL) 
Group 4: negative control (VRI 300 ng/mL) 
Group 5: Vehicle control (0.1% DMSO).  
6.4.5.1 Embryo collection 
Zebrafish were kept separately in 14/10 h light/dark cycle water circulation system. Zebrafish 
embryos were generated by natural pair-wise mating (3–12 months old) and were raised at 
28.5°C in embryo water. Healthy embryo collection was performed according to the previous 
methods (J. Y. Tang et al., 2010). 
Embryos were removed from their chorions at 24 hpf immediately prior to VRI treatment 
by incubating with 1 mg/mL protease at room temperature for 3 min. Dechorionated embryos 
were then treated with VRI and transferred into a 24-well microplate by a siphon tube for 
drug treatment (10 embryos per well).  
6.4.5.2 Drug Treatment/compound addition 
VRI was used to establish vascular insufficiency model, which is an pyridinyl-anthranilamide 
compound that displays anti-angiogenic properties and strongly inhibits the kinase activities 
of VEGF receptors 1 and 2. The 24 hpf zebrafish were treated with 300ng/mL VRI for 3 h and 
then distributed into 24-well plate (10 embryos per well). VRI was washed out and replaced 
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with NXQ of different concentrations (25, 50, 100 and 300 µg/mL). Embryos treated with 
embryo water containing 0.1% DMSO only served as vehicle control. Zebrafish embryos were 
raised in incubators at 28°C for 24 h before morphological observation. 
6.4.5.3 Morphological observation and angiogenesis quantifying in zebrafish 
Zebrafish embryos were placed on glass slices and observed for viability and morphological 
changes with a fluorescence microscope (Olympus IX81 Motorised Inverted Microscope, 
Japan) equipped with a digital camera (DP controller, Soft Imaging System, Olympus, 
Germany). Images were analysed with Axiovision 4.2 and Adobe Photoshop 7.0. 
Intersegmental vessels (ISVs) observed sprouting and elongating from dorsal aorta (DA) or 
posterior cardinal vein (PCVs) to dorsal longitudinal anastomotic vessels (DLAVs) were 
defined as intactness in the control group. In the VRI-only treatment group and the drug 
treatment groups, some of the ISVs observed sprouting from DA or PCVs but not forming 
completed ISVs were defined as defective blood vessels. The number of intact and defective 
ISVs in each zebrafish embryo was counted.  
6.4.5.4 Quantifying angiogenesis in zebrafish 
To evaluate the effects of NXQ treatment on angiogenesis, the intact and defective ISVs 
sprouting were counted. Images were analysed with Adobe Photoshop 7.0. The data (number 
of intersegmental vessels and branching arteries) were exported as a summary log to 
Microsoft Excel. 
6.4.6 Statistical analysis  
Data were analysed with one-way ANOVA followed by Turkey's multiple comparison test. A 
chart was made with GraphPad Prism 5.0 software (San Diego, CA). All relevant data were 
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presented as mean±standard error of mean (x–±SEM). Differences were considered 
significant at p<0.05. 
6.5 Results 
6.5.1 Effects of NXQ extract on EA.hy926 endothelial cell proliferation 
As shown in Figure 6.1, NXQ and kaempferol did not significantly increase cell proliferation in 
comparison to either DMSO (0.1%)-treated control or VEGF (50ng/mL)-treated control 
(P>0.05). VEGF significantly increased cell proliferation when compared to vehicle control 
(p<0.001) (n=3) (Figure 6.1). In contrast, quercetin at concentrations of 100, 250 and 500 
mmol/mL significantly inhibited the cell proliferation compared to control (P>0.05). Similarly, 
Q3:K4 at concentration 500 mmol/mL significantly inhibited the cell proliferation of EA.hy926 
cells compared to control (p<0.05), suggesting a possible antagonist effect between 




Figure 6.1 Effects of NXQ (A), kaempferol (B), quercetin (C) and Q3:K4 combination (D) aqueous extract on cell 
proliferation. V=p<0.01 (n=3) VEGF stimulation (positive control) compared with vehicle control (0.1% DMSO); 
*=p<0.05 (n=3) compared to vehicle control.		
 
6.5.2 Effects of NXQ extract on EA.hy926 endothelial cell migration  
As shown in Figure 6.2, NXQ did not significantly induce cell migration in EA.hy926 cells in 
comparison to vehicle control (p>0.05) (6.2A). Similar results were observed in kaempferol, 




Figure 6.2: Cell migration (relative to control) concentration curve for NXQ (A), kaempferol (B), quercetin (C) and 
Q3:K4 combination (D) aqueous extract on cell proliferation assay (p>0.05, n=3). 
6.5.3 Mechanisms and Signalling pathways  
Activity of the Akt/eNOS signalling pathway were evaluated using Western blotting with the 
result expressed as p-Akt/t-Akt and p-eNOS/t-eNOS ratio. As shown in Figure 6.3, VEGF (100 
µg/mL) treatment increased both the p-Akt/t-Akt ratios in the EA.hy926 cells but not in p-
eNOS/t-eNOS. NXQ treatments (10 and 50 µg/mL) caused a modest increase in p-Akt/t-Akt 
ratios in a concentration-dependent manner in the EA.hy926 cells. However, these changes 




Figure 6.3: Western blot analysis of expression of Akt/eNOS signalling pathway. NXQ 10 and 50 µg/mL showing 
modest increase in p-Akt/t-Akt ratios but these changes did not reach statistical significance (p>0.5, n=3). NXQ 
10 and 50 µg/mL showing no increase on p-eNOS.t-eNOS compare to vehicle control (p>0.5,n=3). 
6.5.4 Effects of NXQ extract on VEGF inhibited zebrafish embryos  
VRI (500ng/mL) significantly inhibited VEGF-stimulated SIV growth when compared to the 
vehicle control. All the NXQ extract dosages tested in the current study (25, 50, 100 and 300 
µg/mL) significantly increased ISV vessel growing against VRI (p<0.05). However, NXQ at 












A. Control B. VRI (500ng/mL) 
  
C. NXQ 25µg/mL D. NXQ 50µg/mL 
  
E. NXQ 100 µg/mL F. NXQ 300µg/mL 
Figure 6.4: Treatment and control groups of Tg(fli1:EGFP) zebrafish larvae observed under co-focal microscope. 
SIV vessels were observed and counted for statistical analysis. (A) SIV vessels of vehicle control (DMSO 0.1%) 
zebrafish larvae (B) negative control by VRI (500ng/mL) zebrafish larvae (C) NXQ treated 25µg/mL (D) NXQ 
treated 50µg/mL (E) NXQ treated100µg/mL and (F) NXQ treated 300µg/mL.  
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Figure 6.5: Angiogenic vessel growth on zebrafish Tg(fli1:EGFP) embryos. V: p<0.001 (n=8) VRI inhibition of vessel 
growth compare to vehicle control (DMSO0.1%); *p<0.05 (n=8) compared to VRI; ***=p<0.001 (n=8) compared 
to VRI. Statistics were conducted using one-way ANOVA (GraphPad) Prism 5.  
6.6 Discussion 
NXQ, a standardised, patent herbal extract, has been used clinically as part of traditional 
Chinese medicine to treat cerebral atherosclerosis, transitory ischaemia syndromes, cerebral 
thrombogenesis, cerebral thrombosis sequelae, apoplexy sequelae and cerebral embolism, 
with minimal adverse effects (Bei et al., 2007; Y. Cai & Yang, 2001). Previous studies suggest 
that NXQ possess potential effects on lipid-lowering, oxidant-scavenging, anti-inflammatory 
and anti-hypertensive actions. It has been reported that NXQ can improve cardiac and 
cerebral ischaemia associated symptoms by improving blood flow. While these studies 
provided some evidence to support the use of NXQ for the management of cerebral ischaemia, 
its role in improving cerebral blood flow was not clearly identified. No previous studies were 
conducted to evaluate the angiogenic property of NXQ and its role on vasculatures of cerebral 
ischaemia. This study evaluated the angiogenic effects of NXQ, and its two major bioactive 
compounds, kaempferol and quercetin, using EA.hy926 cells and Tg(fli1:EGFP) zebrafish 
embryos. NXQ, kaempferol and quercetin and Q3:K4 combination tested under normal 
cellular conditions produced no observations of any significant changes in EA.hy926 cell 
proliferation and migration. Quercetin, however, showed a significant inhibition of cell 
proliferation at concentrations 100, 250 and 500 mmol/mL. The results were similar to those 
of a study by Zhao et al. (2014), who reported that quercetin exerts anti-angiogenic activity 
through regulation of VEGFR-2 activation. VEGFR-2 is the most biologically important 
receptor for VEGF. It regulates endothelial cell proliferation, migration, differentiation, tube 
formation and angiogenesis (Nakatsu et al., 2003). Zhao et al. (2014) investigated how 
quercetin affected VEGFR-2 protein expression in HUVECs using qRT-PCR analysis and 
153 
identified that quercetin significantly inhibited the expression of VEGFR-2 at concentrations 
of 50, 100 and 200 mmol/mL.  
As in to the current study, Donnini et al. (2006) suggest that neither quercetin nor its 
glucuronide exerted any effects on endothelial cell proliferation. It has been suggested that 
quercetin metabolites appear to exert divergent actions on cell proliferation and migration 
depending on the presence of VEGF. Under VEGF stimulation, quercetin and its glucuronide 
metabolites, but not the sulphate conjugate, exhibit an inhibitory effect on cell migration and 
proliferation (Donnini et al., 2006). 
In addition, kaempferol has also been reported to suppress cell proliferation, migration 
and tube formation of HUVECs in high-glucose condition, PI3K expression and Erk1/2, Src and 
Ak1 activation (Tjwa, Luttun, Autiero, & Carmeliet, 2003; Xu et al., 2017). Xu et al. (2017) 
therefore conclude that the anti-angiogenic effects of kaempferol may be mediated via 
suppressing mRNA and protein expression levels of VEGF and placental growth factor (PGF). 
In contrast, kaempferol did not induce cell proliferation in the current study. However, 
significant inhibition of cell proliferation or migration was not observed. It may be that 
kaempferol suppressed VEGF expression only by high glucose-induced VEGF and PGF 
stimulation. In addition, Liang et al. (2015) compared the effects of kaempferol in two cell 
lines, HUVECs and HEK-293 kidney cells, using cell viability assay and showed that kaempferol 
reduced HUVEC viability in a dose-dependent manner: 87% cell viability at 20μM and 52% cell 
viability at 80μM. However, the reduction of HEK-293 cells was relatively insensitive to 
kaempferol. At 80μM, the viability of HEK-293 cells was 93% while HUVECs displayed a 
viability of 52%, suggesting that kaempferol is more selective in inhibiting endothelial cells (F. 
Liang et al., 2015). The divergence of these results from those of Liang et al. may be due to 
the variety of tested kaempferol analyte. Liang and colleague were using fractions of extract 
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from D. versipellis and isolated kaempferol in specific fraction DYVE-D3, whereas the current 
study used pure bioactive compound purchased from Sigma at 97% purity.  
The effects of kaempferol and quercetin on inhibition of angiogenesis factor were also 
demonstrated in zebrafish models in several independent studies. Quercetin was found to 
significantly reduce the SIV vessels of Tg(fli1:EGFP) zebrafish embryos at concentrations of 50, 
100 and 200µM. SIV branch points were reduced in a dose-dependent manner by 26% and 
58% following treatment with 100 and 200µM quercetin respectively, compared to the 
control (0.1% DMSO) group (D. Zhao et al., 2014). Kaempferol, on the other hand, also 
demonstrated anti-angiogenesis effect in zebrafish embryos and larvae (F. Liang et al., 2015; 
Xu et al., 2017). Liang et al. analysed kaempferol compounds using Tg(kdrl:GFP)zn1 zebrafish 
and observed significant inhibition of ISV vessels. While studies demonstrating inhibitory 
effects of kaempferol compounds in zebrafish embryos and larvae are prominent, the 
variation in type of transgenic zebrafish may influence the outcome (F. Liang et al., 2015). 
 Interestingly, although NXQ failed to induce proliferation and migration in Ea.hy926 cells, 
it significantly induced angiogenesis in the in vivo experiments using zebrafish embryos. NXQ 
extracts (25–300 µg/mL) significantly reversed the VRI-inhibited SIV growth in Tg(fli1:EGFP)y1	
zebrafish.	Although this observation was contradicted to our in vitro observations, that may 
be due to the complexity of animal metabolism and conjugations of active components 
including quercetin. This observation was similar to (Donnini et al., 2006) and it is possible 
that quercetin contents are conjugated and exert pro-angiogenic effects that need to be 
activated during metabolism in animals. NXQ significantly induced new vessel formation in 
zebrafish embryos treated with VRI.  
In addition to this, other potential active components within NXQ may also contribute to 
the angiogenic effects when treated against VRI zebrafish embryos. The most abundant active 
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constituent identified after kaempferol and quercetin is astragalin. Astragalin has been shown 
to be a potential pro-angiogenic compound in several studies (Fan et al., 2006; Tu, Shao, Ren, 
Chen, & Yao, 2014; L. Zhang, Yang, Wang, & Gao, 2011). Although the effect of astragalin was 
not evaluated in the current study, it is logical to suggest that the pro-angiogenic effect of 
NXQ extract in zebrafish is at least partly mediated by astragalin. Future study is required to 
confirm the role and contribution of astragalin to inducing angiogenesis. 
We have further assessed the potential mechanisms of action underlying the cellular 
protective effects and angiogenic effect of NXQ targeting the Akt/eNOS pathways. The Akt-
eNOS signalling pathway has been implicated in the regulation of cell survival and 
proliferation (Fei Shi et al., 2012). Akt, or protein kinase B, a serine/threonine protein kinase 
that is recruited to the membrane by its binding to PI3K-produced phosphoinositide. 
Activation of Akt pathways corresponds to the reduction of cell apoptosis and enhances cell 
proliferation. We examined whether NXQ promotes proliferation and migration of the 
endothelial cells via the PI3K-Akt pathway. Our results showed that NXQ (10 and 50 µg/mL) 
caused a modest increase in p-Akt/t-Akt ratios, in a concentration-dependent manner.  
However, these changes did not reach statistical significance (n=3). These results suggest that  
the NXQ-induced cell survival and proliferation may be partially mediated by the p-akt 
pathway. In addition, we also evaluated the cell-protective effects of NXQ via eNOS signalling 
pathway. eNOS is responsible for cell homeostasis and prevents endothelial cell damage by 
increase NO production. However, no significance was observed on NXQ (10 and 50 µg/mL) 
compared to vehicle control (n=3). We anticipated other signalling pathways might be 
involved such as MAPK, p38, or GSK. Due to the limitation of time of this candidature, we 
have only evaluated the Akt and eNOS pathways, further evaluation of additional pathways 
will be conducted in the near future for publication purposes. 
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6.7 Conclusion 
Overall, we observed that NXQ exerted angiogenic effects at various concentrations (25–
300µg/mL) in VRI treated zebrafish embryos. NXQ and its top two bioactive components 
failed to induce proliferation and migration in the current in vitro assays, suggesting a 
complex conjugating reaction of NXQ and its active constituents. Overall, this study provided 
insights into the potential angiogenic effects of NXQ treatment, and future studies on the pro-










Chapter 7. A Randomised, Double-Blind, Placebo-Controlled Trial to 
Evaluate the Effectiveness and Safety of Nao Xin Qing (NXQ), a 
Standardised Herbal Medicine Formula in Patients with Ischaemic 
Stroke – Experiment Protocol 
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7.1 Background  
Stroke, also known as cerebral-vascular accident. It is a disease with multiple overlapping risk 
factors, primarily of vascular origin and typically complicated by ageing and lifestyle factors 
such as dietary habits and smoking. Stroke is one of the leading cause of death in Australia 
after coronary heart disease, and most survivors are left with permanent disabilities. In 2012, 
over 420,000 Australians were living with the effects of stroke; 75% of them suffered from a 
disability severe enough to decrease their employability (Coffey C. Edward, 2000; NSF, 2013) 
and two-thirds require assistance in daily living activities and long-term care (NSF, 2013). This 
number is expected to rise to 709,000 by the year 2032 due to the complexity of risk factors 
and the increase in the aged population of Australia (NSF, 2013).  
Management of stroke, including prevention and rehabilitation, cost A$49.3 billion in 2012 
(Cadilhac et al., 2009; NSF, 2013). Given that the number of disabled survivors is increasing, 
the cost of stroke treatment is expected to increase proportionally (Broderick, 2004).  
Stroke is the rapid development of clinical signs indicating focal or global disturbance in 
cerebral functionality, with symptoms lasting for 24 hours or longer and potentially resulting 
in death with no apparent cause other than it being of a vascular origin (WHO, 1988). 
Ischaemic stroke (IS) is typically associated with disturbance in blood supply and generally 
incurs smaller lesions. Haemorrhagic stroke (HS) refers to the rupturing of blood vessels, 
resulting in larger lesions. IS is the more common type, accounting for approximately 80% of 
all cases. However, the IS mortality rate is generally lower in comparison to HS (Andersen, 
Olsen, Dehlendorff, & Kammersgaard, 2009a). Stroke treatment is predominantly focused on 
IS due to its higher incidence and potential therapeutic outcomes, whereas HS therapies are 
limited due to the rapid and extensive physiological damage, truncated therapeutic window 
and poor overall prognosis. 
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Ischaemic stroke is caused by deprivation of oxygen and energy supply to the brain cells. It 
can be sub-categorised into thrombotic and embolic ischaemic stroke (Lees et al., 2000). 
Thrombotic stroke (TS) is the most common type and occurs when a blood clot adhering to 
the vessel wall (mural occlusive thrombus) reaches a sufficient size to completely block 
cerebral artery blood flow. The development of an occlusive thrombus due to atherosclerosis 
is a major risk factor for stroke (Allen & Bayraktutan, 2008). Atherosclerosis is a condition in 
which plaque builds up within an artery causing a narrowing of the blood vessel. The 
formation of this plaque is associated with fatty materials such as low-density lipids (LDL) and 
triglycerides; however, other factors such, as hypertension, diabetes, smoking and ageing, 
have also been shown to contribute to atherosclerosis (H. Adams et al., 1993; Allen & 
Bayraktutan, 2008). Atherosclerosis is a serious risk factor due to the development of 
atheromas during plaque formation in the cerebral arteries. The first concern regarding 
formation of atheromas is the narrowing of the relatively small arteries in the brain, resulting 
in increased blood pressure and reduced blood flow. Additionally, should the fibrous cap of 
an atheroma ulcerate, the subsequent thrombogenic material released may induce thrombus 
formation overlying the atheroma. This can result in rapid occlusion of the artery and, hence, 
ischaemic stroke. In addition to ischaemic stroke, atheromas produce enzymes that enlarge 
the arteries over time, and this excessive widening may lead to the creation of an aneurysm 
with subsequent rupturing resulting in a haemorrhagic stroke (Dzau, 1994; Kher & Marsh, 
2004). 
In contrast, embolic strokes occur when an embolus (e.g., a blood clot, atherosclerotic 
plaque, fat globule or gas bubble) is carried by the bloodstream to the brain, where the larger 
arteries branch off into smaller vessels. The embolus reaches a point at which it can travel no 
further, thereby plugging a small cerebral artery and cutting off the blood supply to that area 
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of the brain. Most blood clot emboli are caused by non-vascular factors such as atrial 
fibrillation (AF), in which the two small upper chambers of the heart quiver, causing the blood 
to pool and form clots (H. Adams et al., 1993; Lees et al., 2000).  
A number of risk factors have been associated with an increased risk of ischaemic stroke. 
They can be stratified into modifiable and non-modifiable risk factors. Modifiable risk factors 
include those resulting from the environment and lifestyle choices such as a high-fat and high-
glucose diet, lack of exercise and smoking. These risks are typically manageable with the help 
of healthcare professionals, pharmaceutical treatment and continuing education. Non-
modifiable risk factors encompass hereditary or natural features such as ethnicity and ageing 
(Allen & Bayraktutan, 2008).  
Ischaemic stroke is typically the result of a transient or permanent reduction in cerebral blood 
flow to a major arterial branch within the brain caused by the occlusion of arterial blood flow, 
either by an embolus or local thrombosis. Brain injury following the transient or permanent 
focal cerebral ischaemia develops from a complex series of pathophysiological events (Dirnagl 
et al., 1999).  
The brain is the centre of the nervous system and exerts critical centralised control over 
most of the physiological and cognitive functions of the body. As a result, brain tissue requires 
relatively high levels of oxygen and glucose and depends almost exclusively on oxidative 
phosphorylation for energy production (Dirnagl et al., 1999).  
Focal impairment of cerebral blood flow restricts the delivery of oxygen and glucose, 
leading to a functional failure of cellular membrane ion channels such as potassium, sodium 
and chloride pumps, causing the plasma membrane of neurons to depolarise. The resultant 
cascade of pathophysiological processes – such as excitotoxicity, peri-infarct depolarisation, 
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inflammation and apoptosis –directly or indirectly lead to the death of neurons (Dirnagl et al., 
1999; Kehrer & Smith, 1994).  
The ensuing efflux of K+ and influx of Na+ and Cl- across the cell membrane following 
depolarisation causes increased water permeation into the neural cells via osmosis. The 
oedema can negatively affect the perfusion of blood to the regions surrounding the infarct 
epicentre and can also have remote effects due to increased intracranial pressure, vascular 
compression and herniation. 
As a further consequence of the membrane depolarisation, the substantial influx of Ca2+ 
allows for excitatory amino acids to be released into the extracellular space (Dirnagl et al., 
1999). At the same time, energy-dependent processes such as presynaptic re-uptake of 
excitatory amino acids are impeded, further increasing the accumulation of excitatory amino 
acids such as glutamate in the extracellular space. The presence of these excitatory amino 
acids results in the activation of N-methyl-D-aspartate (NMDA) receptors and a specific 
glutamate receptor subtype known as metabotropic receptors. The combined over-activation 
of these receptors from accumulated extracellular excitatory amino acids contributes to the 
cellular Ca2+ overload in the neural cell (Dirnagl et al., 1999; Kehrer & Smith, 1994). 
This increase in Ca2+ is thought to initiate a series of cytoplasmatic and nuclear events that 
result in cellular destruction and activate inflammatory responses, thereby generating free 
radical species that overwhelm endogenous scavenging mechanisms (Dirnagl et al., 1999; 
Ginsberg, 2008). These free radical species damage the cellular membrane, allowing further 
influx of Ca2+ ions. Of these free radicals, reactive oxidation species (ROS) serve as important 
signalling molecules that trigger inflammation and apoptosis (J. T. Coyle & Puttfarcken, 1993). 
Studies show a strong correlation between neurodegenerative diseases, including stroke 
and Alzheimer’s disease, and ROS (J. T. Coyle & Puttfarcken, 1993). It has been reported that 
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there may be a surge in the generation of ROS during cerebral ischaemia, particularly at the 
onset of reperfusion. ROS including superoxide, hydrogen peroxide and hydroxyl radicals are 
highly reactive and can break down cell membranes, damage DNA, create oxidation on 
proteins and amino acids and inactive specific anti-oxidant enzymes. Neurons, in particular, 
consist of abundant polyunsaturated fatty acids and produce low amounts of anti-oxidant 
enzymes; they are, therefore, highly susceptible to ROS (Kehrer & Smith, 1994). Moreover, 
cerebral ischaemia can lead to increased level of excitatory amino acids, such as glutamate, 
which generate more ROS and enhance cellular destruction (van der Worp & van Gijn, 2007). 
As these effects are considerably more pronounced in tissue areas surrounding the focal point 
of the infarct, neuroprotection is therefore a critical yet relatively undeveloped therapeutic 
strategy for minimising neuron damage in ischaemic stroke patients. 
Although recent research focuses on the survival of neurons via neuroprotection and anti-
thrombotic therapies, little attention has been directed to the role of angiogenesis (Krupinski 
et al., 1994). During an ischaemic attack, the brain region of low perfusion (ischaemic), where 
cells have lost their membrane potential, is known as the core; this core is surrounded by an 
area called the penumbra, where intermediate perfusion prevails and cells depolarise 
intermittently (peri-infarct depolarisation). By definition, the penumbra is an area in which 
ischaemic tissue is potentially destined for infarction but is not yet irreversibly injured and is, 
therefore, the primary target of acute therapy (Dirnagl et al., 1999).  
While necrosis at the core of ischaemic infarct is irreversible, studies have suggested that 
the penumbra may remain viable for several hours after an ischaemic event due to alternative 
blood supply from collateral arteries (Dirnagl et al., 1999). A study by Krupinski et al. (1994) 
investigating angiogenesis and ischaemic stroke suggests that adequate perfusion through 
the penumbra can initiate angiogenesis. Evidence suggests that high blood vessel density is 
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correlated with improved patient survival, independency and clinical outcome after stroke 
(Choo, 1993). There is also a strong correlation between the extent of spontaneous 
neurological recovery and the volume of penumbra that escapes infarction (Cheng et al., 2004; 
Dirnagl et al., 1999). Therefore, enhancing the angiogenic effect is another key aspect of 
improving clinical outcomes in stroke recovery. 
7.2 Therapeutic options for ischaemic stroke 
The goal of acute stroke treatment is to increase the survival rate and reduce the 
dependency level of the patient (Dirnagl et al., 1999). The current pharmaceutical treatments 
for ischaemic stroke, including anti-thrombotic therapies, are predominantly time-sensitive 
and have minimal neuropreotective effects (Ringleb et al., 2007). These anti-thrombotic 
therapies, such as anti-platelet agents, anti-coagulants and thrombolytic drugs, typically act 
on thrombosis or embolisms by thinning the blood; however, there is a relatively high risk of 
haemorrhagic incidents (Gubitz et al., 2008; Sandercock et al., 2008; Wardlaw et al., 2009). 
Neuroprotection is considered an important therapeutic strategy in reducing neuron damage 
and dependency levels and, in IS, has been suggested to expand the treatment window and 
reduce reperfusion injury (Cheng et al., 2004; Ginsberg, 2008). However, research into 
neuroprotective agents, such as glycine antagonists and calcium channel blockers, has shown 
discrepancies in the therapeutic benefits between animal studies and clinical trials (Cheng et 
al., 2004). Some researchers suggest this could be due to species-dependent differences and 
that animals such as rodents may be more amenable to neuroprotection than evolutionarily 
higher mammals such as humans (Dirnagl et al., 1999).  
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Rehabilitation is a combination of therapeutic modalities, including physiotherapy, 
occupational therapy, speech and language therapy, designed to assist stroke survivors and 
restore functionality lost due to neurological damage (Feigenson, 1979). In addition to 
rehabilitation therapies, long-term pharmaceuticals are typically prescribed for the 
management of vascular and thrombotic risk factors to prevent recurrence of stroke (Ringleb 
et al., 2007). Aside from these preventative medications, currently there are no known 
pharmaceuticals available for the improvement of cognitive and functional outcomes. There 
is an urgent need for alternative therapeutic options to improve ischaemic stroke outcomes 
by both reducing the damage to the brain and improving functional outcomes. 
 
Traditional Chinese medicine (TCM) originated over 3000 years ago in China and is a form 
of traditional medicine that has integrated philosophical concepts and empirical evidence into 
clinical practice (Deadman, 2006). TCM comprises numerous treatment modalities, including 
herbal medicine, acupuncture, massage therapies, nutritional therapies and mind–body 
exercise regimes such as qigong (Feigin, 2007; M. Liu et al., 2007).  
Preclinical studies have suggested that the use of herbal medicines can increase 
neurological recovery and enhance functional outcomes in stroke patients and, thus, may be 
beneficial in post-stroke rehabilitation (I. Lee et al., 2005; M. Liu et al., 2007; FL Shi et al., 
1989).   
Nao Xin Qing (NXQ) is a standardised and patented herbal extract from the leaves of 
Diospyros kaki that has been used for numerous years in China for the treatment of apoplexy 
syndrome, coronary artery disease and ischaemic stroke (Bei et al., 2004; Bei, Zang, et al., 
2009; Y. Cai & Yang, 2001). The key bioactive components of D. kaki L. have been identified 
as flavonoids (e.g., quercetin and kaempferol) (Bei et al., 2005b). Data from previous studies 
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have shown D. kaki L. offers several therapeutic effects, including anti-thrombotic, 
neuroprotective, haemostatic, anti-oxidative, cholesterol-lowering, and anti-hypertensive 
effects, thereby presenting itself as a potential therapeutic option for both treatment and 
prevention of ischaemic stroke (Y. Cai & Yang, 2001; Y. Yu et al., 1988). 
The herbs used for IS are documented in classical TCM literature for use in blood regulation 
and stasis resolution. These herbal agents, including Danshen, Chuanxiong and Sanchi, have 
been investigated and the bioactive constituents of these herbs have been found to improve 
microcirculation in the brain, protect against reperfusion injury, possess neuroprotective 
and/or anti-inflammatory properties, and inhibit apoptosis (X. Chen et al., 2008a; B Wu, M 
Liu, & S Zhang, 2007; Yuan et al., 2008). 
For instance, preclinical pharmacological studies indicate that Danshen agents can be used 
for dilating cardiocerebral vessels, suppressing the aggregation of platelets, improving 
circulation, removing blood stasis, protecting against ischaemic reperfusion injury and 
enhancing the tolerance of ischaemic tissue to hypoxia (J. L. Li, Liu, H. , 2000; B Wu, M Liu, & 
S Zhang, 2007).  
Furthermore, a Chuanxiong preparation was found to be effective in prohibiting platelet 
aggregation and preventing thrombosis by maintaining the balance of thromboxane 
A2/prostacyclin I2 (TXA2/PGI2) in the blood and increasing the activity of intrinsic superoxide 
dismutase (SOD) (Ge, 1994). Additional studies also found that Chuanxiong could improve 
brain microcirculation through prevention of thrombus formation and platelet aggregation as 
well as the reduction of blood viscosity, thereby highlighting that it may have significant 
beneficial effects in the treatment of ischaemic stroke (H. J. Sun, Wu, W., Chen, H.G., Mi, H.Q., 
2002; J. Wang, Shi, Y. M., Zhen, H. M., Liu, Z. R., Li, X. X., Ding, G. H., 1993; Q. H. Wei, Zhou, D. 
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W., Wang, W., 1994; H. Xu, Shi, D. Z., Guan, C. Y., 2003; J. Y. Zhang, Yang, R. P., Zhu, J. M., 
2001). 
Despite this, the clinical effectiveness and safety of these interventions are yet to be 
confirmed. One systematic review conducted by Wu et al. (2007) evaluates the efficacy and 
safety of 22 traditional Chinese patent medicines (TCPMs) listed in the Chinese National 
Essential Drug list (2004) as potential drugs for ischaemic stroke patient. The pooled analysis 
of randomised and nonrandomised trials showed significant positive effects in lowering 
mortality rates and reducing neurological impairment for the majority of TCPM treatments 
(21 out of 22). However, over 97% of the included clinical trials were noted as having poor 
methodological quality (B Wu, M Liu, H Liu, et al., 2007). The main methodological weakness 
of these trials is lack of bias control, such as double blinding and placebo control. While there 
are numerous issues surrounding the methodology of the clinical trials assessing TCM herbal 
substances for stroke, the existing evidence has highlighted its potential therapeutic benefits. 
7.3 Nao Xin Qing 
Nao Xin Qing (NXQ) is an approved, patented TCM product made from the standardised 
extract of Diospyros kaki leaves (D. kaki L.). NXQ has been used clinically in China for many 
years in the treatment of apoplexy and coronary heart disease and to enhance recovery from 
ischaemic stroke. Previous studies, both clinical and preclinical, have suggested that the 
patent extract has potential therapeutic effects for cerebral atherosclerosis, transitory 
ischaemia syndromes, cerebral thrombogenesis, cerebral thrombosis sequelae, apoplexy 
sequelae and cerebral embolism, with minimal adverse effects (Bei et al., 2007; Y. Cai & Yang, 
2001).  
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7.3.1 Current evidence of NXQ 
Laboratory studies have quantified more than 30 potentially bioactive compounds isolated 
from the leaves of Diospyros species. These can be divided into five main chemical groups: 
acids, biphenyls, flavonoids, polyphenols and triterpenoids (Bei et al., 2004, 2005b). Among 
these chemical compounds, flavonoids were considered to be the key therapeutic 
components responsible for the observed pharmacological and clinical effects due to their 
multiple biological properties, including anti-oxidant, anti-allergenic, anti-inflammatory, and 
vasodilatory actions (Bei et al., 2004; S. Cao et al., 2012).  
Previous research has demonstrated numerous pharmacological effects of D. kaki L. 
extract, such as improved cardiac and cerebral blood flow and anti-hypertensive, lipid-
lowering and radical-scavenging capabilities (S. Cao et al., 2012). A study conducted by Xin, 
Feng and Yao (2007) investigated the effects of intravenous injections of D. kaki L. flavonoids 
in rabbits and found a 30–40% improvement in aortic circulation as well as significant dilation 
in the veins of the ears. These results were supported by Zhang, Wang and Xiao (2004), who 
suggest that the leaves of D. kaki can improve overall circulation in anaesthetised dogs and 
can reduce oxygen consumption of cardiac muscles. Ou, Bei and Lai (2003) found that the 
total flavonoid count can significantly inhibit reperfusion-induced cell apoptosis. Ou, Liu and 
Bei (2004) also suggest that D. kaki L. can inhibit fibrin adhesion (scar tissues) on the 
adventitia stimulated by factors such as advanced glycation end-products (AGEs) and 
advanced oxidation protein products (AOPP).   
In relation to the cerebrovascular system, Cao et al. (2012) studied the fibrinolytic function 
in an ischaemic brain injury model and suggest that D. kaki L. flavonoids can increase tissue 
plasminogen activator (rtPA), which is involved in the breakdown of blood clots and reduction 
of plasminogen activator inhibitor-1 (PAI-1) levels, thereby improving the outcome of 
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thrombotic-related cerebral ischaemia. Cao et al. (2012) further demonstrate that von 
Willebrand Factor (vWF), a blood glycoprotein involved in haemostasis, is reduced in 
ischaemic brain injury rats subjected to D. kaki L. flavonoids. Reduction of vWF has been 
associated with the resolution of thrombosis during an ischaemic attack and restoration of 
damaged endothelial cells. Cao et al. (2012) propose that D. kaki L. flavonoids could reduce 
positive signalling of Intercellular Adhesion Molecule 1 (ICAM-1), an immunoglobulin 
molecule associated with the release of inflammatory factors, and thereby act against 
atherosclerosis and reduce haemostasis.  
Further, Bei, Li et al. (2009) propose that the potential neuroprotective effects of NXQ and 
D. kaki L. flavonoids could activate L-type Ca2+ channels, thus modulating intracellular Ca2+ 
levels to protect neurons in the hippocampus. This action is complemented by the anti-
oxidative ability of NXQ and D. kaki L., which positively inhibits ROS (including hydrogen 
peroxide) thereby reducing neuron damage. 
Kameda et al. (1987) first demonstrated the anti-hypertensive effects of D. kaki L. in 
hypertensive rats. The mechanism of action is thought be through inhibition of angiotensin-
converting enzyme activity. Tan, Lin and Zhang (2009) further investigated these anti-
hypertensive effects and observed an increase in plasma nitric oxide (NO) and reduced over-
production of platelets by essential thrombocytosis (ET) and reduced angiotensin II in rats. 
The results suggest that D. kaki L. flavonoids have the potential to enhance endogenous 
vasodilators and modulate endogenous vasoconstrictors.  
 
Several clinical trials assessing the clinical effects of NXQ have been conducted in China 
recently. One study assessed NXQ as an additional therapy to standard dehydration, anti-
hyperglycaemic and anti-lipidaemic treatment for acute ischaemic stroke in 35 Type 2 
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diabetic participants (B. Tang et al., 2012).This study suggests that NXQ positively improves 
blood rheology by acting on C-reactive protein and blood lipids. Tang et al. (2012) imply that 
the underlying mechanism of action is due to the active component flavonoids from D. kaki 
L. extract having anti-ischaemic effects on cerebral and cardiac blood flow, neuroprotective 
effects through free radical scavenging and anti-atheroscleroma effects by lowering blood 
lipids.  
Another study conducted by Wang et al. (2012) assesses NXQ in combination with acute 
management therapy (mannitol and glycerol fructose dehydration) in comparison to acute 
management therapies alone in patients with cerebro-cardiac syndrome caused by acute 
stroke. A total of 204 participants were included;130 patients suffered from ischaemic stroke, 
61 from intracranial haemorrhages and 13 from sub-cranial arachnoid haemorrhages. A 
standard dose of NXQ was given at the acute phase in addition to acute management therapy 
protocols for a continuous four-week period. The results suggest that the NXQ group had 
superior outcomes in improving cardiac function recovery including arrhythmia, changes in 
ST-T wave and abnormal cardiac enzyme production (A. Wang et al., 2012).  
Chen, Shao and Cheng (2012) conducted a clinical trial assessing NXQ as an adjunct to low-
molecular weight heparin in comparison to heparin alone on 160 cerebral transient ischaemic 
attack patients. Results suggested that both groups had prolonged partial thromboplastin 
time (PTT) and active partial thromboplastin time (APTT); however, NXQ showed significantly 
longer duration in both outcome measures when compared to controls. In addition, no 
significant adverse events were identified (Y. Chen et al., 2012). 
Although limited clinical studies have been conducted on cerebral ischaemic stroke, a 
number of clinical trials were conducted assessing the effects of NXQ for ischaemic heart 
disease and angina, which share a similar underlying pathological process with ischaemic 
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stroke – atherosclerosis. A study conducted by Cai and Yang (2001) assesses the pre- and post-
effects of NXQ in 48 atherosclerosis cases and 12 coronary artery disease-induced angina 
cases. The study concludes that NXQ can significantly lower blood lipids and improve 
symptoms such as vertigo and headaches (Y. Cai & Yang, 2001). Furthermore, a recent study 
by Wu, Wu and Zheng (2013) evaluates 90 patients with coronary artery disease and angina, 
comparing NXQ against a standard vasodilator, and shows similar positive results. The authors 
found statistically significant results in lipid levels and suggested that the significant reduction 
of cardiac stress and cardiac oxygen consumption, and improvements in oxygen supply to 
cardiac muscle, occurred through aorta dilation (D. Wu et al., 2013). This is supported by the 
findings of Xiong, Tang and Zhou (2013), who assess the clinical effects of standard angina 
treatment – including nitrates, aspirin, beta blockers, angiotensin-converting enzyme 
inhibitors and lipid-lowering drugs – compared to standard treatment combined with NXQ in 
120 elderly patients with unstable angina. The results suggest that the NXQ combination 
group experienced significant improvements in symptoms of angina and lower blood lipid 
levels (Xiong et al., 2013). 
In summary, the preliminary clinical evidence suggests NXQ is effective for lipid reduction 
and may also improve cardiac blood flow as well as relieving clinical symptoms such as angina. 
No severe adverse event was identified when used in conjunction with anti-coagulant. 
However, the methodology of these trials did not appear to be rigorous and precise. Of all the 
trials, only Tang et al. (2012) reported a randomisation method, and statistical power across 
all the studies was relatively low due to the small sample sizes. Apart from Wang et al. (2012), 
no study reported the treatment duration of either intervention or control. Furthermore, 
adverse events were not reported in the studies by Cai and Yang (2001), Wu et al. (2013) and 
Wang et al. (2012). Despite the sample sizes and debatable methodological quality, the 
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clinical observations emphasise the potential benefits of NXQ for ischaemic stroke. To date, 
there have been no trials evaluating the neuroprotective effects of NXQ with adapted 
standardised outcome measures. While there is sparse clinical evidence available, there is a 
considerable body of preclinical evidence that provides a preliminary foundation for further 
clinical assessment into the potential use of NXQ in stroke.  
7.4 Research hypothesis 
The aim of this study is to assess the clinical effectiveness and safety profile of NXQ for 
ischaemic stroke patients undergoing rehabilitation. The hypothesis of this study is that a 12-
week intervention of NXQ will improve neurological, motor and cognitive functional 
outcomes for ischaemic stroke patients during the rehabilitation phase. 
7.4.1 Study design and trial group 
This study is a parallel group, double-blinded, randomised, placebo-controlled clinical trial to 
assess a 12-week intervention of NXQ treatment during the rehabilitation of patients 
suffering from ischaemic stroke. Potential participants are randomised to either intervention 
or placebo groups.  
Participants in the intervention group will receive NXQ tablet (4 tablets, tid) over a period 
of 12 weeks. Participants in the placebo control group will receive a placebo (4 tablets, tid) 
dose equivalent to the intervention group over a period of 12 weeks. Primary outcome 
measures include the National Institute of Health Stroke Scale (NIHSS) and the Specific Stroke 
Quality of Life (SSQOL) and will be assessed at baseline and at weeks 6 and 12, and at a follow-
up assessment performed at week 16 of the intervention. Secondary outcome measures will 
be performed at baseline, week 6 and week 12 of the treatment period. Blood rheology and 
coagulation assessment will be performed at week 2 of the intervention as part of safety 
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measures. At week 36, a long-term efficacy follow-up will be conducted assessing adverse 
events, all-causes mortality and reoccurrence of stroke (Table 15). 
The study will be conducted at the Stroke Care Unit, Hornsby Ku-ring-gai Hospital; 
additional sites may be included at a later date. All study procedures will be conducted in full 
compliance with good clinical practice guidelines and with the approval of the University of 
Western Sydney and Hornsby Ku-ring-gai Hospital Human Research Ethics Committees before 
trial commencement. Upon receiving ethical approval, this study will also be registered with 
the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). 
7.4.2. Participant selection and enrolment 
7.4.2.1 Identifying participants 
Potential participants who meet all inclusion and exclusion criteria will be recruited from the 
Hornsby Ku-ring-gai Hospital. These participants will be identified through physician referral 
and poster advertisements placed in the Hornsby Ku-ring-gai Hospital and stroke care units. 
Additional participants will be identified through advertisements through the Stroke Care 
Unit of Hornsby Ku-ring-gai Hospital and University of Western Sydney websites.  
7.4.2.2 Consenting participants 
Once participants are identified, there will be a brief telephone interview to provide 
preliminary details of the study and to confirm eligibility under basic inclusion/exclusion 
criteria and access to the test site for screening, intervention and testing sessions.  
Once confirmed, a suitable day and time for a screening session will be advised to potential 
participants. Following this, a participant information sheet and an appointment letter 
detailing the arranged time and date, location and any additional information to be brought 
with them will be sent via email and/or post. 
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At the screening session, participants will be fully briefed and provided with an information 
sheet in the event they have not received it prior to the screening session. Participants will 
then be required to provide informed written consent before the screening procedure begins 
and will be invited and encouraged to ask questions throughout the recruitment procedure 
and while the study is in progress. 
7.4.2.3 Screening for eligibility 
Participants will undergo physical examination at screening by a trained medical staff and 
NIHSS scores will be assessed by a physician. Full blood tests will follow to assess liver and 
renal function as well as lipids profile. The blood test results will be used as the baseline 
assessment. If no abnormalities are discovered during the questionnaire or physical 
examination, the participant will be tentatively enrolled and asked to complete a training 
session on the COMPASS test battery. During this training session, a researcher will be present 
to answer any questions as well as to correct any mistakes. The results generated from this 
screening session will not be included in data analysis. 
7.4.2.4 Ineligible and non-recruited participants 
Participants deemed ineligible for the study will be notified via email or telephone. They will 
be informed that they do not meet the criteria outlined for the study. 
7.4.3 Inclusion criteria and exclusion criteria 
7.4.3.1 Inclusion criteria  
— Meets standard criteria for atherosclerotic ischaemic stroke. 
—  Disease onset between 2 weeks and 3 months post-stroke. 
— NIHSS score equal or greater than 5 and equal to or less than 25. 
— Age between 40 and 80. 
174 
— Initial onset or recurrent onset but full recovery with mRS score of 0 to 1. 
— Informed consent obtained. 
7.4.3.2 Exclusion criteria 
— Presents with cerebral haemorrhagic history within the past 6 months. 
— Clinical assessment concludes the cause of ischaemic stroke is brain tumour, trauma, 
parasites, metabolic deficits, rheumatic heart disease, coronary artery disease or its 
arterial fibrillation complications. 
— Combined with other complications affecting neural and motor function assessment, 
including lameness, osteoarthritis, rheumatoid arthritis and gout. 
— Severe pulmonary and cardiovascular hepatic (ALT, AST>2 times normal range) and 
renal dysfunction (BUN>1.2 times normal range, Cr>normal range). 
— Pregnancy and breast feeding. 
— Disability patients by law (blindness, deafness, cognitive deficits, metal deficits, physical 
deficits). 
— Known allergy to the medication ingredients or allergic body type. 
— Participated in other clinical trial in the past 3 months. 
— Consuming any other supplements or herbal medicine relevant to stroke treatment. 
 
7.4.4 Concomitant medication provision  
1. Standard anti-platelets/anti-coagulant treatment can be used as required.  
2. Foundation treatment: Bayaspirin Enteric-coated, oral administration of 1 tablet tid 
(0.1g/tablet). If the patients have allergies or adverse reactions to Bayaspirin Enteric-
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coated, they can use Clopidogrel as replacement. However, Bayaspirin and 
Clopidogrel cannot be used at concurrently. 
3. Medication for relevant complications (hypertensive, hyperlipidaemic, 
hyperglycaemic and antibiotics) can be used as normal. 
4. All medications and treatment procedures applied during the trial should be recorded 
in detail including medication type, dosage, method, and treatment duration for 
adverse event reporting and assisting in statistical analysis. 
5. All treatment procedures and medications used during the follow-up period (note: 
protocol does not specify follow-up period duration) for both ischaemic stroke and 
unrelated complications should be recorded and include disease name, medication, 
dosage and mode of administration for adverse event reporting and assisting in 
statistical analysis. 
7.4.5 Intervention and treatment allocation  
Participants in the intervention group will receive NXQ tablets (4 tablets, tid) over a period of 
12 weeks. Intervention: NXQ tablets, weight 0.41g per tablet, oral administration of 4 tablets 
tid. 
Participants in the placebo control group will receive placebo (4 tablets, tid) dose 
equivalent to intervention group over a period of 12 weeks. Placebo Control: NXQ placebo 
tablets, weight 0.41g per tablet, oral administration of 4 tablets tid. 
7.4.6 Sample size and randomisation  
This trial is a pilot study to evaluate the effects of NXQ in comparison to placebo in patients 
with ischaemic stroke during rehabilitation period. The target sample size is 30 participants 
per group; with a 20% dropout boundary, the target will be 72 participants. Previous clinical 
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trial conducted using NXQ were not evaluating the outcome measures relevant to ischaemic 
stroke. According to Connelly (2008), extant literature suggests that a pilot study sample 
should be 10% of the sample projected for the larger parent study. However, Hertzog (2008) 
cautions that this s not a simple or straight forward issue to resolve because these types of 
studies are influenced by many factors. Nevertheless, Isaac and Michael (1995) suggested 10 
to 30 participants are typically considered for a pilot study to examine the practicality and 
feasibility of the methods. 
Once the patients have been recruited, they will be randomly allocated to the NXQ 
intervention group or placebo control group by means of a computer randomisation package. 
Randomisation will be conducted by a NICM Research Program Coordinator external to 
the research team. The research team will be concealed to the randomisation process. The 
NICM Research Program Coordinator will prepare individually assigned and sealed envelopes 
containing the participant's group allocation, which will only be opened once the participant 
is confirmed to be eligible for the study. Participants will also be stratified based on disease 
type and treatment received. 
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Figure 7.4: Schematic trial protocol. 
 
7.4.7 Withdrawal procedures 
Participants have the right to withdraw at any point in the study at their own request. In the 
event of allergic reaction or a severe adverse reaction, participants will undergo a medical 
examination and be withdrawn from the study. If disease prognosis worsens during the trial 
period, participants will undergo medical examination and be withdrawn from the study. In 
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the event that participants do not follow the instruction protocols – including poor 
compliance (<80% and >120%), abstaining from alcohol and caffeine prior to testing sessions, 
abstaining from illicit drug use and other exclusionary medications – investigators reserve the 
right to withdraw participants on the basis that these actions will contaminate the results. 
Should this occur, participants will be notified via email or telephone that they have been 
withdrawn from the study.  
Whether participants are replaced will be determined based on the number of participants 
who choose, or for other reasons are forced, to withdraw. Should the need for additional 
participants arise, additional recruitment will be identical to the initial recruitment procedure. 
7.4.8 Study assessments 
7.4.9.1 Primary outcome measures 
7.4.9.1.1	National	Institute	of	Health	Stroke	Scale	(NIHSS)	
The National Institute of Health Stroke Scale (NIHSS) is a graded neurological examination 
rating speech and language, cognition, visual field deficits, motor and sensory impairments, 
and ataxia and has become a standard part of the clinical assessments used in many recent 
interventional trials. This assessed by neurologist or trained physician based on 11 sections 
scoring accordingly between 0 to 2, 0 to 3 and 0 to 4 of each of the sections (Berger et al., 
1999; Fischer et al., 2005).  
Post-treatment score of each section ≤ 0–1 indicates good clinical recovery; scores ≥ 0–1 
indicate poor clinical recovery. Appropriate statistical methods will be used to analyse the 
comparison of good vs poor clinical recovery ratio between intervention and control groups. 
A total score ≥16 forecasts a high probability of death or severe disability, whereas a score 
≤6 forecasts a good recovery.  
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7.4.9.1.2	Stroke-Specific	Quality	of	Life	Scale	(SSQOL)	
The SSQOL is a more comprehensive questionnaire than the 36-item Short Form Health 
Survey (SF-36). For example, the SF-36 and the Euro Quality of Life questionnaires are 
commonly used in stroke trials but do not assess language, hand function, cognition or vision 
(Muus, Williams, & Ringsberg, 2007; Williams, Weinberger, Harris, & Biller, 1999). 
SSQOL scales have been shown to be more valid and reliable in measuring stroke-specific 
health-related quality of life which is moderately responsive to changes in most domains 
during the first three months after stroke. A study conducted by Williams, Weinberger, Harris, 
Clark and Biller (1999) suggests that the SSQOL is superior to common generic health-related 
quality of life measures.  
The SSQOL includes 12 domains of assessment and covers a broader range of functions 
typically affected by stroke. These areas include mobility, energy, upper extremity function, 
work and productivity, mood, self-care, social roles, family roles, vision, language, thinking 
and personality.  
7.4.9.2 Secondary outcome measures 
7.4.9.2.1	Modified	Rankin	Scale	(mRS)		
The modified Rankin Scale (mRS) is a commonly used scale for measuring degree of global 
disability or dependency in daily activities caused by stroke and other neurological 
impairments. The scale ranges from 0 to 5, from perfect health without symptoms to severe 
disability (Sulter, Steen, & De Keyser, 1999). While mRS is widely applied for evaluating stroke 
patient outcomes, it is also widely used as valid end point in randomised clinical trials 
assessing new treatment paradigms (Banks & Marotta, 2007).  
The primary investigator will be trained in the use of mRS. Scores will be recorded 
according to patients’ degree of disability and dependence.  
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7.4.9.2.2	Barthel	Scale	
The Barthel Scale is a widely used ordinal scale measuring performance in activities of daily 
living (ADL), including feeding, bathing, grooming, dressing, toilet use, mobility and 
ascending/descending stairs (C. Granger, Dewis, Peters, Sherwood, & Barrett, 1979).  
The Barthel index is one of the first contributions to the functional status literature and it 
represents occupational therapists' lengthy period of inclusion of functional mobility and ADL 
measurement within their scope of practice. It has been used extensively to monitor 
functional changes in individuals receiving in-patient rehabilitation, mainly in predicting the 
functional outcomes related to stroke (Collin, Wade, Davies, & Horne, 1988).  
The Barthel Scale will be assessed by asking relevant question and rating responses from 
0 to 100. A score of 100 represents independence; scores between 75 and 95 represent mild 
dependency; scores between 50 and 70 represent moderate dependency; scores between 25 
and 45 represent severe dependency; and scores between 0 and 25 suggest total dependency. 
Responses will be sought from a patient’s direct carer if the patient is highly dependent. 
7.4.9.2.3	Lipid	profile,	blood	rheology,	coagulation	index	and	inflammatory	marker.	
Patients will be sent to a Douglass Hanly Moir Pathology laboratory (multiple locations across 
metropolitan Sydney and regional NSW) for blood sampling and pathology testing. 
Assessment areas for lipid profiles include triglycerides, total serum cholesterol, high-density 
lipids and low-density lipids. Douglass Hanly Moir Pathology and all its laboratories are fully 
accredited with the National Association of Testing Authorities (NATA) and registered under 
the accreditation scheme of the Royal College of Pathologists of Australasia (RCPA). 
A copy of the pathology results will be inserted into the participant file during the study 
and stored in a locked filing cabinet in a secure and lockable room, accessed only by the trial 
research staff. The email copy of results can only be accessed by secure password known only 
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to the Chief Investigator and Principal Researcher. Upon completion of the trial, the pathology 
results will be securely and separately stored from the coded participant files, as the 
pathology results will be identifiable. These paper files will remain securely stored. 
7.4.9.2.4	COMPASS	computer	test	battery		
The Computerised Mental Performance Assessment System (COMPASS) features a number 
of computerised cognitive tasks designed to test various aspects of mental function. The 
COMPASS test battery employs similar tasks to those found in the Computerised Drug 
Research (CDR) and Cambridge Neurological Assessment Battery (CANTAB) test batteries, 
both of which have been used extensively in cognitive studies (Robbins et al., 1994; Sahakian 
& Owen, 1992; Wesnes, Ward, McGinty, & Petrini, 2000). The COMPASS test battery can be 
customised with a range of computerised tests. Alternative forms of each task are to be 




A series of digits from 1 to 9 will be presented sequentially, with a stimulus presentation time 
of 500ms. Participants are required to press the spacebar whenever they detect three 
consecutive even or three consecutive odd digits. The tasks will last for 5 minutes and 
included a total of 40 targets, i.e. runs of three consecutive odd/even digit series. The 
outcome measures will be measured in averaged response time and percentage of correct 
responses. 
7.4.9.2.4.2	Wisconsin	card	sorting	test	
This task will present four static cards at the top of the screen with each card being different 
based on the four variables of colour, shape, number of shapes and arrangement of shapes. 
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Below these four cards, a new card will be presented to the participant. This card will be 
randomised based on the abovementioned four variables. The participant is required to 
match this card to one of the four static cards at the top of the screen based on the 
abovementioned variables. Participants will not be given instructions as to which variable has 
been chosen as the key variable to which they should match. Periodically, the test will 
randomly switch the key variable; again, participants will not be notified when this occurs. 
The outcome measure will be measured in number of correct and incorrect responses, 
average reaction time and accuracy per category shift. 
7.4.9.2.4.3	4	Choice	reaction	time	(4CRT)	
This task employs an on-screen representation of the four directional arrows found on a 
standard keyboard. One of the four arrows will light up and participants will be instructed to 
press the corresponding directional key with the index finger of their dominant hand as 
quickly and as accurately as possible. There will be 48 trials (12 per choice) presented with a 
varying inter-stimulus interval of 1–3 seconds. The outcome measure will be measured in 
averaged response time and percentage of correct response. 
7.4.9.2.4.3.5	N-Back		
The participant will be presented with a series of letters one at a time. The participant will be 
required to decide if the current letter is the same as the letter shown three letters earlier. 
To reduce visual recognition strategies, a mix of upper and lower case letters are used. 
Participants are required to press the ‘Z’ key for NO and the ‘M’ key for YES. The outcome 
measure will be measured in averaged response time and percentage of correct response. 
7.4.9.2.4.3.6	Word	presentation,	immediate	word	recall,	delayed	word	recall	and	word	recognition	
In word presentation, participants will be presented with a list of ten words to be 
remembered. These will be presented on the monitor for one second at a rate of one per 
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second. Immediately after presentation, participants will be given one minute to recall as 
many of the ten words as possible. The outcome measures to be measured are number of 
correct responses.  
At the end of the COMPASS session, participants will be given one minute to recall as many 
of the ten words from the word presentation as possible. The outcome measures will be 
measured in number of correct responses. Following this delayed word recall task, 
participants will be presented with the original ten words from the word presentation task as 
well as ten distracter words. Participants are required to decide whether the word being 
presented is from the original ten or not. Participants are required to press the ‘Z’ key for NO 
and the ‘M’ key for YES. The outcome measures will be measured in correct responses. 
7.4.9.2.5	Ultrasound	–	flow-mediated	dilation	(FMD)	
High-resolution B-mode ultrasonography will be performed using a 13Mhz linear-array 
transducer on a GE Vivid I ultrasound system to determine brachial artery diameter and 
change due to flow-mediated dilation (both dependent and independent). Doppler 
ultrasound will be employed to determine peak blood flow velocity and shear rate when 
combined with additional diameter data. 
Pre-processing configurations will be held constant during all examinations. The image 
should clearly show vascular boundaries in the longitudinal plane allowing for visualisation of 
the double lines of Pignoli and distinguishable demarcated boundaries for precise diameter 
measurement (≤0.05mm) by automated edge-detection software.  
7.4.9.2.6	Dependent	endothelial	function	
With the subject lying supine, a blood pressure cuff will be attached below the imaged 
brachial artery and inflated to 250mmHg to ensure complete arterial occlusion. Prior to cuff 
inflation, baseline vessel diameter and blood flow velocities will be captured. The cuff will 
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remain inflated for a period of 5 minutes and once the cuff is deflated, measurements will be 
conducted using a Doppler beam-vessel angle of ≤60° that will allow for an estimation of 
blood flow velocity. Continued measurements for peak arterial diameter will be conducted 
over a period of at least 180 seconds post-cuff deflation.  
Subjects will be fasted and have avoided exercise, caffeine, alcohol, drugs, stimulants and 
medications for a consistent period of time (at least 6 h) to minimise the effect of these 
confounding factors. The assessments should be conducted after a standardised period of 
time following any necessary medication and a careful history of medication use and timing 
should be collected. Furthermore, assessments are to be conducted at similar times of day in 
a quiet (preferably darkened), temperature-controlled thermoneutral room after the subject 
has been resting quietly for 5 minutes. 
7.4.9.2.6	Safety	measures	
7.4.9.2.6.1	Adverse	events	and	severity	criteria	
The presence and frequency of adverse events will be recorded at each assessment session 
on a paper-based form. Participants will be encouraged to note any adverse events during 
the trial period between the assessment time-points and to contact the researchers 
immediately. For classification of adverse events, refer to Appendix B. 
7.4.9.2.6.2	General	medical	assessment		
General medical information, including body temperature, heart rate, breathing and blood 
pressure, will be measured and recorded at each assessment visit. 
7.4.9.2.6.3	Blood	Test,	LFT	and	RFT	
Routine blood, urine and faeces tests, liver function (ALT, AST, TBIL, γ-GT, ALP), kidney 
function (BUN, Cr) and electrocardiogram (ECG) will be assessed at each assessment in week 
2, week 6 and week 12 of the treatment period.  
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7.4.9.2.6.4	Long-term	efficacy	assessment	
Participant will be followed up by phone at week 16 (4 weeks post-treatment) and week 36 
(24 weeks post-treatment) during the trial period. Any incidents – including death, recurrence 
of ischaemic stroke, cerebral-vascular incidents and cardiovascular incidents – will be 
recorded and the reasons analysed. 
7.4.10 Data collection and statistics 
7.4.10.1 Treatment duration 
A 12-week treatment duration and a 24-week follow-up period. 
Table 15: Data collection timeline 
 
Data will be collected using proprietary software employed by equipment manufacturers for 
the COMPASS and Vivid I. Data from COMPASS will be exported from an Excel spreadsheet 
Exam Screening Baseline Wk2 Wk 6 Wk 12 Wk16 Wk 36 
Screening Medical History •       
Physical Exam •       
Primary NIHSS  •  • • •  
SSQOL  •  • • •  
Secondary MRS  •  • • •  
Barthel Scale  •  • • •  
Lipids Profile     •   
Blood rheology  • • • •   
Coagulation Study  • • • •   
Blood Pressure  •  • •   
Inflammatory 
marker 
C-RP  •  • •   
TNF-a  •   •   
COMPASS  •   •   
Ultrasound  •   •   
Safety Adverse event  • • • • • • 
Full blood count •   • •   
LFT; RFT •  • • •   
Long-term 
efficacy 
Death; Reoccurrence of IS; 
incidents of CardioVD or 
CerebroVD  
     • • 
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directly to an SPSS database. Data from the Vivid I system, pathology results and stroke 
outcome assessments will be entered into or collected by Evado Clinical Trial Software during 
the course of the trial and exported to a SPSS database for analysis. 
Analysis will take the form of ANCOVA of each variable at post-treatment while controlling 
for baseline measurements and other possible confounders such as age, gender, ethnicity and 
BMI. Only participants with complete datasets on the relevant variables will be included in 
the analysis. Results will be considered statistically significant when p<0.05. 
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Chapter 8. Summary and Conclusion 
 
Ischaemic stroke is responsible for 80% of stroke incidence (Andersen et al., 2009b). Patients 
who suffer ischaemic stroke may be left with permanent neurological and motor dysfunctions 
and increased risks of vascular dementia (Desmond et al., 2000). Current conventional 
treatment for ischaemic stroke, whether surgical or pharmaceutical, is focused on restoring 
cerebral blood flow and preventing expansion of ischaemic damage (Prabhakaran, Ruff, & 
Bernstein, 2015). However, the restoration of blood flow typically induces reperfusion injury, 
which contributes to major neuron damage additional to that of ischaemic origin (Hausenloy 
& Yellon, 2013). Currently, no therapeutic options are available to prevent neuron damage 
associated with reperfusion injury; therefore, patients who suffer ischaemic stroke are at 
great risk of motor and neurological deficits and increased risk of developing vascular 
dementia.  
NXQ, a standardised, patented herbal extract derived from Diospyros kaki. L., has been 
used as therapeutic agent in China for apoplexy syndromes, atherosclerosis, cardiovascular 
diseases such as angina, and cerebral ischaemia (Bei et al., 2007; Y. Cai & Yang, 2001). 
Preclinical research demonstrates that NXQ has neuroprotective effects against H2O2-induced 
NG108 neuron cells and reduces cerebral infarction in MCAO transient focal cerebral 
ischaemic rats (Bei et al., 2007). However, its role in vascular protection and angiogenic 
vascularisation has not been not evaluated. Quercetin and kaempferol are reported to be the 
main bioactive components of D. kaki. L. responsible for the therapeutic effects of NXQ (Bei 
et al., 2007). However, no studies have been conducted to evaluate how these individual 
components contribute to the therapeutic effects of NXQ, or whether they interact to 
generate synergistic effects. Moreover, the efficacy and safety of NXQ in the management of 
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ischaemic stroke has not been evaluated in rigorous clinical trials (Y. Cai & Yang, 2001; Y. Chen 
et al., 2012; B. Tang et al., 2012; A. Wang et al., 2012; D. Wu et al., 2013).  
This doctoral project contains four components. Three experimental studies were 
conducted to determine the ratio of quercetin and kaempferol in NXQ extracts and to 
evaluate NXQ’s anti-oxidant and pro-angiogenesis properties. In the last study, a randomised 
clinical trial protocol has been developed to evaluate the effectiveness and safety of NXQ.  
In the first study, the analytical methods previously developed for seven key analytes of 
NXQ, including quercetin and kaempferol, were re-established and briefly validated. The 
seven analytes were identified and quantified in NXQ extracts and the ratio of quercetin and 
kaempferol was determined in NXQ extract (3:4). 
The second study demonstrated that NXQ significantly attenuated H2O2-induced ROS 
generation and LDH leakage and restored cell viability. Further to this, a combination of 
quercetin and kaempferol in the ratio of 3:4 significantly restored cell viability when 
compared to quercetin and kaempferol used alone, suggesting a potential synergistic or 
additive interaction. In addition, quercetin appeared to possess a greater anti-oxidant effect 
than kaempferol. A combination of two components produced a greater anti-oxidant effect 
than that used alone, further demonstrating potential synergistic/additive interactions 
between the two components. This series of studies also attempted to develop a zebrafish 
hypoxia model to evaluate the in vivo neuroprotective effects of NXQ. However, we were 
unable to successfully develop this model due to several methodological issues. Some 
preliminary results were presented and discussed. 
In the third study, it was demonstrated that NXQ significantly induced angiogenesis in VRI-
inhibited Tg(fli1:EFGP) zebrafish embryos. However, NXQ did not promote cell proliferation 
or migration in EA.hy926 endothelial cells.  
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In the last study, a protocol for a randomised, double-blind, placebo-controlled trial was 
developed. This pilot clinical trial protocol aims to evaluate the safety profile and clinical 
effects of NXQ on neurological and cognitive functions in patients suffering from ischaemic 
stroke. Ethics approval was obtained and recruitment centres established. This study provides 
a solid foundation for the conduct of this important trial in the future. 
In summary, it has been demonstrated that NXQ possesses vascular protection effects 
against H2O2-induced oxidative stress and may play a role in post-stroke revascularisation via 
angiogenesis. It has also been demonstrated that a quercetin and kaempferol combination at 
a ratio similar to that in the NXQ extract has superior effects against H2O2-induced EA.hy926 
cell damage compared to the constituents alone, suggesting a potential synergistic or additive 
effect.  
The current study provides preliminary evidence to support NXQ’s role in vascular 
protection and angiogenesis. However, several limitations were identified in these studies. 
All these studies were conducted in an in vitro setting, and in vivo evaluations of these findings 
are needed. Only two of the key bioactive components of NXQ were studied and more 
research is needed to evaluate interactions among other components. In addition, more 
rigorous synergistic models should be used to determine and quantify the synergistic effects. 
For safety reasons, the clinical trial protocol was designed to evaluate the clinical effects of 
NXQ during the rehabilitation phase of ischaemic stroke. However, reperfusion injuries 
typically develop from the moment of regained blood flow until several days post-reperfusion. 
It is, therefore, desirable to consider the timing of administration of NXQ in future trials to 
evaluate its effects on restoring and preventing neuron damage induced by reperfusion.  
In conclusion, these studies have provided some useful in vitro data to deepen our 
understanding of mechanisms underlying NXQ’s effects in ischaemic stroke. Future studies 
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have been planned, including further development of the hypoxia model in zebrafish using 
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Appendix A. Experiment Protocol – Participant Information sheet 
Project title 
A Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and 
Safety of Nao Xin Qing (NXQ), a Standardised Herbal Medicine Formula in Patients with 
lschaemic Stroke. 
Who is carrying out the study? 
You are invited to participate in a study conducted by Miss Yu-Ting Sun, a PhD candidate from 
the National Institute of Complementary Medicine (NICM) and the University of Western 
Sydney (UWS). This research will form a part of a PhD degree at the University of Western 
Sydney under the supervision of Associate Professor Dennis Chang, Professor Alan 
Bensoussan, NICM, UWS and Professor Hasan Kiat, School of Advanced Medicine, Macquarie 
University. Amongst the primary investigators of this study is a stroke rehabilitation specialist 
Dr. Alan Lam, MBBS (Syd), FAFRM from Mt Wilga Private Hospital and Lady Davidson Private 
Hospital. 
What is the study about? 
The purpose is to investigate the clinical effects and safety profile of NXQ for patients with 
ischaemic stroke to determine the merit of future research into this treatment. You will be 
selected as a possible participant in this study if you are diagnosed with ischaemic stroke 
within the past 6 months, currently undergoing rehabilitation, and between 40 to 80 years of 
age. 
lschaemic stroke accounts for more than 80% of all stroke incidences and has substantial 
disability rates. The currently available pharmaceuticals for the treatment and prevention of 
ischaemic stroke such as anti-thrombotics possesses relatively high risks of side effects such 
as bleeding while only having a low therapeutic impact on rehabilitation. NXQ has been used 
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over the past 10 years in China for ischaemic condition such as coronary artery disease and 
ischaemic stroke. Preclinical studies have revealed that NXQ has a number of therapeutic 
effects including neuroprotective, anti- inflammatory, anti-hypertensive, anti-cholesterol and 
anti-thrombotic. This study aims to assess whether NXQ can improve neurological 
functionalities and quality of life of ischaemic stroke patients during their rehabilitation phase. 
What does the study involve? 
This trial runs for a total period of 36 weeks including a 12 week intervention and a 24 week 
follow up. You will be required to attend a total of 6 clinical visits and will be randomly 
allocated in a ratio of 1:1 manner to one of the two treatment groups (active treatment of 
NXQ or placebo). The dose regimen will involve the oral ingestion of 4 tablets, 3 times a day. 
The outcome measure will be collected in the form of Case Record Files (CRF), blood samples, 
medical measurements and questionnaires. 
 
Initial screening: Prior to the commencement of study, you will be asked to attend an initial 
medical screening session. Before beginning the session, detailed information about the study 
will be provided to you and have any of your questions answered. If you wish to continue, 
you will be requested to sign a consent form for this trial before commencing of the medical 
screening session. The screening session is organised to clarify whether you are eligible for 
the study which will involve a medical questionnaire, a medical examination on neurological 
function conducted by a physician/neurologist, a questionnaire on the status of disability, and 
a blood pathology test. You will then be given a short practise session on the computer testing 
system used to measure your memory and cognitive functions. You will then be randomized 
into either active treatment group or placebo group. 
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First week of the Study: On the first day (Day 1), you will be required to attend the at Mt Wilga 
Private Hospital or Lady Davidson Private Hospital for approximately 2 hours for the 
assessment session before treatment intervention is given. These assessments include a 
questionnaire on quality of life (Stroke Specific Quality of Life); a short answer questions on 
status of disability - Modified Rankin Scale; a short answer questions on daily living activities 
- Barthel index; a blood pathology test; a computer based test battery on your memory and 
cognitive function and ultrasound to assess flow medial dilation. After the baseline 
assessment you will be given either trial medication or a placebo and you are required to take 
4 tablets, three times a day, continuously for 12 weeks. A diary will be given to you for your 
to record any missing dose or additional medication used. 
 
Week 2 of the study: You are required to visit the hospital where you were recruited for this 
study or a designated pathology lab for a blood sample test. 
 
Week 6 and Week 12 of the study: You are required to visit the hospital where you were 
recruited for a mid-treatment assessment (week 6) and a post-treatment assessment (week 
12). The assessments will be the same as your baseline assessment as well as a neurological 
function tests performed by a physician or neurologist. 
 
Follow up sessions: You are required to attend this last clinical visit at week 16 of the study 
for a follow up assessment. This assessment will be a neurological function test (NIHSS) 
performed by the physician, a questionnaire on quality of life, a questionnaire on the status 
of disability and a questionnaire on daily living activities. Upon the completion of this visit, a 
follow up call will be made on week 36 to assess long term efficacy of the intervention. 
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How much time will the study take? 
You will be asked to attend 6 clinical visits in total. These sessions Includes a screening, 
baseline, week 2, mid-treatment (week 6), post-treatment (week 12) and a follow up 
session (week 16). Each assessment session will be approximately 1 2 hours. 
Will the study benefit me? 
This study aims to further medical knowledge and may improve future treatment for 
ischaemic stroke, however it may not directly benefit you if you are randomly allocate into 
placebo group. If you are randomly allocated to the active treatment group you may 
experience temporary improvements in neurological functions, quality of life and reduction 
of vascular risk factor as a result of this intervention; however, no long term improvements 
are known at this stage. 
 
Your participation of the current study will provide important data on whether NXQ tablets 
have the potential to improve post-stroke neurological functionality, improvement of 
quality of life and has implication for the vascular risk factors management of recurrence of 
ischaemic stroke. 
Will the study have any risks? 
During the initial screening session, participants may feel some discomfort during the blood 
test and may experience minor bruising. Participants may also feel some discomfort while 
having blood pressure measurements taken. All blood tests will be performed by a trained 
professional to ensure all discomfort are minimised. 
 
NXQ has been listed and approved by the Therapeutic Goods Administration for human 
therapeutic consumption. NXQ has been using clinically for the treatment of coronary heart 
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disease and stroke more than 10 years. Some minor adverse events such as abdominal 
bloating, abdominal pain and diarrhoea has been reported, but these symptoms are 
alleviated when stop administration of the intervention medication. No major side effects 
are reported. To minimise the risk, all adverse events will be recorded and monitored 
throughout the trial. Potential participants will undergo safety tests including full blood 
counts, liver function test, renal function test, blood rheology and coagulation index before 
intervention, 2 weeks into intervention, 6 weeks into intervention and at week 12 (post-
treatment) to monitor the safety index. Participant is encouraged to contact the primary 
investigator or the chief investigator at any time during the trial if any adverse events are 
experienced. 
How much is this study being paid for? 
You will be reimbursed with $100 (approximately $17 per visit) to compensate for travel 
related expenses incurred during your attendance to study visits at the completion of the 
trial. If you withdraw from the study prematurely, the compensation will be calculated on a 
pro rata basis. 
Will anyone else know the results? How will the result be disseminated'? 
All aspects of the study, including results, will be confidential and only the researchers will 
have access to information on participants. Data will be de-identified when published as 
thesis, journal articles and presentation in the conferences. 
Can I withdraw feom the study? 
Participation is entirely voluntary. You are not obliged to participate and if you do 
participate you can withdraw at any time without giving any reason. Whatever your 
decision, it will not affect your medical treatment or your relationship with the research 
team and their affiliations. 
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Can I tell other people about the study? 
Yes, you can tell other people about the study by providing them with the chief 
investigator's and primary investigator's contact details. They can contact the chief 
investigator or primary investigator to discuss their participation in the research project and 
obtain an information sheet. 
What if I require further information? 
When you have read this information, Miss Yu-Ting Sun the primary investigator will discuss 
it with you further and answer any questions you may have. If you would like to know more 
at any stage, please feel free to contact Miss Yu-Ting Sun on (02) 4620 3278 or 0468 672 521 
or Associate Professor Dennis Chang on (02) 46203310 or 0404453682 
What if I have a complaint? 
This study has been approved by the University of Western Sydney Human Research Ethics 
Committee. The Approval number is [to be inserted after approval granted by HREC]. 
 
If you have any complaints or reservations about the ethical conduct  of this research, you 
may contact Ethics Committee through the Office of Research Services on Tel +612 4736 
0229 Fax +61 2 4736 0013 or email humanethics@uws.edu.au. 
 
Any issues you raise will be treated in confidence and investigated fully, and you will be 
informed of the outcome. If you agree to participate in this study, you may be asked to sign 
the Participant Consent Form. 
 
The information sheet is for the participant to keep and the consent form is retained by the 
researcher.  
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Appendix B. Experiment Protocol – Adverse Events 
 
The Investigator is responsible for the detection and documentation of events meeting the 
criteria and definitions detailed below. 
Full details of contraindications and side effects that have been reported following 
administration of the trial Investigational Product can be found in the Investigator’s Brochure. 
Participants should be instructed to contact their Investigator at any time after consenting 
to join the trial if any symptoms develop. All reported adverse events (AEs) that occur after 
joining the trial must be recorded in detail in the CRF.  In the case of an AE, the Investigator 
should initiate the appropriate treatment according to their medical judgment.  Participants 
with AEs present at the last visit must be followed up until resolution of the event. 
 
Definitions 
An adverse event (AE) is any untoward medical event affecting a clinical trial participant. An 
AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.  Each initial AE will be 
considered for severity, causality or expectedness and may be reclassified as a serious event 
or reaction based on prevailing circumstances. 
An adverse reaction (AR) is where it is suspected that an AE has been caused by a reaction 
to a trial drug 
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected unexpected 
serious adverse reaction (SUSAR) is any AE, AR or UAR that at any dose: 
• results in death; 
• is life threatening (i.e. the subject was at risk of death at the time of the event; it does 
not refer to an event which hypothetically might have caused death if it were more 
severe); 
• requires hospitalisation or prolongation of existing hospitalisation; 
• results in persistent or significant disability or incapacity; 
• is a congenital anomaly or birth defect. 
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Note: Hospitalisations for treatment planned prior to randomisation and hospitalisation for 
elective treatment of a pre-existing condition will not be considered as an AE. Complications 
occurring during such hospitalisation will be AEs. 
 
Detecting AEs and SAEs 
All AEs and SAEs must be recorded from the time a participant consents to join the study until 
the last study visit. 
The Investigator and designated study personnel will monitor each subject for adverse 
events during the study. All adverse events reported between consent and final follow-up will 
be recorded in the case report form (CRF). The investigator or designee will ask the subject 
non-leading questions in an effort to detect adverse events eg:  
 “How are you feeling?”  
 or  
“Since you were last asked, have you felt unwell or different from usual?”  
 In addition, subjects should be encouraged to spontaneously report any unusual feelings or 
sensations.  
Participants should also be asked if they have been admitted to hospital, had any accidents, 
used any new medicines or changed concomitant medication regimens.  If there is any doubt 
as to whether a clinical observation is an AE, the event should be recorded. 
 
Recording AEs and SAEs 
Depending on severity, when an AE/SAE occurs, it is the responsibility of the Investigator to 
review all documentation (e.g. hospital notes, laboratory and diagnostic reports) related to 
the event.  The Investigator should then record all relevant information in the CRF and on the 
SAE form. 
Information to be collected includes dose, type of event, onset date, Investigator assessment 
of severity and causality, date of resolution as well as treatment required, investigations 
needed and outcome. 
 
Evaluation of AEs and SAEs 
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Seriousness, causality, severity and expectedness should be evaluated as though the 
participant is taking active drug.  Cases that are considered serious, possibly, probably or 
definitely related to drug and unexpected (i.e. SUSARs) are likely to be un-blinded.  
 
Assessment of Seriousness 
The Investigator should make an assessment of seriousness as defined in Section 10.1. 
 
Assessment of Causality 
The Investigator must make an assessment of whether the AE/SAE is likely to be related to 
treatment according to the following definitions: 
Unrelated: where an event is not considered to be related to the study drug. 
Possibly: although a relationship to the study drug cannot be completely ruled out, the nature 
of the event, the underlying disease, concomitant medication or temporal relationship make 
other explanations possible. 
Probably: the temporal relationship and absence of a more likely explanation suggest the 
event could be related to the study drug. 
Definitely: The known effects of the study drug or its therapeutic class, or based on challenge 
testing, suggest that study drug is the most likely cause. 
All AEs/SAEs judged as having a reasonable suspected causal relationship (e.g. possibly, 
probably, definitely) to the study drug will be considered as ARs/SARs. All AEs/SAEs judged as 
being related (e.g. possibly, probably, definitely) to an interaction between the study drug 
and another drug will also be considered to be ARs/SAR. 
Alternative causes such as natural history of the underlying disease, concomitant therapy, 
other risk factors and the temporal relationship of the event to the treatment should be 
considered. The blind should not be broken for the purpose of making this assessment.  
 
Assessment of Severity 
The Investigator should make an assessment of severity for each AE/SAE and record this on 
the CRF according to one of the following categories: 
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Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not 
interfering with every day activities.   
Moderate: an event that is sufficiently discomforting to interfere with normal everyday 
activities.   
Severe: an event that prevents normal everyday activities.   
Note: the term ‘severe’, used to describe the intensity, should not be confused with ‘serious’ 
which is a regulatory definition based on participant/event outcome or action criteria.  For 
example, a headache may be severe but not serious, while a minor stroke is serious but may 
not be severe. 
 
Assessment of Expectedness 
If an event is judged to be an AR/SAR, the evaluation of expectedness should be made based 




Once the Investigator becomes aware that an SAE has occurred in a study participant, they 
must report the information to the Pharmacovigilance Sponsor within 24 hours of becoming 
aware of the event.  The SAE form must be completed as thoroughly as possible with all 
available details of the event, signed by the Investigator or designee. If all the required 
information is not available at the time of reporting, the Investigator must ensure that any 
missing information is provided as soon as this becomes available.  It should be indicated on 
the report that this information is follow-up information of a previously reported event. 
The SAE report must provide an assessment of causality and expectedness at the time of 
the initial report to the Pharmacovigilance Sponsor according to Sections 10.4.2, Assessment 
of Causality and 10.4.4, Assessment of Expectedness. 
 
Follow Up Procedures 
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After initially recording an AE or recording and reporting an SAE, the Investigator is required 
to follow each participant until resolution.  Follow up information on an SAE should be 
reported to the Pharmacovigilance Sponsor. 
Unless otherwise stated in the protocol, AEs and SAEs should be followed up until 
resolution or death of the trial subject. 
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Appendix C.  Experiment Protocol – Monitoring and Quality Assurance 
 
Project Management Group 
The trial will be coordinated by a Project Management Group, consisting of Chief Investigators, 




A trial committee consisting of the chief and principal investigators, co-supervisors and a 
NICM Research Program Coordinator who is external to the research team will be formed to 
monitor this research project. 
This committee will attend regular scheduled meetings to provide updates on the study 
progression as well as addressing any issues regarding the conduct and progression of the 
project. This committee will also ensure that the study is being conducted in accordance to 




The risk of harm to participants will be minimal as NXQ has been proven safe with minimal 
adverse events. NXQ has been listed and approved for human consumption by the 
Therapeutic Goods Authority (TGA). Toxicity test of NXQ has been conducted on rats including 
acute toxicity and long-term toxicity. No adverse reaction was reported on maximum 
administration dose (350 times of the adult’s clinical dose) was identified for acute toxicity 
test and basic safety administration dose was identified at 16time of the adult’s clinical dose 
in long-term toxicity study.  
The formula has previously been used in clinical trials on patients with apoplexy syndrome 
such as ischaemic stroke and coronary artery diseases and no major side effect was reported. 
A recent ongoing clinical trial conducted in China on NXQ for ischaemic stroke has 74 
participants completed to date identified 1 participant with decreased in platelet counts 
which may be affected by NXQ but no other adverse  events were identified. The clinical data 
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from the past 10 years on NXQ for apoplexy syndrome has identified a total of 21 minor 
adverse events which may be related to the use of NXQ. The reported adverse events are 
nausea, abdominal bloating, abdominal pain and diarrhoea, which are alleviated after stop 
administration of the medication. 
Participants may feel some discomfort during FMD ultrasound assessment (which involves 
blood pressure measurements). During pre-, mid-, post- testing and safety measurement 
sessions participants may also feel discomfort when blood samples are taken and may have 
minor bruising as a result. 
 
Minimising Risk 
To minimise the risk of adverse events from the use of NXQ, potential participants will 
undergo safety tests including full blood counts, liver function test, renal function test, blood 
rheology and coagulation index at baseline, 2 weeks, 6 weeks and week 12 (post-treatment) 
to monitor the safety index. 
The risk to participants are minimal as all procedures will be carried out by an trained  
researcher and blood samples taken by trained venipuncturist at the register and reputable 
Douglas Hanly Moir Pathology Laboratory.  
Participants are encouraged to inform the principle investigators as soon as any adverse 
event is noticed where the investigator will report to the trained physician/ neurologists and 
chief investigator to evaluate the severity of the adverse event in accordance to the guideline. 
Blood samples may produce mild pain however all samples will be taken from participants 
by trained and qualified nurses and couriered to Sydney Adventist Hospital Pathology 
Laboratories (San Pathology) where pathology testing will be conducted. 
All Adverse Events (AE) will be recorded and signed off by the principal research. Serious 
Adverse Events (SAE) will be immediately reported to local Human Research Ethics 
Committees in accordance with the guidelines. 
Given the increasing burden of cerebro-vascular disease, particularly when viewed as a 
chronic disease, the importance of improving quality of life and reducing recurrences, the 
minor discomfort consenting participants may experience is justified given the potential 





Appendix E. Experiment Protocol – Good Clinical Practice Module 
 
Ethical Conduct of the Study 
This study will be carried out according to the Declaration of Helsinki, the NHMRC National 
Statement on Ethical Conduct in Research Involving Humans (1999) and the Notes for 
Guidance on Good Clinical Practice as adopted by the Australian Therapeutic Goods 
Administration (2000) (CPMP/ICH/135/95) and the ICH GCP Guidelines.   
The protocol and related documents will be submitted for review by the Human Research 
Ethics Committee (HREC) and written approval received before the study can commence.   
The amount of blood to be sampled in the study is not considered to be excessive in 
healthy adult subjects.   
 
Regulatory Compliance of the Study 
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained from the 
appropriate Regulatory Authority.  The protocol and study conduct will comply with the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and any relevant amendments. 
 
Investigators Responsibilities 
The Investigator is responsible for the overall conduct of the study at the site and compliance 
with the protocol and any protocol amendments.  In accordance with the principles of GCP, 
the following areas listed in this section are also the responsibility of the Investigator.  
Responsibilities may be delegated to an appropriate member of study site staff.  Delegated 
tasks must be documented on a Delegation Log and signed by all those named on the list. 
 
Informed Consent 
The Investigator will obtain written informed consent from each participant prior to 
participation in the study, in accordance with International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good 
Clinical Practice (GCP) Guidelines, Declaration of Helsinki 2000, and any local regulatory 
requirements 
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The decision of a participant to participate in clinical research is voluntary and should be 
based on a clear understanding of what is involved.   
Participants will receive adequate oral and written information; Participant Information 
and Informed Consent Forms will be provided.  The oral explanation to the participant should 
be performed by the Investigator or designated person, and will cover all the elements 
specified in the Participant Information Sheet/Informed Consent.  
The participant must be given sufficient time to consider the information provided.  The 
participant may withdraw their consent to participate at any time without loss of benefits to 
which they otherwise would be entitled. 
The participant should be informed and agree to their medical records being inspected by 
regulatory authorities but understand that their name will not be disclosed outside the 
hospital. 
The Investigator or delegated member of the trial team and the participant will sign and 
date the Informed Consent Form(s) to confirm that consent has been obtained.  The 
participant will receive a copy of this document and a copy filed in the Investigator Site File 
(ISF).   
 
Subject Reimbursement 
All enrolled participants will be reimbursed $100 for their travel/parking costs. 
 
Notification of Primary Care Physician 
With the consent of the volunteer, it is the Investigator’s responsibility to notify the primary 
care physician of the subject’s participation in the study, provided that such a physician can 
be identified for the subject and this notification is relevant for the particular circumstances 
of the trial. Where relevant, a letter will be sent to the physician stating the nature of the 
study, treatments, expected benefits or adverse events and concomitant drugs to be avoided. 
A copy shall be retained by the study site for verification by the Study Monitor. 
 
Investigator Indemnification 
The study is being conducted subject to the ‘Guidelines for Compensation for Injury Resulting 
from Participation in a Company-sponsored Clinical Trial’ published by the Medicines 
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Australia.  University of Western Sydney will reimburse subjects for costs of medical care that 
occur as a result of complications directly related to participation in this study.  
 
Study Site Staff 
The Investigator must be familiar with the Investigational Product, protocol and the study 
requirements.  It is the Investigator’s responsibility to ensure that all staff assisting with the 
study is adequately informed about the investigational product, protocol and their trial 
related duties.  
 
Data Recording 
The Investigator is responsible for the quality of the data recorded in the CRF.   
 
Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be identified in 
a manner designed to maintain participant confidentiality.  All records must be kept in a 
secure storage area with limited access.  Clinical information will not be released without the 
written permission of the participant, except as necessary for monitoring and auditing by the 
Sponsor, its designee, Regulatory Authorities, or the HREC.  The Investigator and study site 
staff involved with this study may not disclose or use for any purpose other than performance 
of the study, any data, record, or other unpublished, confidential information disclosed to 
those individuals for the purpose of the study.  Prior written agreement from the Sponsor or 




All Investigators and study site staff involved with this study must comply with the 
requirements of the appropriate Data Protection or Privacy Act with regard to the collection, 
storage, processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to those clinicians treating the 
participants. 
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Computers used to collate the data will have limited access measures via user names and 
passwords. 






Appendix D. Experiment Protocol – Study Administrative Procedures 
 
Protocol Amendments 
Any changes in research activity, except those necessary to remove an apparent, immediate 
hazard to the participant, must be reviewed and approved by the Chief Investigator.  
Amendments to the protocol must be submitted in writing to the appropriate HREC, for 
approval prior to participants being enrolled into an amended protocol. 
 
Protocol Violations and Deviations 
The Investigator should not implement any deviation from the protocol without agreement 
from the Chief Investigator and appropriate HREC approval except where necessary to 
eliminate an immediate hazard to trial participants. 
In the event that an Investigator needs to deviate from the protocol, the nature of and 
reasons for the deviation should be recorded in the CRF.  If this necessitates a subsequent 
protocol amendment, this should be submitted to the HREC for review and approval if 
appropriate. 
 
Study Record Retention 
The Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) annotated with TGA 
comments requires study documentation to be retained for a minimum of 15 years.  
Participant files and other essential documents (study protocol, signed informed consent 
forms, IP dispensing logs, correspondence, CRFs, source documents and other documents 
pertaining to the conduct of the study) must be kept for the maximum period permitted by 
the research institute in accordance with these requirements.  
Should the Investigator wish to assign the study documentation to another party or move 
to another location, the trial Coordinating Centre/ Study Sponsor should be notified. 
 
End of Study 
The end of study is defined as the last participant’s last visit. 
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The Investigators and/or the trial steering committee have the right at any time to 
terminate the study for clinical or administrative reasons.  
A summary report of the study will be provided to the HREC at the end of the study. 
 
Reporting, Publications and Notification of Results 
 
Authorship Policy 
Ownership of the data arising from this study resides with the study team. On completion of 




The clinical study report will be used for publication and presentation at scientific meetings. 
Investigators have the right to publish orally or in writing the results of the study. 
Summaries of results will also be made available to Investigators for dissemination within 
their clinics (where appropriate and according to their discretion). 
 
 
